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“I am among those who think that science has great beauty. A  
scientist in his laboratory is not only a technician: he is also a  
child placed before natural phenomena, which impress him like 
a fairy tale. We should not allow it to be believed that all 
 scientific progress can be reduced to mechanisms, machines, 
 gearings, even though such machinery also has its beauty. 
 
Neither do I believe that the spirit of adventure runs any risk 
of disappearing in our world. If I see anything vital around me, 
it is precisely that spirit of adventure, which seems  
indestructible and is akin to curiosity.” 
 
Marie Curie  
 
During a debate in Madrid, “The Future of Culture” (1933).  
In Eve Curie Labouisse, Eve Curie and Vincent Sheean, Madame Curie (1937), 341 
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 RESUMO 
 
Os lipossomas catiónicos constituídos pelo lípido catiónico Brometo de 
Dioctadecil Dimetilamónio (DODAB) são sistemas de entrega eficazes com poder 
adjuvante, possibilitando a proteção/veiculação do antigénio, tendo sido anteriormente 
descritos como imuno-estimuladores. Assim, o principal objectivo deste trabalho foi o 
desenvolvimento e caracterização de lipossomas, constituídos pelo DODAB e pelo lípido 
não-iónico Monooleína (MO), com poder adjuvante para o establecimento de uma 
estratégia imunomoduladora contra infecções sistémicas causadas pelo fungo  
Candida albicans. 
Inicialmente, demonstrámos que o aumento na concentração de MO melhora a 
estabilidade coloidal, a viabilidade e a internalização celular quer dos lipossomas vazios, 
quer carregados com BSA (BSA nanoparticulas liposomais (LNPs). Estes lipossomas 
foram internalizados via endocitose, sendo que a internalização da BSA foi aumentada 
quando veiculada pelos lipossomas. Selecionámos a razão molar DODAB:MO (1:2) 
como a mais adequada e demonstrámos que este sistema para além de funcionar como um 
nanotransportador também aumenta a ativação de células apresentadoras de antigénio 
(APC). Esta mesma razão molar foi selecionada para preparar sistemas de entrega de 
antigénios (ADSs LNPs) carregados com proteínas da superfície da parede celular de  
C. albicans (CWSP). Foram avaliadas as propriedade físico-químicas destas ADSs LNPs 
a diferentes razões de massa entre as proteínas e os lípidos (p/l) para selecionar duas 
formulações ADS1 (p/l 0.056) e ADS2 (p/l 0.376). Ambas as formulações apresentaram 
estabilidade coloidal, carga superficial negativa, tamanho médio de cerca de 200 nm e 
não provocaram efeitos citotóxicos. Estudos in vitro possibilitaram verificar que os ADSs 
induzem uma libertação lenta das CWSP e, como tal, prolongam a estimulação das APCs, 
tendo sido confirmado o seu potencial imunogénico em estudos in vivo, usando ratinhos 
BALB/c imunizados com os ADSs. Neste sentido, usando um modelo murino (BALB/c) 
de candidíase disseminada, mostrámos que a imunização com ADS1 prolonga a 
sobrevida dos ratinhos, comparando com ratinhos imunizados com as CWSP livres. A 
resposta humoral observada distingue-se pela existência de anticorpos específicos capazes 
de aumentar a fagocitose de C. albicans, e a resposta celular específica desenvolvida 
apresenta o fenótipo Th1/Th17, conhecido como protetor neste tipo de infeções. 
Em resumo, os resultados apresentados nesta tese, revelam o potencial dos 
lipossomas DODAB:MO como sistemas de entrega de antigénios com poder adjuvante. 
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 ABSTRACT 
 
Cationic liposomes, composed by the cationic synthetic lipid 
dioctadecyldimethylammonium bromide (DODAB) are effective adjuvant delivery 
systems that offer antigen protection and have been shown to be immunostimulatory. 
Thus, the main objective of this thesis was the design and characterization of a novel 
adjuvant delivery system composed by DODAB and the neutral lipid monoolein (MO) 
for use as an imunomodulatory strategy against Candida albicans systemic infections. 
Initially, we demonstrated that DODAB:MO liposomes, empty or loaded with 
BSA (BSA Liposomal Nanoparticles, LNPs), benefit in terms of colloidal stability, 
cellular viability and uptake with the increase in MO molar fraction. Both empty 
liposomes and BSA LNPs were internalized by endocytosis, with increasing BSA uptake 
upon loading in DODAB:MO liposomes. The most suitable molar ratio of DODAB:MO 
(1:2) was selected and we demonstrated that this formulation not only acts as antigen 
nanocarrier, but also enhances activation of bone marrow derived dendritic cells 
(BMDCs). Following, we used these liposomes to prepare antigen delivery systems 
liposomal nanoparticles (ADS LNPs) with C. albicans cell wall surface proteins (CWSP) 
as antigens. The physicochemical properties of these LNPs were assessed at different 
protein/lipid weight ratio (p/l) and selected two formulations ADS1 (p/l of 0.056) and 
ADS2 (p/l of 0.376). Both ADSs exhibited negatively charged surfaces with mean sizes 
of approximately 200 nm, good colloidal stability and no associated cytotoxicity. ADSs 
LNPs not only enhanced but also prolonged BMDCs activation, indicating that entrapped 
antigen is released in a slow and sustained manner. ADSs immunized mice provided 
evidence that the LNPs could have potential to be use in an immunoprotective strategy 
against disseminated candidiasis. Finally, in a murine (BALB/c) model of systemic 
candidiasis, we showed that mice immunized with ADS1 LNPs significantly extended 
mice survival in comparison with mice immunized with free CWSP. Mice vaccinated 
with ADS1 LNPs developed a strong humoral response with specific antibodies able to 
enhance phagocytosis of C. albicans cells and boost a protective and specific Th1/Th17 
response. 
In summary, in this thesis we show that DODAB:MO-based liposomes can act as 
adjuvant delivery systems and confer immunoprotection against C. albicans systemic 
infections. 
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RT Room temperature 
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s.c.  Subcutaneous 
SAP Secreted aspartyl protease  
SD Standard deviation  
SDS Sodium dodecyl sulphate  
SDS-PAGE Sodium dodecyl sulphate polyacrylamid gel electrophoresis 
SUV Small Unilamellar Vesicle 
TB Trypan Blue 
TCR T T cell receptor  
TDB Trehalose 6,6’-dibehenate 
Th T helper  
TLR Toll-like receptor  
TM Phase transition temperature 
TNF Tumour necrosis factor  
Treg Regulatory T cell  
USA United States of America  
WT Wild-type 
YEPD Yeast extract, Peptone and Dextrose  
β -ME β-mercaptoethanol 
ζ-Potential Zeta Potential 
χDODAB Molar fraction of DODAB 
χMO Molar fraction of Monoolein 
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1. MOTIVATION 
 
The work developed in our research group has led to a novel and efficient 
liposomal system composed by dioctadecyldimethylammonium bromide (DODAB) and 
monooleoyl-rac-glycerol (monoolein, MO) used for DNA transfection. These studies 
have demonstrated that this liposomal system can be used as a competent molecular 
nanocarrier for cell transfection, which led to the legal protection of this technology. 
Since liposomes are versatile tools that can act not only as nanocarries of genes or 
different types of drugs but also as vaccine adjuvants. In this thesis we exploited the 
ability of this particular lipidic combination to serve as both nanocarries for antigen 
delivery and as adjuvants in the development of vaccine.  
Currently, systemic infections caused by Candida species represent the fourth 
leading cause of nosocomial bloodstream infection in modern hospitals with a mortality 
rate associated of 30-40% due to failures in the current treatment and prevention 
measures. Thus, new immunomodulatory strategies are needed to decrease this high 
mortality rates. Subunit vaccines represent safer, less toxic and a more immunological 
defined approach for vaccine design. Due to the poor immunogenicity of pathogen 
subunits when used alone, in this thesis we decided to develop a vaccine strategy against 
systemic candidiasis using the nanodelivery system developed by our team. 
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2. OBJECTIVE 	  
The overall objective of the present thesis is to design and characterize a novel 
antigen delivery system taking advantage of cationic liposomes, composed by DODAB 
and MO lipids and finally use this system for the design of novel immunomodulatory 
strategy against systemic C. albicans infection.  
For this purpose, experimental work was divided in the following detailed objectives:  
§ Biophysical characterization of empty DODAB:MO liposomes and protein loaded 
DODAB:MO liposomal nanoparticles (LNPs).  
§ In vitro characterization of the DODAB:MO liposomes ability to improved 
antigen immunogenicity.  
§ In vivo evaluation of DODAB:MO LNPs potential in increase cellular and 
humoral responses towards C. albicans antigens.  
§ In vivo evaluation of DODAB:MO LNPs potential in protecting against a lethal  
C. albicans systemic infection.  
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3. THESIS OUTLINE 
 
The present thesis is organized in 7 different chapters. The chapters regarding the 
experimental work (chapters 3 to 6) are presented in form of articles. The manuscripts 
presented in chapter 3 and 5 are published in the Journal Microbiology Methods and in 
the European Journal of Pharmaceutics and Biopharmaceutics, respectively, while the 
manuscripts presented in chapters 4 and 6 are being prepared for publication. 
 
Chapter 1 presents the context, motivation and objectives of this thesis, as well as 
its  global structure. 
 
In Chapter 2 an overview of the literature related with the theme of the thesis is 
presented. This chapter starts with an introductory review of the immune system and 
types of vaccines followed by a review on immunological adjuvants with a focus on 
cationic liposomes. In addition the immunology of Candida albicans infections together 
with strategies that used delivery systems for vaccination against this pathogen are briefly 
discussed.  
 
In Chapter 3, the work “A new method for yeast phagocytosis analysis by flow 
cytometry” is presented, describing a novel, fast and simple method to study the 
interaction between phagocytes and Candida yeast cells. 
 
In Chapter 4, the work “DODAB:monoolein as protein delivery systems: the 
role of monoolein” is presented, showing the effect of monoolein in the liposomal BSA 
loaded nanoparticles (BSA LNPs). Furthermore, in this chapter DODAB:MO (1:2 molar 
ratio) liposomes were selected and explored as nanocarriers with the ability to enhance 
the activation of antigen presenting cells (APCs) promoted by the free antigen.  
 
In Chapter 5, the work “DODAB:monoolein liposomes containing Candida 
albicans cell wall surface proteins: A novel adjuvant and delivery system” is 
presented. In this chapter, DODAB:MO (1:2 molar ratio) liposomes loaded with Candida 
albicans proteins are characterized and explored “in vitro” and in “vivo”, as protein 
delivery vehicles and immunoadjuvants.  
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In Chapter 6, the work “Candida albicans cell wall surface proteins 
incorporated in DODAB:monoolein liposomes confer protection against the fungal 
infection in BALB/c mice ” is presented, showing that an immunization protocol based 
on the DODAB:MO (1:2 molar ratio) liposomes loaded with Candida albicans proteins 
effectively protect against a lethal C. albicans systemic infection, being considered a 
promising vaccination approach. 
 
In Chapter 7, the overall conclusions and significance of the work is presented. 
Suggestions for future work are also exposed. 
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1. TYPES OF VACCINES 
 
A vaccine can be defined as a biological preparation that enhances immunity against 
disease and either prevent (prophylactic vaccines) or treat disease (therapeutic vaccines). The 
word ‘vaccine’ originates from the Latin Variolae vaccinae (vacca meaning cow) known by 
the name of cowpox, a virus affecting cows, with which Edward Jenner demonstrated in 1798 
could prevent smallpox in humans [1]. 
An advantageous vaccine produces a long-term adaptive immune response that 
prevents invasion or multiplication of its target pathogen and essentially produces no 
significant adverse effects on the host. The effectiveness of the immunoprotection induced by 
the vaccine depends on various factors including the nature of the pathogen and on the 
immunocompetence of the host [2]. 
Vaccines can be grouped into three main types: live-attenuated, inactivated (killed) 
pathogens or pathogen subunits (protein-based, polysaccharide-based or conjugates). Live-
attenuated vaccines are based on a viable pathogen with reduced virulence or ability to cause 
disease that has been weakened under laboratory conditions, normally attenuated by in vitro 
passages, chemically, genetically, or by other means. These vaccines are extremely potent 
because the pathogen will grow in the vaccinated host. However, obvious disadvantages such 
as reversion to virulent, unwanted host reactions like induction of exacerbated inflammation 
or autoimmune responses, and perseverance and production issues (like the need to be 
refrigerated to stay potent) can be spawned with this kind of vaccines [3]. Nevertheless, live-
attenuated vaccines are still in clinical use for protection against tuberculosis (BCG), polio 
(OPV), and yellow fever, among others. Inactivation of pathogens, using chemicals, heat, or 
radiation, benefit from a safer administration since inactivation reduces danger to the host. 
However, several disadvantages are associated, as they are less potent and the immune 
response is largely limited to a humoral response. In many cases for this type of vaccine an 
adjuvant is needed, since without it vaccination requires additional dosages that may incur 
undesirable host reactions [4]. For these reasons, there has been a shift towards developing 
subunit vaccines composed by one or several specific units of the pathogen. Lacking any 
potential to replicate in the host they represent safer, less toxic and a more immunological 
defined approach for vaccine design [5]. Although they are promising candidates as the next 
generation of immunotherapeutics, pathogen subunits are also poorly immunogenic when 
used alone as vaccines [6]. In this sense subunit vaccines have to be delivered with potent 
immunostimulatory adjuvants to effectively activate the innate and adaptive arms of the 
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immune system [7]. In some cases the vaccines are multivalent, targeting diverse organisms 
combining inactivated pathogens and pathogen subunits (as shown in Table 1). As we move 
toward the era of modern vaccines novel adjuvants and novel delivery systems that boost 
immunogenicity are increasingly needed. 
 In Table 1 a summary of the current licensed vaccines manufactured in Europe that 
take advantage of licensed adjuvants, are represented and grouped according to the type of 
vaccine used. 
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Table 1: Licensed vaccines manufactured in Europe grouped according to the vaccine type.  
Only vaccines that take advantage of licensed adjuvants are represented. Type	  o	  vaccine	   Target	  Disease	   Vaccine	  Name	   Country	   Adjuvant	  Inactivated	  pathogen	   Influenza	   Arepanrix	  (H1N1)	  Humenza	  (H1N1)	  Pandemrix	  (H1N1)	   Belgium	  France	  Germany	   ASO3	  AFO3	  ASO3	  	  Hepatitis	  A	  	   Avaxim	  Epaxal	   Netherlands	  	   	  Al(OH)3	  Virosome	  	  Pathogen	  subunits	   Pneumococcal	  	   Synflorix	  	  	   Belgium	   Al(PO)4	  Hepatitis	  B	  	   Engerix	  B	  Fendrix	  HBvaxPRO	   Belgium	  Belgium	  France	   Al(OH)3	  AS04C	  Al(OH)3	  Influenza	   Celtura	  (H1N1)	  Focetria	  (H1N1)	   Germany	  Italy	   MF59	  Papillomavirus	   	  Cervarix	  	   Belgium	   VLP	  and	  ASO4	  Tetanus	  toxoid	  	   Tetatox	  TT	  vaccine	  TETAVAX	   Bulgaria	  France	   	  Al(OH)3	  	  Diphteria,	  tetanus	   DifTet	  diTe	  booster	  DT	  VAX	  IMOVAX	  dT	  adult	  Teta-­‐dif	  
Bulgaria	  Denmark	  France	  France	  Bulgaria	  
Al(OH)3	  
DTaP	   Boostrix	  DtaP	  Infanri	   Belgium	  Belgium	   Al(OH)3	  and	  Al(PO)4	  Al(OH)3	  Inactivated	  Pathogen	  +	  subunit	   DTaP	   D.T.COQ/D.T.P	   	  France	  	   	  Al(OH)3	  	  DTaP,	  	  IPV	   Infanrix	  IPV	  Repevax	   Belgium	  France	   Al(OH)3	  Al(PO)4	  DTaP,	  HepB	   Tritanrix	  HB	   Belgium	   Al(OH)3	  and	  Al(PO)4	  
DTaP,	  Hib	   Quattvaxem	  TETRAct-­‐HIB	  TriHIBit	   Italy	  France	  France	   Al(PO)4	  Al(OH)3	  KAl(SO4)2	  DTaP,	  IPV,	  	  Hib-­‐IPV	   Pentaxim	  Pediacel	   France	  France	   Al(OH)3	  Al(PO)4	  DTaP-­‐HepB-­‐Hib-­‐IPV	   Hexavac	  Infanrix	  hexa	   France	  Belgium	   Al(OH)3	  Al(OH)3	  and	  Al(PO)4	  	  DTaP-­‐HepB-­‐IPV	   Pediarix	   Belgium	   Al(OH)3	  and	  Al(PO)4	  
HepA	  and	  HepB	   Vivaxim	   Belgium	   Al(OH)3	  and	  Al(PO)4	  
DTaP: Diphtheria, Tetanus, Pertussis; Hep: Hepatite; IPV: Inactivated polio; Hib: Haemophilus influenzae type 
B. AS03: emulsion with squalene, α-tocopherol and polysorbate 80; AS04: emulsion with monophosphoryl lipid 
A (MPL) preparation and aluminum salt; MF59: emulsion with squalene, polysorbate 80 and sorbitan trioleate; 
VLP: virus like particles. 
CHAPTER II 
_________________________________________________________________________________________________________________ 
	  12	  
2. STIMULATING THE IMMUNE SYSTEM 	  
Vaccine formulations should be designed rationally to induce specific protective 
responses. After the first encounter with a specific antigen the immune response is usually 
slow since the immune system hasn´t yet acquired the necessary knowledge to deal with the 
pathogen, which makes the human body vulnerable to infection. Throughout this initial 
encounter the body can develop an acquired immunity. Consequently, a number of T- and B- 
cells can survive and differentiate into highly reactive memory and effector cells. So, upon re- 
infection, in a second encounter, these memory cells react to the previously encountered 
antigen in a stronger and faster manner in comparison to naive cells, reflecting the pre-
existence of clonally expanded antigen-specific memory cells [8, 9]. In fact, the conceptual 
basis for preventative vaccination and possibly the most significant consequence of adaptive 
immunity is the induction of immunological memory [4]. 
 
2.1. The Immune system 
The organs of the immune system, the lymphoid organs, are distributed throughout the 
body. They can be divided mainly into primary and secondary lymphoid organs. Primary 
lymphoid organs are constituted by the bone marrow and the thymus, where leucocytes are 
generated and maturate. Adaptive immune responses are initiated at secondary lymphoid 
organs (also called the peripheral lymphoid organs) constituted by the lymph nodes, spleen 
and the skin-, mucosal- and gut-associated lymphoid tissues, SALT, MALT and GALT, 
respectively [10]. 
Immunity can be provided by the innate and adaptive immune system [11]. The innate 
arm of the immune system is characterized by limited specificity and the absence of 
immunological memory. However, the innate responses play a decisive role in the magnitude, 
quality and duration of adaptive responses [10]. The adaptive arm of the immune system is 
characterized by long lasting and specific recognition of pathogens [9].  
 In order to obtain an effective immune response both systems continually interact 
with each other in a process that involves recognition, uptake and presentation of antigen with 
subsequent establishment of a memory population composed by T and B cells [12].  
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2.2. Innate immunity 
The innate immune system, which can be activated within a few minutes of the initial 
invasion through nonspecific recognition of a pathogen [13], relies on the combined action of 
humoral and cellular components, that fight pathogens in a non- specific manner [11]. 
 
2.2.1 Innate humoral immune responses 
A crucial factor to the stimulation of innate immune responses is the detection of 
molecular components commonly belonging to the pathogen that Charlie Janeway dubbed 
pathogen associated molecular patterns (PAMPs) [14]. Innate humoral response relies on 
multitude of soluble pattern recognition molecules belonging to several protein families that 
detect conserved PAMPs on microorganisms. Some mechanism of humoral defense are based 
on the protease cascades of the complement system as well as naturally occurring antibodies 
(NAb) and pentraxins [15]. 
The complement system can be activated through three activation pathways, the 
classical, the alternative and the lectin pathway. The classical pathway is triggered when 
immunoglobulin M (IgM) or certain IgG subclass antibodies bind to the surface 
markers/antigens on a pathogen. The alternative pathway is triggered by the deposition of the 
complement protein, C3b, onto microbial surfaces and does not require antibodies for 
activation. The lectin pathway, is triggered by the attachment of plasma mannose-binding 
lectin (MBL) to pathogens and is also independent of antibodies for activation [11]. 
Ultimately, complement activation results in the binding of complement component 
fragments to the pathogen cell surface (opsonization), which enhances phagocytosis. 
Continuous deposition of other complement components will lyse the pathogen due to the 
formation of the membrane attack complex (MAC) that perforates microorganisms  [16]. 
Complement activation also results in the formation of other complement fragments with 
anafilatoxin effects that attracts phagocytic cells to the activation site, enhancing the 
inflammatory response [16]. 
NAb are germ line encoded Ab with restricted epitope specificities and are produced 
in the absence of external antigen stimulations. Natural IgM Abs opsonize a wide range of 
pathogens, promoting the recognition of pathogens by professional antigen-presenting cells 
(APCs), and may guide the ensuing functional polarization of T-cell responses, as well the 
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isotype class-switch recombination of the induced B-cell response and induction of long-term 
immune memory [17]. 
Pentraxins are acute phase proteins and therefore markers of infection and 
inflammation. Pentraxins recognize and bind multiple pathogens which facilitates clearance 
of pathogens and cell debris, by complement activation and phagocytosis enhancement [15]. 
 
2.2.2 Cell based innate immunity  
Cells of the innate immune system represent a very diverse set of cells that derive 
from a common myeloid progenitor on the bone marrow. This set is constituted by tissue-
residing cells (such as macrophages and dendritic cells) and “moving” cells (such as 
neutrophils, eosinophils and monocytes). These cells express pattern recognition receptors 
(PRRs) - such as Toll-like receptors (TLRs), C-type lectin receptors (CLRs) and the galectin 
family protein that recognized PAMPS [18-20].  
Neutrophils and macrophages contribute to the cellular innate immune response 
mostly through phagocytosis, either directly through PRRs or indirectly through recognition 
of pathogen coating by complement or antibodies. Phagocytosis represents an important 
effector mechanism of the innate immune response that takes place upon contact between 
phagocyte and pathogen. After engulfment, the pathogen is trapped within an intracellular 
vesicle and targeted for destruction by a complex set of digestive enzymes or toxic reactive 
oxygen species (ROS) produced within the host cell [21]. For that reason, the phagocyte 
response to microbes is often referred to as “oxidative burst” [22]. Furthermore, PRRs 
binding to PAMPs activate a signaling transduction cascade that culminates in NFκB 
activation [23]. NFκB is a transcription factor that controls the expression of numerous 
immunologically important cytokines and chemokines as well as membrane receptors [24]. 
Upon binding of a PAMP to its cognate PRR, NFκB is liberated to translocate to the nucleus, 
seek out its target genes and initiate transcription [25]. In consequence, diverse groups of 
chemokines, with the ability to activate and guide other cells of the immune system to the site 
of infection, as well as cytokines, that induce differentiation, are produced, resulting in the 
amplification of immune responses. Other transcription factor cascades, involving most 
notably the interferon-regulated factors (IRFs), are also activated downstream the PRRs. 
Some of the most important inflammatory mediators synthesized and released in response to 
PRR engagement include the antiviral interferons, the small protein cytokines interleukin-1β 
(IL-1β), IL-6, IL-12, and tumor necrosis factor α (TNFα), which activate other cells through 
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binding to specific receptors [23, 25]. The elevated secretion of cytokines and chemokines 
leads to the recruitment of cells and soluble mediators, with anti-microbial activity, to the site 
of infection through increased vessel permeability, leading to the classical signs of 
inflammation (increased swelling, redness, pain and heat) [10, 26]. 
Like macrophages, dendritic cells (DCs) are considered professional phagocytes 
however DCs are not directly involved in immediate pathogen clearance. After efficiently 
phagocyte pathogens, DCs process antigens derived from these pathogens into peptides and 
load these peptides on major histocompatibility complex (MHC) class I or MHC class II 
molecules and therefore are considered potent antigen-presenting cells (APC), capable of 
activating resting T cells and of initiating primary and memory immune responses. Although 
macrophages are also capable of presenting antigens on MHC class I and II molecules, they 
do so less inefficiently. 
 
2.3. Adaptive immunity 
The adaptive immune system takes advantage of the innate system’s ability to 
discriminate between dangerous pathogens and innocuous or even beneficial microbes and 
environmental factors [27]. 
In order to achieve a successful activation of antigen-specific adaptive immune 
responses, it is first necessary to activate the pathogen-detection mechanisms of the innate 
immune system. However, innate responses do not improve upon frequent encounter with the 
same antigen, thus unlike the adaptive immune system, they do not confer long-lasting 
immunity on the host. For that adaptive immunity follows the innate immune response [20, 
28]. Cell mediated and humoral immunity represent the two major types of adaptive immunity 
and culminate in the proliferation of pathogen-specific T or B lymphocytes together with T 
and B memory cells, providing long-term protection against disease [28].  
 
2.3.1 T and B cells 
T and B-lymphocytes develop from a common lymphoid progenitor in the bone 
marrow. During B cell development in the bone marrow, each B lymphocyte expresses 
numerous copies of a unique antibody as a cell surface receptor (B cell receptor, BCR) and 
emerges in the bone marrow periphery when the immature B cells express immunoglobulin 
IgM. Here, B cells further differentiate into naive B cells, which also express IgD, leave the 
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bone marrow and circulate in secondary lymphoid tissues, where they may encounter specific 
antigen [29].  
The development/maturation of T cells starts in the thymus after T lymphocytes 
migration from the bone marrow. In the thymus, progenitor T cells undergo stringent positive 
or negative selection resulting in naive T cells populations that leave the thymus with a 
unique collection of T cell receptors (TCRs) on the cell surface and either CD4 or CD8 co-
receptor [30]. Intact TCRs and BCRs formed the antigen-specific receptors of the adaptive 
response. The assembly of antigen receptors from a collection of a few hundred germline-
encoded gene elements permits the formation of millions of different antigen receptors, each 
with potentially unique specificity for a different antigen [27]. In a marked contrast, B cell 
receptors (BCRs) can react to a wide spectrum of antigens while T cells can only be activated 
in response to protein antigens [10].  
 
2.3.2 T cell activation 
In order to be effectively activated T-cells require APC cells function. APCs uptake 
antigen by endocytosis or phagocytosis, broken it down in the lysosomes and migrate from 
the site of infection to the regional lymph nodes. At this site, antigen presentation occurs via 
presentation of antigenic material in the major histocompatibility complex (MHC) class I and 
class II receptor molecules [31]. In essence, MHC molecules function as serving platforms for 
dismembered proteins since T-cells can only recognize antigen when presented within the 
cleft of an MHC molecule. T-cells examine antigen presented on DCs using TCR specificity 
and successful recognition (signal 1 - the antigen specificity) results in activation and the 
acquisition of various immune-related functions by the T-cell (Figure 1). However, for the 
activation of protective T cells, signal 1 is not sufficient. Indeed, the presentation of antigen 
alone is insufficient to cause naive T cells to mature into effector T cells. That is why an ideal 
vaccine should contain an immunopotentiator agent besides the antigen in order to enhance 
DCs co-stimulatory signals. In fact, the membrane ligands, B7-1 and B7-2 (also called CD80/ 
CD86) engagement with CD28 on the surface of the T-cell (signal 2 - the co-stimulation) and 
cytokine secretion (signal 3 - the polarization) are required for strategic T cell responses 
(Figure 1) [32-34].  
Primed T cells undergo a pattern of clonal expansion and acquisition of effector cell 
functions, followed by formation of memory cell populations that are long-lived [6, 35, 36]. T 
cells can be grouped into two main subsets the CD4+ T-cells, often referred as T helper cells, 
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that express the CD4 co-receptor and, and the CD8+ T-cells, also known as cytotoxic T cells 
that express CD8 co-receptor. 
Three separate T helper (Th) cell lineages can be regulated depending on the cytokine 
milieu: Th1, Th2, and Th17. IL-12 and IL-4 have previously being shown to regulate Th1 and 
Th2 differentiation respectively, with Th17 cells differentiation from naive CD4+ T-cells have 
been shown to be due to IL-6, IL-23 and tumour growth factor-beta (TGF-β) [37]. 
Two further subsets of CD4+ T-cells have also been identified, the regulatory T-cells 
and follicular helper T cells. Regulatory T-cells or Tregs are critical for homeostasis and 
tolerance and are activated by IL-10 producing dendritic cells. Follicular helper T cells (Tfh), 
appear to be important for guiding B-cell development, class switching and survival within 
germinal centers [10]. T helper subclasses have distinctive cytokine secretion patterns and 
functions [38, 39] that are strongly related to the type of microorganism or antigen that first 
interacts with the host and also depends on antigen dose and vaccine administration route. 
CD8+ T cells form the main subset that mediates cytotoxicity being capable of induce 
the death of infected or otherwise damaged host cells (like tumor cells) [40].  
 
 
Figure 1: Mechanisms of T cell activation upon uptake and presentation of a liposomal encapsulated antigen 
(Ag) by APCs. Liposomal encapsulated antigens are uptaken by APCs and processed for display on MHC II 
molecules. CD4+ T cells recognize antigen via their T cell receptor (TCR) and with co- stimulation, intracellular 
signaling pathways leads to CD4+ T cell activation.  
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2.3.3 B cell activation 
B cells are responsible for the recognition of pathogen-derived antigen in its native 
form and circulate in secondary lymphoid tissues. The BCR play two roles in B-cell 
activation. First, it transmits signals directly to the cell’s interior upon binding antigen (Signal 
1). Second, they deliver the antigen to intracellular sites where it is digested and returned to 
the B-cell surface as peptides bound to MHC class II molecules. The peptide-MHC class-II 
complex can be recognized by antigen-specific CD4+ cells, enhancing co-stimulatory 
molecules such as CD40 ligand (Signal 2), which in turn causes B cells to divide and 
differentiate into plasma cells and memory B cells [41, 42].  
Plasma cells represent the terminal stage of differentiation for all antigen activated B 
cells and release high-affinity antibodies that attach to antigens forming antibody-bound 
complexes that are phagocytized more avidly [26, 43]. Two types of genetic changes occur 
during B cells differentiation: somatic mutations and class switching. The first changes the 
antigen binding properties so that binding affinity of B-cell receptor to its cognate ligand 
increases and the last results from a change in the heavy chain constant region within the Ig, 
giving rise to the expression of antibodies with the same antigen specificity but of differing 
isotypes, and therefore of differing effector functions [29]. Roughly Y-shaped, antibodies are 
flexible molecules made up of two heavy chains and two light chains linked together [44]. 
The type of heavy chain determines the class, or isotype, of the antibody molecule, i.e. IgA, 
IgG, IgD, IgE and IgM antibodies. The capacity of a given antibody to reach the site of 
infection and recruit the adequate effector mechanisms is determined by the type 
immunoglobulin class. In fact, the binding of an antibody to its target is often sufficient to 
render the antigen harmless [10]. 
Antibodies can be considered as bifunctional molecules, that can both recognize and 
enhance the elimination of a given antigen or pathogen by opsonization rendering the 
pathogen more susceptible to phagocytosis, by cells of the innate immune system. Depending 
on their isotype, antibodies can also activate the complement family of proteins, leading to 
cell lysis and destruction of the target pathogen [10]. The response elicited following an 
antigen primary injection is slow and is characterized by low affinity IgM antibodies. If the 
same antigen is encountered again, the secondary response develops more rapidly and is 
mostly composed of IgG antibodies of higher affinity. The secondary response is 
characterized by both quantitative (higher and more sustained antibody titers) and qualitative 
(class switch and affinity maturation) traits that are under the control of T helper cells. [64].  
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3. IMMUNOLOGICAL ADJUVANTS  	  
Adjuvants (from the latin word adjuvare, meaning to “help” or “to enhance” aid) were 
originally identified in the 1920s by Gaston Ramon a French veterinarian working at the 
Pasteur Institute. Ramon described it as “substances used in combination with a specific 
antigen that produced a more robust immune response than the antigen alone” [45]. 	  
3.1. The requirement of vaccine adjuvants  
In general, vaccine antigens themself are very weakly immunogenic, therefore an 
adjuvant is needed to intensify the immune response. Additionally, an adjuvant can also be 
included in vaccine formulation in order to guide and accelerate the type of protective 
immune response generated [46, 47]. Moreover, a potent adjuvant has the ability to improve 
the effectiveness of vaccines by preventing competition between antigens when combination 
vaccines are administered, increase antibody titers, invigorate cellular immunity, increase 
extent of response to overcome pathogen diversity, induce sustained responses for a longer 
duration and enhance vaccine efficacy in infants, elderly or immunocompromised individuals. 
Adjuvants can also be applied to increase cost-effectiveness by minimizing antigen required 
per vaccine dose [48-50].  
 
3.2. How do adjuvants enhance the immune response? 
Currently in widespread use, either in man or in animals, adjuvants have for the most part 
been developed empirically, without a clear understanding of their cellular and molecular 
mechanisms of action. This is well captured in a famous quote by Janeway (1989) who 
observed that adjuvants are “the immunologists’ dirty little secret” [14]. In fact, that lack of 
knowledge delayed the progress and approval of novel adjuvants [51].  
Some authors suggested that adjuvants may exert their effects employing one or more 
of the following mechanisms to elicit immune responses: (1) formation of a depot-effect, (2) 
cellular recruitment, (3) up-regulation of cytokines and chemokines at the site of injection, (4) 
increase antigen uptake, (5) activation and maturation of APC, and (6) activation of 
inflammasomes [52-54]. The details of the various mechanisms of action are crucial for the 
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rational vaccine design and essential for the approval of new adjuvants for use in vaccine 
formulations.  
 
3.2.1 The depot-effect 
The formation of a depot at the injection site is perhaps the oldest and most widely 
recognized mechanism of adjuvant action. The depot-effect refers to the antigen trapping 
(with or without adjuvant) at the injection site. The adjuvant can act by prolonging the release 
of the antigen at injection site, which results in lengthy presentation of antigen ensuring a 
constant stimulation of the innate immune cells. The depot-effect is therefore dependent on 
numerous factors such as the route of injection, the tissue found at the injection site and 
characteristics associated with the formulation itself such as viscosity and particulate size [54, 
55]. A recent example is the use of the cationic adjuvant formulation (CAF), a combination of 
dimethyldioctadeclammonium/trehalose-6,6-dibehenate (DDA/TDB), currently in phase I 
clinical trial, which is thought to induce long lasting depot effect [56]. 
 
3.2.2 Cellular recruitment and up-regulation of cytokines and chemokines 
Particulate adjuvants have been shown to create a local pro-inflammatory environment 
with the recruitment of immune cells to the site of infection, some of which then transfer the 
antigen to the draining lymph nodes to induce specific immune responses [57, 58]. In fact, 
recent studies on the mechanisms of adjuvants have focused on recruitment of innate immune 
cells at the site of injection involving the increase production of several cytokines, 
chemokines, up-regulation of innate immune receptors and interferon-induced genes [59-61], 
and intensification of antigen transportation to the draining lymph nodes [58, 62, 63]. A 
previous study demonstrated that both Aluminum and an oil-in-water adjuvant named MF59 
induce secretion of chemokines involved in cell recruitment from blood into peripheral tissue. 
Alum appears to act mainly on macrophages and monocytes, whereas MF59 additionally 
targets granulocytes. However, further studies are required to elucidate the detailed 
relationship between recruited immune cells and adjuvant activity. 
 
3.2.3 Antigen presentation and APC maturation  
A crucial step in the induction of adaptive immune response is the antigen 
presentation by MHCs on APCs. In this regard, many adjuvants including alum, oil-based 
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emulsions, and microparticles act by “targeting” antigens to APCs resulting in enhanced 
antigen presentation by MHC [64-66]. Therefore the antigen trafficking from the site of 
injection towards the nearest draining lymph nodes is enhanced [67]. Maturation of DCs is 
essential for T lymphocyte activation and differentiation [54]. Several adjuvants, such as 
Freund’s complete adjuvant, lipopolysaccharide (LPS), liposomes, CpG-ODN, MF59, AS04, 
or a-galactosylceramide (a-GAL), stimulate DC maturation and enhance the expression of 
MHC and co-stimulatory molecules [63, 68-72].  
 
3.2.4 Activation of inflammasomes 
The physical insertion of the needle and vaccine components into the tissue milieu 
leads to tissue damage. In fact, particulate adjuvants cause local tissue damage and cell death 
at the injection site [73]. Cells will inevitably be ruptured and molecules associated with 
tissue damage such as uric acid, nucleotides, adenosine triphosphate (ATP), reactive oxygen 
intermediates, and cytokines are release [58, 63, 74].  
These non-infectious damage signals have been named damage-associated molecular patterns 
(DAMPs) to distinguish them from pathogen-associated molecular patterns (PAMPs). PRRs 
can also be activated by DAMPs initiating specific signaling that trigger non-specific 
activation of the innate immune system, resulting in the production of pro-inflammatory 
cytokines, chemokines and co-stimulatory molecules required for the productive activation of 
the T cell upon antigen presentation [75]. The nucleotide-binding oligomerization domain 
receptors (NLR) family, which includes various other receptors, such as the NODs (NOD1- 
5), NLRPs (NLRP1-14), NLRP1 (NAIP), NLRC4 (IPAF), and the major histocompatibility 
complex II transactivator (CIITA), play a critical role in the assembly and activation of 
inflammasomes, which are large cytosolic multi-protein innate immune signaling complexes 
that activate caspase-1 [76]. This enzyme is crucial for the maturation and release of 
proinflammatory cytokines that in turn play crucial roles in directing host responses to 
infection and injury [77, 78]. 
Consequently, inflammasomes have been one of the most widely investigated topics due to 
their potential role in adjuvant activity. Several studies reported the role of inflammasomes in 
the adjuvant activity of Alum [79, 80], MF59 [81], and monophosphoryl lipid A (MLP) [82]. 
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3.3. Different types of adjuvants 
Various classifications have been proposed for adjuvants in an attempt to better 
understand them. In general, adjuvants can be broadly grouped as antigen delivery systems, 
immunomodulatory molecules and adjuvants formed by both delivery and 
immunostimulatory components [49, 54]. Despite this classification, it is currently accepted 
that some antigen delivery systems may have inherent immunomodulatory properties [49]. 
Table 1 includes some examples of clinical approved adjuvants. 
Immunomodulatory molecules may activate the immune system directly or through 
PRRs. Cytokines, pathogen derived components, as wells as other ligands of innate immune 
receptors, (TLRs, NOD-like receptors, C-type lectins and RIG-I–like receptors), directly or 
indirectly induce the expression of cytokines and chemokines, thereby modulating the local 
microenvironment to activate and stimulate the immune cells [46]. Among the most advanced 
compounds are monophosphoryl Lipid A (MLP) and CpG oligodeoxynucleotide (ODN). The 
first comprises part of the adjuvant system in the Cervarix HPV vaccine against human 
papillomavirus and the second is the adjuvant in the Hepislav vaccine candidate for hepatitis 
B [83, 84].  
In contrast, particulate delivery system, such as alum, liposomes, emulsions and other 
particulates, generally work by promoting the uptake of co-administered antigens into APCs 
[50]. The combination of imunomodulatory molecules coupled to a delivery system provides 
a great opportunity since generally antigens are not adequately immunogenic and co-
administration of successful adjuvant is crucial for the establishment of precise immune 
responses [48, 85]. In fact, an essential point in the investigation of modern adjuvants is not 
only the initiation of a potent immune response but mainly targeting APCs receptors to 
achieve such response, avoiding as much as possible the toxicity associated. Moreover, the 
ideal adjuvant should be able to promote an antigen-specific immune response, and should be 
nontoxic, biocompatible, readily biodegraded and eliminated, inexpensive to produce, stable 
before administration, and physicochemically well defined to facilitate quality control 
important to ensure reproducible manufacturing and activity [86].  
 
3.4. Delivery systems for use in vaccine formulations 
A description of the most well-known delivery systems used in vaccination strategies, 
aluminium-based adjuvants, polymeric nano and microparticles, emulsions, 
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immunostimulating complexes (ISCOMs), virosomes, virus like particles (VLP) and 
liposomes follows below.  
 
3.4.1 Aluminium-based adjuvants  
Aluminium based mineral salts, normally known as alum, were originally identified as 
adjuvants in the twenties [87] and remain the most widely used vaccine adjuvants with 
granted approval for human administration. Aluminium hydroxide (Al(OH)3), aluminium 
phosphate (Al(PO)4) and aluminium potassium sulphate (KAl(SO4)2) constitute the general 
range of salts included in this group [88]. In addition to their inherent adjuvant activity, 
aluminium salts function as delivery systems and consist in general of crystalline 
nanoparticles that aggregate to form a heterogeneous dispersion of particles of several 
microns. They are highly charged and conducive to the adsorption of antigens or 
immunomodulatory molecules [49, 66, 89, 90]. Indeed, it is widely accepted that physical 
association between aluminium and the antigen is required for the vaccine adjuvanticity to be 
retain [91].  
Aluminium adjuvants elicit strong humoral immune responses, which are mediated 
primarily by secreted antigen-specific antibodies, particularly IgG. However they are 
relatively poor inducers of cell-mediated immune responses, being predominant activators of 
Th2 biased immunity, and therefore unsuitable for use in vaccines where strong cellular 
immunity is essential [92, 93]. 
Albeit the substantial progress in understanding aluminium salts mode of action their 
mechanism are still poorly understood. In general, it is accepted that alum absorption prevents 
the rapid removal and degradation of antigen and enhances cell uptake [62, 94]. In addition, a 
wide range of literature strongly suggests that injection of alum leads to tissue damage and 
cell death with release of endogenous danger signals and inflamassome activation [73, 76, 88, 
95]. 
Currently, aluminium adjuvants are in clinical used in several vaccines alone or in 
combination with immunomodulatory molecules, such as Cervarix vaccine that contains MPL 
and aluminum salt (combination known as AS04) (Table 1) [6, 90, 96].  
 
3.4.2 Polymeric nano and microparticles 
Particles prepared from biodegradable and biocompatible polymers have been 
evaluated for drug delivery since the early 1980s [97]. Polymeric nanoparticles are colloidal 
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carriers and can be divided into two categories: nanocapsules and nanospheres depending on 
the preparation method used [98]. Nanocapsules are vesicular systems in which the antigen is 
confined to a cavity surrounded by a polymer membrane, whereas nanospheres are polymeric 
matrix in which the antigen is physically and uniformly dispersed [99].  
Polymers including poly (α-hydroxy acids), poly (amino acids), or polysaccharides 
can be used for preparation of this nanoparticles. Poly (lactic-co- glycolic acid) (PLGA) or 
poly (lactic acid) (PLA) are the most commonly used poly (α-hydroxy acids), which are often 
synthesized using a double emulsion-solvent evaporation technique [100-102]. Among others, 
Poly(γ-glutamic acid) (γ-PGA) is the most well known poly (amino acids) with unique 
characteristics of enzymatic degradation and reduced immunogenicity [103]. In addition, 
hydrophilic polysaccharide polymers such dextran and chitosan are also good candidates for 
vaccine delivery [104-107]. 
Despite the numerous efforts, polymeric nanoparticles have not yet been approved as 
vaccine adjuvants despite extensive efforts over the past years. However, scale up, processing 
and manufacturing are already in place for this technology [108]. Their adjuvant effect is 
associated with their rapid phagocytosis by macrophages and dendritic cells and prolonged 
antigen presentation in vitro [109, 110]. The surface of these nanoparticles can be conjugated 
with antibodies or other specific ligands to improve tissue, cellular, or subcellular targeting 
specificity [86]. Moreover, these nanoparticles have the potential to co-delivery adsorbed 
antigens and entrapped immunomodulatory molecules that activate APCs and induce 
subsequent T-cell immunity and can act as depot from which the encapsulated antigen is 
gradually release [111-113]. 
 
3.4.3 Emulsions 
An emulsion is a mixture of two non-miscible liquids. One liquid is dispersed, as the 
internal phase, in another liquid, the continuous outer phase. An emulsifier is required as a 
substance that stabilizes the emulsion by increasing its kinetic stability. Depending on the 
water-to-oil ratio, the type of emulsifier, and the mixing procedure, a water-in-oil (W/O) or an 
oil-in-water (O/W) emulsion may be produced [114]. Emulsion adjuvants have been use since 
1940s in vaccine formulation, dating back to the initial studies with Freunds’s adjuvants 
[115].  
Freund’s complete adjuvant (FCA) is a mixture of mineral oil (Marco 52) and 
emulsifier (Arlacel A, mannide monooleate) prepared as an emulsion of 85% mineral oil and 
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15% emulsifier with 500 µg of heat-killed and dried Mycobacterium tuberculosis per milliliter 
of emulsifier mixture. FCA is effective in stimulating cellular immune response and may lead 
to the potentiation of the production of IgG and IgA however undesirable side effects are 
associated, such as increased pain and suffering [115]. The incomplete form IFA induces 
predominantly a Th2-biased response through the formation of a depot at the injection site 
and the stimulation of antibody producing plasma cells [116-118]. Both Freund’s adjuvants 
are only use for research proposes. 
The MF59 is the first oil-in-water adjuvant to be developed and approved for use in 
human vaccines in 1997 in combination with a seasonal influenza vaccine. It has the property 
of rapid recruitment and activation of helper CD4+ cells [119]. This successful adjuvant is 
composed by squalene, polyoxyethylene sorbitan monooleate (TweenTM 80), and sorbitan 
trioleate [120]. In response to MF59 injection APCs are recruited and up-regulation of 
multiple inflammatory cytokines, chemokines, receptors and genes responsible for antigen 
processing and presentation occurs [60]. However like alum, MF59 is predominantly a Th2 
inducer [5]. Moreover, despite their excellent adjuvant effect, there have been reports that 
post-immunization reactions associated with emulsion adjuvants are becoming more frequent 
[46, 121].  
Despite this, completely biodegradable squalene oil is currently a component in 5 
approved o/w adjuvanted vaccines, Fluad® (MF59 adjuvanted seasonal influenza), Aflunov® 
(MF59 adjuvanted prepandemic influenza), Focetrea® (MF59 adjuvanted pandemic 
influenza), Prepandrix® (AS03 adjuvanted prepandemic influenza), and Pandremix® (AS03 
adjuvanted pandemic influenza) [50].  
Furthermore, several emulsions have been investigated using different families of 
natural oils in order to find a more stable, potent and less toxic formulation, such as 
Montanide [122] and W805EC a soybean based emulsion [123].  
 
3.4.4 ISCOMs 
ISCOMs are particulate antigen delivery systems composed by cholesterol, 
phospholipid and saponin forming cage-like structures [124]. Generally, the immunological 
potency of ISCOMs is linked with the marked adjuvancy of Quillaja saponins [125]. Loading 
of protein antigens to ISCOM matrices results in more potent immune responses, presumably 
because antigen and immunostimulatory Quillaja saponins are taken up by the same APC 
[126, 127].  
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ISCOM vaccines have been extensively studied with regard to their immunogenicity 
and it has been demonstrated that such vaccines are able to retained the adjuvant activity of 
the Quillaja, while increasing its stability, reducing its hemolytic activity, and producing less 
toxicity [128]. Furthermore, less antigen and adjuvant are required in ISCOMs vaccines for 
induction of protective immunity in the host when compared with vaccination with a simple 
mixture of free antigen and saponins/antigen. Indeed, both Th1 and Th2 responses are 
induced to a wide range of antigens in different animal models using this type of delivery 
systems [129-131]. As limitation, ISCOM technology is challenging because most soluble 
proteins do not usually contain exposed hydrophobic regions and are therefore difficult to 
incorporate into ISCOM structure [132]. 
 
3.4.5 Virosomes 
Virosomes are prepared with solubilized viral spike glycoproteins reconstituted with 
phospholipids, forming unilamellar structures with a typical mean diameter of 150 nm.  
 The antigen is incorporated in these empty enveloped particles, which results in enhanced 
immunogenicity. The greatest advantage of these delivery systems is the exposure of viral 
proteins on their surface, which may help antigen uptake and immune cell activation [133]. 
Even though the basic principle is applicable to any enveloped virus, influenza virosomes 
remain the only virosome type applied in clinical stage vaccine candidates and in licensed 
products. The first of these was EpaxalTM, a hepatitis A vaccine registered in 1994 in several 
European, Asian and South American countries [134]. 
 
3.4.6 Virus like particles (VLPs) 
Noninfectious and non-replicating VLP constitute another delivery system for 
antigens. VLP are self-assembling nanoparticles of approximately 20-100nm made from 
recombinant viral envelop and/or capsid proteins capable of displaying multiple antigen 
peptides on their surface [135]. While virosomes use the envelope phospholipid bilayers as a 
platform to which additional viral components or antigens are attached, VLPs are self-
assembled viral capsid proteins [4]. The morphology and cell penetrating ability is similar to 
infective viral particles.  
VLPs promoted uptake by APCs via endocytosis and stimulate both cellular and humoral 
immunity [136, 137]. The success of VLPs is well exemplified by the vaccine already 
approved for human papillomavirus (HPV) (GardozilTM) (USA) [138, 139]. 
GENERAL INTRODUCTION 
_________________________________________________________________________________________________________________ 
 
	   27	  
4. LIPOSOMES 	  
Liposomes are, without any doubt, the most studied vesicular systems for drug delivery. 
The hematologist Alec Bangham described liposomes essentially as bilayer vesicles 
composed of lipids, with or without additional lipophilic components, that in aqueous systems 
could form closed bilayer structures [140]. Since their discover liposomes moved a long way 
from being just another exotic object of biophysical research to becoming a pharmaceutical 
carrier of choice for numerous practical applications [141].   
 
Table 2: Liposome-based drugs currently in clinical use. 
Liposome	  formulation	   Target	  disease	   Drug	  name	   Lipids	  used	   Company	  	  Liposomal	  Amphotericin	  B	  	   Fungal	  Infection	   Abelcet	   DMPC	  	  DMPG	  
Enzon	  Pharmaceutical	  (USA)	  	  	  Liposomal	  Amphotericin	  B	  	   Fungal/Protozoal	  infection	   AmBisome	  
PC	  Cholesterol	  	  DSPG	   Gilead	  Sciences	  	  (USA)	  	  Liposomal	  Amphotericin	  B	  	   Fungal	  Infection	   Amphotec	   Cholesterol	  
Sequus	  Pharmaceuticals	  (USA)	  
Liposomal	  Cytorabine	   Malignant	  lymphomatous	  meningitis	   DepoCyt	  
	  DPPG	  	  DCPC	  Cholesterol	  
Skye	  Pharma	  (UK)/Enzon	  Pharmaceutical	  (USA)	  	  Liposomal	  Daunorubicin	   HIV-­‐related	  Kaposi’s	  Sarcoma	   DaunoXome	   DCPC	  Cholesterol	   Galen	  	  (Ireland)	  Liposomal	  Doxorubicin	   Metastatic	  breast	  cancer	   Myocet	   DCPC	  Cholesterol	   Zeneus	  Pharma	  	  (USA)	  
Liposomal	  Morphine	   Post-­‐surgical	  analgesia	   DepoDur	   DPPG	  DOPC	   Pacira	  Pharmaceuticals	  (USA)/Skye	  Pharma	  (UK)	  	  Liposomal	  Vertepofin	   Macular	  degeneration	   Visudyne	   Egg	  PG	  DMPC	   Novartis	  	  (Switzerland)	  	  Liposome	  PEG-­‐Doxorubicin	   HIV-­‐related	  Kaposi’s	  Sarcoma,	  Breast	  &	  Ovarian	  cancers.	   Doxil	   DSPE	  HSPC	  Cholesterol	   Merck	  (USA)	  
DMPC:dimyristoylphosphatidylcholine ; DMPG: 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol 
DCPC: distearoylphosphatidylcholine; Egg PG: egg phosphatidylglycerol; 
DSPG: 1,2-Distearoyl-sn-glycero-3-phosphoglycerol, sodium salt 
DPPG: 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol; DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine 
DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; HSPC: hydrogenated soy phosphatidylcho 
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Gregoriadis was the pioneer on the subject and highlighted the ability of liposomes to 
entrap drugs [142], revealed the ability of liposomes to induce immune responses to 
incorporated or associated antigens [143-145], described methods to improve liposomal 
stability [146] and discussed the difficulties associated with liposomal clearance in vivo [147, 
148]. Since then, liposomes have become important carrier systems and the interest for 
liposome-based vaccines has markedly increased. Moreover, liposomes are known to be safe 
and well tolerated as shown by the extensive use of approved liposomal-based drugs (Table 
2). 
 
4.1. Self- assembling of lipids 
Molecular self-assembly can be defined as the process of spontaneous and reversible 
association of molecular species to form larger, more complex supramolecular entities 
according to the intrinsic characteristics contained in their components [149]. 
Liposomes, are colloidal micro- or nano-structures formed by self-assembly of lipid 
amphiphiles in water resulting in a bilayer of lipid surrounding an aqueous core [150]. The 
amphiphilic nature of lipids, a nonpolar hydrophobic tail covalently linked to a polar 
hydrophilic moiety, defines the way in which liposomes assemble. In most lipids the 
hydrophobic part consists of hydrocarbon chains, while the hydrophilic part consists of what 
is called a polar headgroup, that depending on the lipid composition can either have a net 
negative (anionic), neutral or positive (cationic) surface charge [151]. Above a critical lipid 
concentration, known as critical vesicle concentration (CVC), and in order to minimize the 
exposure of the hydrophobic tails to water, the polar heads form a single layer of lipid, with 
the nonpolar tails in touch with each in the central zone of the layer, which ideally results in 
bilayer formation. Intermolecular polar interactions, such as electrostatics and hydrogen 
bonding, can also occur and help define the structural specificity [152-154].  
As delivery systems, the liposomes most important feature is the ability to encapsulate 
hydrophilic drugs inside the water compartment and to incorporate hydrophobic drugs into the 
liposome bilayer [155].  
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4.2. Lipid polymorphism 
The actual form assumed by an aggregate depends on the molecular constitution of the 
amphiphilic and is highly dependent on its geometry. The fact that lipids assemble in closed 
structures or phases, for minimization of exposure of the hydrophobic tails to water, leads to 
an increase in membrane curvature. The phase behavior can be predicted by comparing the 
area of the polar group relative to the length of the nonpolar tail of the lipid. Generally, a 
simple geometric property of the lipid molecule, the so-called Israelachvili–Mitchell–Ninham 
packing parameter, p = v /a × l, can be applied for determination of the self-assembled 
morphology. In the equation, v is the molecular volume, a is the cross-sectional area of the 
head group, and l is the length of the molecule [156-158]. Consequently, for p values close to 
1, lipids exhibit cylindrical shape, having nearly equal headgroup to hydrocarbon proportions 
and are perfect for bilayer forming (Figure 2). Lipids with cone-like geometry with a large 
headgroup area and a small hydrocarbon tails, presents a p<1/3 and self-assemble into 
spherical micelles with a positive membrane curvature. For 1/3 <p< 1/2 cylindrical micelles 
are formed and for 1/2<p<1 perfect bilayers vesicles assemble. When p >1, the hydrophobic 
body is much larger than the polar head of lipid, resulting in inverted micelle formation such 
as the inverted hexagonal (HII) phase or cubic phases that are said to exhibit negative 
membrane curvatures [159]. Furthermore, the effective molecular shape and consequently 
lipid phase behavior can also be modulated by changes in hydration, state of ionization, 
presence of divalent cations and temperature [160]. 
 
 
Figure 2: Relationship between the packing parameter (p) and the self-assembled morphology of amphiphilic 
molecules under aqueous conditions (adapted from Elizondo et al. 2011 [161]). 
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4.3. Lamellar phase transitions  
A lipid bilayer is not static but is a dynamic surface. Consequently, lipids can diffuse 
over the lipid plane and the faster they do this, the more fluid the membrane is [162, 163]. 
Effectively, lipid physical state can change from gel phase to liquid phase, at a particular 
phase transition temperature (Tm), that is mainly dependent on chemical composition of the 
bilayer, in particular on the length and saturation of the lipid tail, number and saturation of the 
acyl chain and the size and ion strength of the headgroup. The gel phase, solid-ordered state, 
is characterized by tightly packed tails neatly ordered where only little diffusion is possible, 
making the membrane more rigid. When the temperature is raised the tails are more fluid but 
still ordered (intermediate phase) till Tm is reached and the membrane passes into the fluid 
phase (disordered state) where the tails are less organized and the membrane is more fluid and 
has a higher permeability (Figure 3). Therefore, lipids with a high Tm are more tightly packed 
because the phase equilibrium shifts to the gel phase [162-164]. Thus, liposomal formulations 
should be prepared above the transition temperature of lipid mixture in order to allow the lipid 
to hydrate in its fluid permeable phase. 
 
 
Figure 3: Illustration of the lipid bilayer structure as the temperature is increased above the lipid bilayer 
transition temperature. 
 
4.4. Liposome preparation methods 
A varied range of lipids with well-characterized biophysical behavior can be used for 
liposome formation. In fact, a key advantage of liposomes is their versatility and plasticity. 
Thus, selecting the appropriate combination of lipids and the method of assembly provides 
control over liposome macrostructures, biophysical characteristics, and subsequent in vivo 
behavior [165].  
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The correct choice of liposome preparation method should depend on the following 
parameters: the physicochemical characteristics of the drug to be entrapped and of the lipid 
mixture, the nature of the solvent in which the liposomes will be dispersed, the effective 
concentration of the entrapped drug, its potential toxicity and ultimately the application 
purpose. In addition, the method should proportionate optimum size, polydispersity and shelf-
-life of the liposomes according to the intended application and batch-to-batch reproducibility 
and possibility of large-scale production of safe and efficient liposomal products [166, 167].  
The more representative liposome preparation methods used are thin film hydration 
method, the reverse-phase methods and the detergent depletion method. In the different 
methods, the drug can be loaded simply by adding it to lipid mixture in the organic solvent, 
dissolving it in the aqueous solution or added to the liposome dispersion. After formation of 
liposomes other techniques can be applied to improve loading, normally the freeze/thaw cycle 
method or the dehydration–rehydration procedure. Moreover, in order to further control the 
size, lamellarity, and homogeneity other methods can be performed post-formation of 
liposomes, such as sonication and extrusion [161].  
Actuality, liposomes can be classified according to their size and lamellarity, which 
are important structural parameters that need to be controlled, since they are crucial factors 
affecting the performance of liposomes [168]. These structural properties can be fully 
explored depending on the preparation method applied. In this manner, according to their 
diameter (d) liposomes can be classified as small unilamellar vesicles (SUVs, d ≤ 200 nm), 
large unilamellar vesicles (LUVs, d ≥ 200 nm), multilamellar vesicles (MLVs 500 ≤ d ≤ 1000 
nm) composed of concentric layers of bilayers, or multivesicular vesicles (MVVs. 500 ≤ d ≤ 
1000 nm) composed of eccentric layers of bilayers (Figure 4) [161, 169]. 
 
 
 
Figure 4: The different types of liposomes according to their size and lamellarity. SUV, small unilamellar 
vesicle; LUV, large unilamellar vesicle; MLV, multilamellar vesicle; MVV, multivesicular vesicle.  
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4.4.1 Thin film hydration or Bangham method  
This method is the most widely used technique for liposome formation. A mixture of 
lipids is dissolve in an organic solvent such as ethanol or chloroform. The solvent is removed 
by rotatory evaporation, at reduced pressure, and the formed dried lipid film is hydrated with 
a pre-heated, above Tm of the lipid mixture, aqueous solution. This technique provides large 
and nonhomogeneous multilamellar vesicles (MLVs) with low encapsulation efficiencies 
[140, 170].  
 
4.4.2 Reverse-phase methods  
The reverse-phase methods include the reverse-phase evaporation (REV) method and 
the solvent injection method. The REV method consists of adding a small volume of aqueous 
phase to an organic solution of the lipids and results on the formation of inverted micelles. 
Removal of the organic solvent by rotatory evaporation generates a viscous gel that collapses, 
yielding an aqueous suspension of MLVs [171]. The solvent injection method starts by slowly 
injecting a solution of lipids in ethanol or ether into an aqueous phase with continuous 
vortexing, which forces the organic solvent to evaporate or disperse and lipid molecules to  
self-assemble in the aqueous phase [172]. Reverse-phase techniques present higher 
encapsulation efficiencies than thin film hydration, however they are limited by the solubility 
of the lipids in the organic phase, the subsequent removal of the solvent from the final 
preparation and the impossibility to control the morphology of formed liposomes, that can 
range from SUVs to MLVs [161]. 
 
4.4.3 Detergent depletion method 
This method involves the formation of detergent–lipid micelles by the hydration of a 
lipid film with a detergent solution and results in the production of LUVs. The micelles 
coalesce and the lipids adopt a bilayer configuration forming sealed vesicles after detergent 
removal. The most common methods for detergent depletion are dialyses, dilution and gel 
filtration. However, a major problem associated with of this technique is the difficulty in 
removing the detergent. In addition, low trapping efficiency and length of preparation limit 
their use [173, 174]. 
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4.4.4 Freeze/thaw cycle  
This method is based on repeated cycles of rapid freezing of liposome dispersion, 
normally using liquid nitrogen, followed by thawing in warm water. It is often used for 
improving the loading when liposomes are formed using hydration method, resulting in 
MLVs. As a result, other techniques are need for the production of homogeneous SUVs. 
Industrial production is not easily viable since its reproducibility and yield are low, requiring 
multiple time- and energy-consuming steps to reach the final product [175].  
 
4.4.5 Dehydration–rehydration procedure  
Described by Kirby and Gregoriadis, this method involves the freeze-drying or the 
lyophilization of preformed vesicles dispersed in an aqueous medium with the drug followed 
controlled rehydration. During the drying process, lipid vesicles are concentrated 
concomitantly with solute, and at some point, fuse into large aggregates containing the drug to 
be trapped. Since the drug is already present in many of the interbilayer spaces when 
rehydrating, efficient trapping occurs. The method results in the production of MLVs with 
high trapping efficiency, however heterogeneous systems with low sample reproducibility are 
formed [176]. 
 
4.4.6 Sonication 
Sonication is applied to the aqueous lipid dispersion by bath sonication or probe 
sonication. The ultrasounds disrupt the lipid bilayers of the large vesicles and leads to the 
formation of relatively homogenous population of SUVs. As the SUV form the lipid 
suspension begins to clarify yielding a slightly hazy transparent solution. The haze is due to 
light scattering caused by residual large particles remaining in the suspension. As main 
drawbacks of this technique are the use of probe tip sonicators which deliver high-energy 
input to the lipid suspension often causing oxidation and degradation [177, 178].  
 
4.4.7 Extrusion  
Lipid extrusion is a technique in which a lipid suspension is repeatedly forced through a 
polycarbonate filter with a defined pore size to yield particles with diameters near the pore 
size of the filter. It is primarily used to homogenize the dispersion followed by downsized the 
dispersion according to the size of the filter used. The main disadvantages of the extrusion 
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method are loss of material in the filters, the difficulty in maintain a high temperature (above 
lipid phase transition temperature), the extended time needed and the low working volumes of 
liposome dispersions [179, 180]. 
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5. CATIONIC LIPOSOMES  	  
The emphasis during the course of this thesis is the use of cationic liposomes, so they 
will be further analyzed.  Cationic liposomes can be prepared using cationic lipids (mainly of 
synthetic nature) alone or in combination with a helper lipid, typically used for improvement 
of the membrane liposome stability and decrease the toxicity that is generally associated with 
cationic lipids.  
 
5.1. Cationic lipids 
Cationic lipids are amphiphilic molecules that structurally consist of a hydrophobic 
domain, a cationic polar head-group, and a linker group connecting the polar head-group with 
the non-polar tail [181].  
In general, the different types of headgroups fall into the following categories: 
primary, secondary, tertiary amines or quaternary ammonium salts and guanidinium salts, 
amidine, as well as heterocyclic ring. The hydrophobic domains are mainly derived from 
either simple aliphatic hydrocarbon chains or steroid [182]. 
Cationic lipids with double-chain hydrocarbons in the hydrophobic domain represent 
the majority of cationic lipids synthesized so far because they are capable of forming 
liposomes by themselves or with a helper lipid. Therefore, most of the aliphatic chains in the 
cationic lipids are double-tailed. In addition, the hydrophobic domain of cationic lipids 
determines the phase transition temperature and the fluidity of the bilayer, and influences the 
stability and toxicity of liposomes [183].  
The linker group that bridges the cationic lipid headgroup with the hydrocarbon 
moiety controls the biodegradability of a cationic amphiphile. Most of the linker bonds are 
ether, ester, or amide bonds [184].  
The chemical structure of the most common cationic lipids used for liposomes 
production with immunostimulatory abilities are represented in the Figure 5.  
 
CHAPTER II 
_________________________________________________________________________________________________________________ 
	  36	  
 
Figure 5: Cationic lipids already described as potential vaccine adjuvants. Diagrams were obtained from 
www.avantilipids.com.  
DODAB: N,N-dioleyl-N,N dimethylammonium bromide;  
DODAP: 1,2-dioleoyl-3-dimethylammonium-propane;  
DOTMA: 1,2-di-O-octadecenyl-3-trimethylammonium propane;  
DOTAP: 1,2-dioleoyl-3-trimethylammonium-propane;  
DC-Chol: 3β-[N-(N',N'- dimethylaminoethane)-carbamoyl] cholesterol hydrochloride.  
 
5.2. Cationic liposomes as antigen delivery systems 
Liposomes were first described as being able to act as immunological adjuvants by 
Allison et al in the mid-1970s [143]. Since them, several advantages were found in the use of 
liposomes as adjuvant delivery systems. It is widely accepted that physical association 
between the liposomes and the antigen is a general prerequisite for adjuvanticity to occur 
[185]. The antigens can be entrapped within the liposomal aqueous compartment, 
electrostatically adsorbed onto the bilayer surface or hydrophobically inserted into the lipid 
structure, which allows a wide range of antigens (including peptides, proteins, carbohydrates, 
nucleic acids and haptens) to be incorporated in the liposome formulations. Either way 
liposomes offer antigen protection against host enzymatic degradation. The most important 
feature of liposomes, as vaccine delivery systems, is their natural ability to be avidly taken up 
by APCs, which promotes not only the antigen ingestion but also their processing and 
presentation on MHC molecules [181, 186-188]. Furthermore, due to liposomes flexibility 
and versatility, formulations can be tailored in terms of lipid composition, liposomal charge, 
size/lamellarity, and/or membrane fluidity in order to obtain optimal retention and 
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presentation of the vaccines antigens, leading to the desire vaccine-specific immune 
responses.  
In particular, the surface charge of liposomes has a major importance in the immune 
response, with cationic liposomes having an advantage over their neutral and anionic 
counterparts. Indeed, the high surface density of positive charges offers an important platform 
for antigen adsorption due to electrostatic interactions. Moreover, the interaction between the 
positively charge liposomes and the negatively charged membranes of APCs enhances 
liposome uptake increasing the vaccine potency without the need to increase the concentration 
of antigen [189-192]. 
A wide range of cationic liposomes has been shown to mediate immunostimulatory 
effects. For example, DOTIM (octadecenoyloxy[ethyl-2-heptadecenyl- 3-hydroxyethyl] 
chloride) is the cationic lipid used for preparation of  the cationic liposome complex CLDC, 
which is prepare by mixing liposomes with DNA. Several CLDC vaccines have been tested 
[193-196], and in particular, CLDC combined with cholesterol shows promise results as an 
adjuvant for human pre-pandemic inactivated H5N1 virus [193]. DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane) nanoliposomes containing soluble Leishmania antigens not 
only induced a Th1 type of immune response but also mediated protection against L. major, in 
BALB/c mice [197]. DC-Chol [N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol) 
liposomes were also used in several strategies alone or mixtured with other lipids, proving 
their potential as immunomodulators by forming an antigen depot at the site of injection 
(SOI) and inducing immunological recall responses against coadministered tuberculosis 
vaccine antigen Ag85B-ESAT-6 [190] or by inducing protection in mice against Helicobacter 
pylori [198]. Several other cationic lipid adjuvant complexes were evaluated in various 
vaccine models and recent reviews report their effects [181, 192, 199-201]. 
 
5.2.1 DODAB liposomes as adjuvants 
The focus throughout this thesis, is on N,N-dioleyl-N,N dimethylammonium bromide 
(DODAB). DODAB is a cationic surfactant that was first synthesized by Kunitake and 
Okahata, who prepared and characterized small unilamellar DODAB vesicles [202].  
DODAB exhibits a hydrophobic group consisting of two 18-carbon-long acyl chain 
(C18:0) linked to a stable quaternary ammonium headgroup carrying the positively charged 
monovalent counterion bromide [203, 204]. The phase behavior of this lipid has been 
extensively studied [205, 206] thus its physicochemical characteristics can be easily 
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controlled, making it straightforward to design DODAB-based formulations with specific 
molecular structures. Due to its amphiphilic character, DODAB can form liposomal structures 
when dispersed in aqueous media above its relatively high Tm (Tm = 44 °C) [207] with an 
enthalpy of 47.4 kJ/mol [208]. In addition, DODAB presents a pretransition temperature (Tp) 
due to the tilting of the DODAB chains prior to the melting temperature [208]. 
Over the years, DODAB has been used for different applications in drug [208-213] 
and vaccine delivery [214-217]. The DODAB immunological properties were first observed 
by Gall in the mid-1960s [218]. The author tested a wide range of compounds for their ability 
to adjuvant diphtheria or tetanus toxoids in guinea pigs. In the surfactants compound group, 
Gall observed increased adjuvanticity for those expressing cationic quaternary ammonium 
head groups and long alkyl chains. Since then, DODAB liposomes have been tested in 
combination with a wide range of other molecules and their immunological proprieties 
explored. DODAB is known to enhance antigen uptake [219], induce cell-mediated immunity 
and delayed-type hypersensitivity [220] and capable of promoting a depot effect at the 
injection site (both after subcutaneous or intramuscular injection) longer than neutral 
liposomes [56, 190]. In the mouse model, the depot effect was accompanied by a stronger Th1 
response characterized by IFN-γ production and IgG2 antibody titers and a general bias 
towards humoral immunity [56, 189, 190, 221-223]. In fact, the particular case of DODAB 
plus trehalose dibehenate (TDB) cationic liposomes, known as CAF01, have been extensively 
characterized and their potential as strong adjuvant system for vaccines against a wide range 
of diseases evaluated, showing particular promising results as a vaccine against tuberculosis 
[217, 224-227]. In another strategy also in a formulation for tuberculosis-unit vaccines 
DODAB was used in combination with monophosphoryl lipid A (MPL) promoting elevated 
immune responses [228, 229]. A formulation containing DODAB liposomes with 
monophosphoryl lipid A (MPL) or with trehalose 6,6'-dibehenate (TDB) were used as 
adjuvants and Chlamydia T cell antigens as molecular subunits and elicited protective 
immune responses when used in a vaccine strategy against Chlamydia [230]. In another study, 
the combination of DODAB with a major antigen of Paracoccidioides brasiliensis resulted in 
the lowest numbers of viable yeast cells in comparison with the use of other adjuvants such as 
aluminum hydroxide, CFA or flagellin in previously infected mice with P. brasiliensis [231]. 
Quil A cholesterol in combination with DODAB were used for the enhancement of Bovine 
viral diarrhea virus killed vaccines and elicited higher viral neutralizing antibodies levels and 
reduced injection site inflammation [232]. In other study, DODAB was used to enhance the 
efficacy of a DNA vaccine against pseudorabies virus and the authors demonstrated that only 
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DODAB, but not other adjuvants (such as CpG immunostimulatory motifs), induced 
significantly stronger immune responses than plasmid vaccination alone [233].  
5.2.2 The use o monoolein as a helper lipid in DODAB liposomes 
Monooleoyl-rac-glycerol (monoolein, MO) was first proposed as helper lipid in a 
DODAB liposomal formulation as non-viral transfection system [234]. MO is a natural-
occurring neutral surfactant featuring a glycerol polar headgroup attached to a non- polar 
unsaturated acyl chain (C18:1) by an ester bond (Figure 6).  
 
 
Figure 6: Chemical structure of Monoolein (MO). 
 
MO has the ability to exist in several different phases, with one-, two-, and three- 
dimensional periodicity, such as lamellar phases (Lα), inverted micelles (L2), hexagonal (H2) 
and bicontinuous cubic phases, under rather easily accessible temperatures and pressure 
conditions. In particular MO has the peculiarity of forming two inverted bicontinuous cubic 
phases (QIID and QIIG) in excess water (Figure 7) [60, 61]. The cubic phase is said to be 
bicontinuous since it consists of a curved bilayer extending in three dimensions, separating 
two congruent water channel net- works (Figure 7) [235]. 
This polymorphism has been explored in the past in different industrial, scientific and 
technological areas ranging from pharmaceuticals, food, cosmetics and agriculture to protein 
crystallization so serve as a emulsifier, solubilizer, absorption enhancer, ora/parental/vagina 
or periodontal drug delivery system, colloidal carrier system, storage system for protection of 
macromolecules susceptible to degradation and bioadhesive among others (revised by 
Ganem-Quintanar et al) [235].  
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Figure 7: Monoolein phase diagram (right) presenting two inverse bicontinuous cubic phases (illustrated on the 
left) on the high water side of the lamellar Lα phase (adapted from Neves Silva et al. 2008 [234]).Micellar (M), 
hexagonal (H), lamellar (L), cubic (Q). 
 
Phase scan imaging shows that DODAB liposomal formulations benefit from the 
structural richness of MO content, revealing that, at MO higher proportion, DODAB/MO 
liposomes are dominated by densely packed cubic-oriented particles [236]. This improvement 
in the structural complexity of DODAB liposomes can be used for the design of novel vaccine 
delivery systems. However, this is not the only advantage of MO incorporation, the 
introduction of a helper lipid to formulate drugs or vaccines, at reduced doses of the cationic 
lipid, is essential for minimization the cytotoxic effect associated with the charged lipid. 
Effectively, as cationic amphiphilic DODAB exhibits a dose-dependent cytotoxicity, 
requiring dose minimization for administration in vivo [211, 237, 238]. The incorporation of a 
helper lipid with a lower Tm value, such as cholesterol or DOPE, into DODAB liposomal 
membranes has been shown to improved membrane fluidity [236], which in turn leads to an 
improvement in liposome stability both in vitro and in vivo [146]. The transition phase 
temperature of DODAB is relatively high, in fact it is superior to the human physiological 
temperature, which confers to DODAB bilayers a strong rigidity, rendering DODAB 
liposomes an in vivo poor stability. The incorporation of MO in DODAB formulation at a 
higher percentage (MO > 50%) tends to abolish the pretransition temperature (Tp) of 
DODAB. Despite that, a slight increase in Tm is observed upon MO incorporation, which can 
be related to the asymmetric distribution of MO in the bilayer, leading to the formation of 
lipid domains rich in MO (more fluid) and rich in DODAB (more rigid) [208]. However, the 
energy required for the transition phase occur decreases suggesting that fewer molecules 
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contribute to the gel-to-liquid crystalline transition when the MO content is higher than 
DODAB content. In these sense, MO can be incorporated in DODAB liposomal systems for 
membrane stabilization without altering their Tm. This property can be an advantage since 
liposomes using high transition temperature lipids are known to retained a higher percentage 
of antigen at the injection site, thus leading to significantly higher Th1 responses, in 
comparison with liposomes made by low transition temperature lipids [239].  
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6. IS A VACCINATION NEEDED FOR PROTECTION AGAINST  
CANDIDA ALBICANS? 	  
In the design of vaccines against fungal pathogens a good understanding of fungal–
host interactions, including the possible antigen targets as well as innate and specific immune 
responses, is essential for the development of a protective immunity. Undoubtedly, other 
important factor for success in the endeavor to develop future vaccines is the refined selection 
of adjuvants that can direct the immune response toward the desired protective response. 
 
6.1. C. albicans and candidiasis 
The genus Candida is ubiquitous and composed of more than 150 yeast species, yet 
only a few are recognized as opportunistic fungal pathogens [240].  
C. albicans and other Candida species are part of the normal flora of the skin, mucous 
membranes and gastrointestinal tract thus the risk of an endogenous Candida infection is 
always present. Consequently, under certain risk factors, C. albicans is capable of cause 
severe infections [241, 242]. These infections can range from ‘superficial candidiasis’, mainly 
in the skin, nail, oral and vaginal surfaces to ‘systemic or invasive candidiasis’, generally 
located in the respiratory, urinary tract or other internal organs that can disseminate via the 
blood stream (candidemia) and virtually infect any other organ. 
Currently, systemic infections caused by Candida species, mainly caused by  
Candida albicans, represent the fourth leading cause of nosocomial bloodstream infection in 
modern hospitals, despite the administration of antifungal agents that have potent activity in 
vitro and in vivo in preclinical studies. The mortality of affected patients exceeds 30%–40%, 
and thus this type of infection is considered a significant public health problem, indicating 
that disease treatment and prevention measures are failing [243, 244]. 
Several studies have defined the risk factors that predispose patients to developing 
invasive Candida infections. Most of these factors are easily identifiable and precede the 
infection, which open a window of opportunities to vaccinate acutely at-risk patients before 
the onset of infection.  
Generally, susceptibility to infection is enhanced for hospitalized patients submitted to 
procedures that involve: the disruption of the anatomical defenses, including 
surgery/transplantation, cytotoxic chemotherapies, the introduction of central venous 
catheters, parenteral nutrition, the insertion of indwelling devices (for example prosthetic 
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heart valves) which are susceptible to develop biofilms (that are more resistant to drugs and 
capable of greater tissue invasion). In addition, or burn injury and prolonged periods without 
feeding can lead to gut mucosal wasting (from lack of use) and exposure to broad spectrum 
antibiotics, which wipes out the normal bacterial flora and also represent risk factors [245-
254].  
In fact, despite the widespread belief that only immunocompromised patients are 
susceptible to fungal infection, patients with profound defects in immunity (neutropenic, 
corticosteroid-treated, treated with cancer chemotherapy, infected with HIV, etc.) represent 
only 10–20% of occurring Candida disseminated candidiasis [255-257]. And even those 
patients can benefit from vaccination since there is extensive literature confirming the 
immunogenicity and efficacy of vaccines in patients with extremely weakened immune 
systems, for example, those with active leukemia, HIV infections, or receiving immune-
suppressing corticosteroids [258-263].  
Of course commensal host colonization by Candida is the first step in the 
pathogenesis of disseminated candidiasis of endogenous origin. Patients with higher 
colonization burdens and more sites colonized have a proportional higher risk of developing 
candidemia. Indeed, treatments that lower colonization burden simultaneously decrease the 
risk of fungemia [264, 265]. 
 
6.2. C. albicans cell wall surface proteins (CWSP)  
The cell wall of C. albicans is not only a dynamic structure that confers osmotic 
stabilization, protection against mechanical stress and morphological plasticity, important for 
the transitions that many fungi undergo, but is also a significant source of candidal antigens 
[266].  
Structurally, the cell wall is constituted by three major polysaccharides, chitin, glucans 
and mannans (Figure 8). In C. albicans, these polysaccharides are organized as two layers: an 
inner skeletal layer of chitin and β-1,3-linked glucan covalently linked to an outer layer of 
β1,6-glucan [267]. Attached to this meshwork of structural polysaccharides the outer layer is 
enriched with cell wall proteins (CWP). The CWPs are normally highly glycosylated with 
mannose-containing polysaccharides (sometimes called mannan), and carbohydrates can 
account for up to 90% of their molecular mass [268].  
This proteins can be grouped in three main classes, two of them covalently coupled to 
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cell wall polysaccharides: glycosyl-phosphatidylinositol cell wall proteins (GPI-CWPs) are 
the more abundant and generally indirectly linked to β-1,3-glucan through a connecting β-1,6-
glucan moiety, and Pir proteins (proteins with internal repeats, Pir-CWPs), which are 
presumed to be directly linked to β-1,3-glucan through the γ-carboxyl group of glutamic 
acids, arising from specific glutamines [269]. 
 
 
Figure 8: The structure of the Candida albicans cell wall (adapted from Netea et al. 2008 [268]).  
 
The third class of proteins lacks the covalent attachment to the polysaccharide matrix 
and can be released from intact cells using a reducing agent. This suggests that they might be 
disulphide-linked to other cell wall proteins [270, 271].  
Both carbohydrate and protein moieties are able to trigger immune responses [272]. In 
particular, the cell wall proteins of C. albicans are highly glycosylated with elaborate 
carbohydrate structures comprised of α- and β-linked mannose units. Protein mannosylation, 
occurs during protein synthesis in the endoplasmic reticulum (ER) and is further elaborated as 
the protein is passed through the Golgi apparatus [273]. Mannoproteins, including O-
glycosylated oligosaccharide and N-glycosylated polysaccharide moieties, involve 
phosphodiester groups that confer to the outer surface of yeasts numerous negatively charged 
components [274].  
 The glycosylated proteins represent 30-40% of the cell wall dry weight and due to its 
outer location are readily recognized by the host immune cells, triggering and modulating the 
anti-Candida host immune responses, and therefore considered as the most important 
pathogen-associated molecular patterns (PAMPs) of C. albicans [275-277], inducing mainly 
GENERAL INTRODUCTION 
_________________________________________________________________________________________________________________ 
 
	   45	  
Th1-type cytokine profiles [278]. In fact, it is known that cell wall proteins are recognized by 
immune cells and therefore relevant as antigens and vaccine targets [279, 280].  
 
6.3. Immune response to C. albicans infection  
C. albicans is an effective colonizer of the human body, very well adapted to its host. 
The immune system does not remain ignorant of commensal fungi, and so a balanced between 
pro-and anti-inflammatory signals is required for the conservation of such a stable host-fungi 
interaction. For that immune system responses to C. albicans are based in two main strategies: 
resistance and tolerance. The resistance compromises the ability to limit fungal burden, and 
tolerance the ability to limit the host damage cause by the immune response or other 
mechanism [281]. 
The initial mechanism of innate immunity against Candida infections includes the 
barrier function of the skin and mucosal epithelial surfaces [282]. After disturbance of these 
barriers, elimination of fungi by the innate immune cells, especially by macrophages and 
neutrophils, is crucial for impaired host defense against candidiasis. Microbial antagonism, 
defensins, collectins and the complement system also play an important role in the innate 
resistance to fungal infections [283].  
The innate recognition of fungi by phagocytes is achieved largely through the sensing 
of cell wall constituent (Table 3) [268]. Indeed, it is known that alterations in the cell wall 
composition, that varies between different fungal species and between the different 
morphological forms of the same species, affects phagocyte migration towards the fungus 
[284-286].  
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Table 3: Pattern recognition receptors sensing C. albicans PAMPS at the membrane level. 
 (adapted from Brown et al 2011[287] and Netea et al. 2010 [288]) PRR	   C.	  albicans	  PAMP(s)	   Cytokines	  secreted	  	   Type	  of	  response	  TLR2	   Mannan,	  Phospholipomannan,	  GXM	   IL-­‐10,	  TGFβ,	  	  TNF,	  IL-­‐12,	  IL-­‐1,	  1L-­‐6.IL-­‐8	   Treg	  Th1	  TLR4	   Mannan,	  O-­‐mannan,	  GXM	   TNF,	  IL-­‐12,	  IL-­‐1,	  1L-­‐6.IL-­‐8	  IFN	  type	  1	  family	   Th1	  Dectin-­‐1a	   β-­‐1,3-­‐glucan	   IL-­‐12,	  IL-­‐10,	  	  TNF,	  IL-­‐1,	  IL-­‐23,	  Il-­‐6	   Treg	  Th17	  Dectin-­‐2	   α-­‐mannan	   TNF,	  IL-­‐1	   DC	  activation	  
DC-­‐SIGN	   Mannan,	  galactomannan	   IL-­‐10	   	  
Mannose	  receptor	   Mannan,	  N-­‐mannan,	  GlcNAc,	  glycoprotein	   TNF,	  IL-­‐1,	  IL-­‐23,	  Il-­‐6	   Th17	  CD14	   Mannan,	  GXM	   TNF,	  IL-­‐12,	  IL-­‐1,	  1L-­‐6.IL-­‐8	   	  
FcγR	   Mannan,	  GXM	   TNF,	  IL-­‐1,	  IL-­‐23,	  Il-­‐6	   Th17	  
Mincle	   α-­‐mannose	   TNF,	  IL-­‐1,	  IL-­‐23,	  Il-­‐6	   Th17	  
SCARF	   Mannan,	  β-­‐glucan	   TNF/IL-­‐8	   	  
CD36	   β-­‐glucan	   TNF/IL-­‐8	   	  
Uknown	   Chitin	   IL-­‐44	   Th2	  
CD36	   β-­‐glucan	   TNF/IL-­‐8	   	  
Uknown	   Chitin	   IL-­‐44	   Th2	  
 
 
Phagocytic clearance of opsonized and non-opsonized fungal pathogens may be 
considered to consist of four distinct stages; (i) accumulation of phagocytes at the site where 
fungal cells are located; (ii) PAMP recognition through membrane bound and soluble PRRs 
(PRRs involved in C. albicans recognition and the respective cell wall PAMPs are depicted in 
table 3) (iii) engulfment of fungal cells bound to the phagocyte cell membrane, and (iv) 
processing of engulfed cells within phagocytes by fusion with lysosomal vesicles to form the 
phagolysosome, an organelle with acidic pH and several antimicrobial compounds [289]. 
Degradation of phagocytized C. albicans cells is carried out by oxidative mechanisms, 
including generation of reactive oxygen and nitrogen intermediates, as nitric oxide, and by 
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non-oxidative mechanisms, such as antimicrobial peptides [290]. Conversely, in order to 
manipulate host immune responses and survive, or even replicate within the host, fungal 
pathogens employ several strategies to avoid phagocytes recognition and killing by masking 
cell wall PAMPS among others. Moreover, many fungi resist to phagocytic killing producing 
anti-oxidant enzymes, such as catalase and superoxide dismutase, and/or by inducing 
protective responses, such as DNA damage repair systems and heat shock proteins, that help 
the fungal cell cope with oxidative damage [291]. 
One of the major virulence attributes of C. albicans is its ability to reversibly switch 
between yeast and filamentous forms that is known to contribute to the fungus pathogenicity 
[287]. Whereas the yeast form may be the mode of proliferation in infected tissues, the hyphal 
forms are used to adhere and invade epithelial cells during mucosal infections, resulting in 
extensive damage to host cells. Moreover, this yeast to hyphae transitions is also induced 
upon phagocytosis by macrophages, allowing pathogen evasion from immune capture.[292]  
For efficient control of C. albicans infections an activated innate immune system is 
not sufficient. The evidence suggests that both innate and adaptive responses integrate to 
produce effective anti-fungal protection [293, 294]. Upon interaction of fungi with the 
different PRRs, activated phagocytes, such as DCs, initiate the adaptive immune response via 
secretion of pro-inflammatory cytokines and chemokines and presentation of antigens and 
ultimately initiate Th-cell differentiation [295].  
T-cell activation is a crucial step in the development of optimal protective immunity 
against C. albicans.  Although, both CD4+ and CD8+ T cells are necessary for elimination of 
fungal cells, in the primary stages of disease, the presence of CD4+ T cells are important for 
the survival of the host. Although CD8+ T cells are believed to produced cytokines crucial for 
fungal defense their role in candidiasis is not clearly defined [296] .  
It is accepted that antifungal CD4+ T helper 1 (Th1)-mediated responses play a central 
role in C. albicans defenses, providing control of fungal burden through the concerted action 
of several cytokines such and INF-γ (interferon gamma), IL-6 (interleukin 6), TNF-α (Tumor 
necrosis factor alpha), and IL-12, required for optimal activation of phagocytes at the site of 
infection and necessary for the formation of some protective antibodies against the fungus [2, 
281]. Interestingly, though protective immunity against C. albicans is primarily mediated by 
Th1 cells, some Th2 cytokines, such as IL-4 are required for the maintenance of the anti-
fungal immune protection [281, 297, 298]. Regulatory T-cells (Treg) are involved in the 
induction of memory protective immunity by allowing the balance between the two types of 
responses, limiting collateral damage to tissues and restoring a homeostatic environment, 
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down-regulating the antifungal Th1 reactivity. Secretion of IL-10 represents one of the 
mechanisms by which Treg cells mediate suppression and control inflammatory responses 
[299]. Activation of Th17 cells, characterized by the production of interleukin-17 (IL-17), 
also occurs in fungal infections. Th17 cells mobilize neutrophils and induce the production of 
defensins, which greatly contributes to efficient control of an infection at different body sites 
[300].  
Although, cell-mediated immunity is acknowledged as the predominant host defense 
mechanism against fungal infections, antibodies can play a decisive role in the overall 
resistance to fungi [301]. 
The mechanism(s) by which specific antibodies mediate protection against fungi is a 
contentious issue. It has been observed that the protective potential of antibodies with 
enhanced phagocytosis and killing of the fungus is dependent on a multiple and perhaps 
interdependent characteristics such as epitope specificity, isotype, serum titer, and ability to 
rapidly and efficiently fix complement to the fungal surface [302-304]. In this sense, several 
researchers reported antibody-mediated protection against Candida infections, using different 
antigen targets, such as mannans, glucans, heat-shock proteins, Saps, and adhesins, with the 
purpose of producing monoclonal or recombinant antibodies as potential novel treatments 
[305-309]. 
 
6.4. Delivery systems used in C. albicans vaccination strategies 
As proof of interest in the development of vaccines against C. albicans is the 
numerous vaccine candidates that have been reported [310-319]. However, despite extensive 
investigations, only two are in clinical trials, and none have yet been approved by regulatory 
agencies for either active or passive immunization in humans. 
In the effort to use safer and simpler fungal antigens that could be used as novel 
strategies for vaccination, adjuvants have become relevant as immunostimulators to elicit 
successful protective immune responses.  
Several highly innovative strategies that take advantage of delivery systems have been 
published in recent years and the most important will be selectively highlighted herein. Of 
note, is the fact that the majority of this strategies lack the knowledge of the physiochemical 
and biological properties of the particles that are formed after mixing the antigens with the 
delivery systems. However, it is important to consider the adequate selection of adjuvant and 
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antigen, and to characterized and optimized the final particle in order to improve the 
immunogenicity and obtain the desire vaccine-specific immune responses with minimal 
toxicity associated.  
 
6.4.1 C. albicans vaccination strategies that take advantage of aluminium adjuvant 
delivery systems  
NDV-3 is a cell wall protein based-vaccine strategy composed by the N- terminal 
portion of the Candida albicans agglutinin-like sequence 3 protein (Als3p) formulated with 
an aluminum hydroxide adjuvant in phosphate-buffered saline.  Of note is the fact that initial 
studies were preformed using Freund’s adjuvant. Preclinical studies demonstrated that NDV-3 
vaccine antigen protects mice from oropharyngeal, vaginal and intravenous challenge with C. 
albicans and other selected species of Candida. IFN-γ and IL-17A were necessary for 
vaccine-induced protection in mice [320]. Interestingly, ‘cross-kingdom’ protection against 
S. aureaus was demonstrated [321]. The results obtained with this strategy led to a Phase I 
clinical trial in human subjects performed by NovaDigm Therapeutics. NDV-3 proved to be 
safe and generally well-tolerated in healthy adults, eliciting quick and robust B- and T-cell 
immune responses [322]. 
In another strategy the use of the N-terminus of C. albicans cell surface prHyr1 
protein (rHyr1p-N) mixed with alum significantly improved the survival and reduced the 
fungal burden of hematogenously disseminated candidiasis in both immunocompetent and 
immunocompromised mice. Furthermore, using a passive immunotherapy strategy, a pooled 
of rabbit anti-Hyr1p polyclonal antibodies raised against 8 different peptide regions of 
rHyr1p-N, also protected mice from a hematogenously disseminated candidiasis model. These 
antibodies directly neutralized the Hyr1p virulence function, rather than enhanced 
opsonophagocytosis for subsequent killing by neutrophil in vitro. Both active and passive 
immunization novel strategies against Candida infections can be design using the rHyr1p-N 
vaccine [323].  
 
 
6.4.2 C. albicans vaccination strategies that take advantage of emulsions adjuvant 
delivery systems  
Lam–CRM conjugate is a vaccine formulation design to protect against a variety of 
human pathogenic fungi, including C. albicans, and is based on laminarin (Lam), a well-
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characterized but poorly immunogenic β-glucan from the brown alga Laminaria digitata, 
conjugated with the nontoxic mutant protein of diphtheria toxin CRM197 (a carrier protein 
used in some glyco-conjugate bacterial vaccines), using Freund’s Complete Adjuvant (FCA) 
as an adjuvant. This Lam–CRM conjugate proved to be immunogenic and protective against 
both C. albicans systemic and vaginal infections in mice. Furthermore, the protective role of 
the anti-β -glucan antibodies was confirmed when passive transfer of whole immune serum, 
immune vaginal fluid, and the affinity-purified anti-glucan IgG fractions provided protection 
in naive mice [307]. 
MF59, the oil-in-water adjuvant, has been also tested in combination with Laminarin-
CRM conjugate in various experimental vaccines. Administrated systemically, this 
adjuvanted conjugate stimulated protective immune responses against vaginal candidiasis 
[324]. The protection was associated with the production of serum and vaginal anti-β-glucan 
IgG antibodies as inferred by the efficacy of passive transfer of immune vaginal fluid and 
passive protection by an anti-β-1,3-glucan mAb [324].  
Another highly innovative approach against Candida infections has been developed by 
Xin et al. [325]. These investigators synthetize six peptides from C. albicans cell wall 
proteins and conjugated which one with fungal cell wall β -mannan trisaccharide emulsified 
in CFA creating six new adjuvanted glycopeptide conjugates. Five conjugates protected mice 
against murine disseminated candidiasis using a dendritic cell (DC)-based immunization 
approach. The beta-(Man)(3)-Fba, beta-(Man)(3)-Met6 and beta-(Man)(3)-Hwp1 induced 
protection evidenced by survival and reduced kidney fungal burden, the beta-(Man)(3)-Eno1 
and beta-(Man)(3)-Gap1 gave moderate protection. In particular, for beta-(Man)(3)-Fba 
conjugate, protection was uniquely acquired through immunity against the carbohydrate and 
the Fba peptide.  
 
6.4.3 C. albicans vaccination strategies that take advantage of liposomal adjuvant 
delivery systems  
Multilamellar liposomes were used for encapsulation of a mannan extract from  
C. albicans and used to vaccinate mice. Liposomes based on phosphatidylcholine and 
cholesterol (3.2:1) were used for entrapment of the extract.  Vaccinated mice showed more 
resistance to disseminated candidiasis than did mice vaccinated with the free extract. In 
addition, antiserum from immunized animals protected naive BALB/cByJ mice against  
C. albicans serotype A and B strains and C. tropicalis [326]. 
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In another study, C. albicans cytosolic proteins (Cp) were entrapped either in plasma 
beads, liposomes or in liposomes further entrapped in plasma beads. The efficacy of the 
different formulations in protecting mice against a lethal challenge of C. albicans was 
determined, showing that the preparation containing liposomized Cp entrapped in plasma 
beads was more immunogenic and imparted superior protection in immunized mice, as 
evaluated by the survival rate and fungal burden in systemic circulation and vital organs, 
compared with the results obtain with the Cp entrapped only in plasma beads or only in the 
liposomes. This vaccination strategy successfully elicits desired cell mediated and  antibody 
humoral responses [246].   
Another liposomal vaccine was formulated with C. albicans ribosomes and the lipids 
dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) (9:1 
molar ratio). Some of the evaluated formulations contained lipid-A as an additional adjuvant. 
The efficacy of these vaccines in mice was evaluated using the survival rate against a 
challenge with C. albicans; the induction of delayed type hypersensitivity (DTH) and the anti-
Candida antibody titer. Unimmunized mice and mice vaccinated with ribosomes 
supplemented with Incomplete Freud’s Adjuvant (IFA) were used for comparison. The results 
indicate that the liposomal vaccines were at least as effective as the IFA-based vaccine with a 
survival rate that ranged between 60-80% [327].  
 
6.4.4 C. albicans vaccination strategies that take advantage of virosomes adjuvant 
delivery systems 
A novel vaccine candidate (PEV7; Pevion Biotech) with the aim to prevent recurrent 
vulvaginitis is in clinical trial since 2010. This vaccine is based on a recombinant, truncated 
form of Sap2p, a secreted aspartyl proteinase, incorporated into virosomes. Prior to virosome 
assembly, antigen rtSap2 was conjugated to 1,2-dipalmitoyl-sn- glycero-3-
phosphoethanolamine (DPPE) moieties and then mixed with synthetic lipids and then 
combined with the influenza envelope components at the desired concentration. In a rat model 
of candidal vaginitis, PEV7 induced significant, long-lasting, likely antibody-mediated 
protection following intravaginal immunization. PEV7 was also found to be safe in a 
repeated-dose toxicological study in rats [328]. Although a full description Phase I trial results 
is not currently in the public domain and interim data indicate that PEV7 it is well tolerated 
and is ‘effective’ at low doses. 
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ABSTRACT 
 
Herein we developed a method based on the quenching effect of propidium iodide 
over Sytox-Green fluorescence to assess yeast phagocytosis by flow cytometry. It allows 
accurate quantification and distinction of living from dead phagocytes; internalized from non-
internalized cells, maintaining yeast fluorescence within phagocytes; and the different 
associations between phagocytes and fungal cells.  
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1. INTRODUCTION 
 
Candida species are known as common colonizers of the human gastrointestinal, 
respiratory, and reproductive tracts. However, in immunosuppressed patients they are by far 
the most common cause of fungal invasive infections. Host defense against candidiasis relies 
mainly on the ingestion and elimination of the yeasts by the phagocytic cells [1]. 
Phagocytosis of fungal pathogens is a complex process that may be divided into several 
distinct stages: (i) migration of phagocytes towards fungal cells; (ii) recognition of fungal 
pathogen-associated molecular patterns (PAMPs) through phagocyte pattern recognition 
receptors (PRRs); (iii) engulfment of fungal cells; and (iv) processing of engulfed cells within 
phagolysosomes [2]. Yeast cell wall consists of a matrix of β-glucan, chitin and 
mannoproteins, surrounding the plasma membrane, in which the composition and structure of 
cell wall mannoproteins and glucans, constitute the major yeast PAMPs [3]. However, the 
cell wall is a dynamic structure and changes during cell growth and transition of yeast to 
hypha, changing the composition and structure of their PAMPs [3]. Although this dynamic 
change is an advantage for the pathogen it hampers studies addressing the contribution of 
specific PAMPs to the different stages of the phagocytic process. Traditionally, studies 
focusing on phagocytes–yeast interaction use live yeast cells however, it was establish that 
the phagocytes recognize and respond to cell wall PAMPS present in both live or dead cells, 
with differences in the efficiency of phagocytosis only relevant after yeast multiplication 
takes place, around 45 min after co-incubation of the two types of cells [4]. 
Numerous methods have been developed to study yeast phagocytosis, being fluorescence 
microscopy and flow cytometry (FCM) the most reliable [2, 5-7]. FCM combines the 
advantage of being fast, able to count hundreds of cells, and easily discriminate 
morphological heterogeneity within cell populations [6]. In this work we evaluated the 
feasibility of the main phagocytosis assessing methods previously described to be adapted to 
FCM analysis and, to overcome some methodological limitations, we propose a new efficient 
method based on a combination of only two fluorochromes (Sytox Green and propidium 
iodide (PI) for FCM analysis of macrophage interaction with Candida sp. cells and show that 
this new methodology can be used to study the contribution of different PAMPs to the 
phagocytic process.  
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2. MATERIALS AND METHODS  	  
2.1. Materials  
All fluorescent reagents were prepared as stock solutions and then diluted in the cell 
incubation medium at the desired concentrations. Fluorescein isothiocyanate (FITC) (Sigma 
Aldrich), was freshly prepared at 750 µg/ml in 0.1 M sodium carbonate buffer (pH 9), from a 
5 mg/ml dimethyl sulfoxide (DMSO) solution; Trypan Blue (TB) (Sigma Aldrich) solution 
(0.4%) was used directly as stock solution; 50 µM Sytox Green (Invitrogen) was prepared in 
1X PBS from a 5 mM solution in DMSO; propidium iodide (PI) (Sigma Aldrich) was 
dissolved in sterile water at 1 mg/ml, Calcofluor White (CFW) (Sigma Aldrich) was 
dissolved in sterile water at 10 mg/ml stock solution. Stock solutions were stored in the dark 
at -20 °C. Dulbecco's Modified Eagle's medium (DMEM) was supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Valbiotech), 2 mM L-glutamine, 1 mM sodium 
pyruvate, and 10 mM HEPES.  
 
2.2. Preparation of yeast cells  
Wild type strains of Candida albicans (SC5314), Candida glabrata (PYCC 2418), 
Candida bracarensis (153M), Candida parapsilosis (ATCC 22019), Candida orthopsilosis 
(HSM CAN 138), and Candida krusei (PYCC 3341) were used in this study. Yeast cells 
grown overnight at 26 °C in YEPD medium (2% glucose, 1% bactopeptone, and 2% yeast 
extract) were recovered by centrifugation, washed twice in sterile 1X PBS buffer and 
sonicated (2 cycles, 5 s) to eliminate aggregates.  
To fix cell wall PAMPs, yeast cells were incubated for 10 min in formol/ethanol (1:9) 
and washed five times with 1X PBS for complete removal of formol/ethanol. Yeast cells 
were incubated for 10 min with 1 µM Sytox Green at room temperature (RT) in the dark, 
washed with 1X PBS to remove unbound dye, and brought to the desired cell density in 
complete DMEM.  
Live-cells were labeled with FITC or CFW. FITC, previously prepared at a 
concentration of 50 µg/ml, was added directly to the yeast cells pellet and incubated for 10 
min at room temperature in the dark. CFW was added to yeast cells at a final concentration of 
5 µg/ml and incubated for 5 min at room temperature in the dark. Labeled cells were then 
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washed with 1X PBS to remove unbound dye, and brought to the desired cell density in 
complete DMEM.  
 
2.3. Analyses of labeled yeast cells and quenching effect  
Sytox Green, CFW or FITC labeled yeasts were incubated with TB at a final 
concentration of 120 µg/ml or with PI at a final concentration of 6 µg/ml, in order to validate 
the quenching efficiency of TB or PI over Sytox Green, CFW or FITC. As neither TB nor PI 
enters viable cells, the internalized yeast cells will retain the original unquenched 
fluorescence. The pH fluorescence stability of the labeling dyes was evaluated by incubating 
labeled yeasts in a solution with 1 mM of acetic acid pH of 3.9. The yeast cells were then 
analyzed by fluorescence microscopy or/and by flow cytometry.  
 
2.4. Preparation of J774A.1 macrophage cell line  
The murine macrophage-like cell line J774A.1 was cultured in complete DMEM at  
37 °C in a 5% CO2 atmosphere. After confluent growth, macrophage cells were recovered, 
washed, and resuspended in complete DMEM to a final concentration of 5 × 105 cells/ml. For 
fluorescence microscopy assays, 1 ml of the resulting cell suspension was transferred to  
24-well tissue culture plates containing clean sterile glass coverslips (Ø13 mm). For flow 
cytometry (FCM) 3 ml of the cell suspension were transferred to a 6-well tissue culture plate, 
and for confocal microscopy, 0.2 ml of the cells were plated in a microscopy chamber plate 
(Ibidi). Cells were then incubated overnight, at 37 °C in a 5% CO2 atmosphere, to allow 
macrophage adherence. In the following day, phagocytic cells were washed twice with 1X 
PBS buffer to remove non-adherent cells, and cells were promptly used for phagocytic 
assays. Triplicates were done in each plate.  
 
2.5. Phagocytosis of Candida cells  
Macrophages were incubated with labeled yeast suspensions at MOI of 1M:5Y for 30 
min, at 37 °C and 5% CO2. After incubation plates were kept on ice to stop phagocytosis, and 
wells rinsed twice with 1X PBS to remove unbound yeasts. Macrophages and associated 
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yeasts were then incubated with TB at a final concentration of 120 µg/ml or with PI at a final 
concentration of 6 µg/ml, for 5 min at RT. Cells were analyzed by fluorescence microscopy 
(Leica DM5000B), confocal microscopy (Leica SP2 AOBS SE) and by flow cytometry 
(FCM) (EPICS XL-MCL, Beckman-Coulter Corporation). Fluorescence microscopy images 
were analyzed using ImageJ cell counter software. Confocal microscopy images were 
analyzed using Fiji software. FCM data was analyzed by using Flowing software (version 
2.5; Turku Centre for Biotechnology, University of Turku), as indicated in the following 
section.  
The statistical significance values were tested by means of repeated ANOVA 
measures. Multiple comparisons were performed according to the Bonferroni test using 
GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA).  
 
2.6. Flow cytometry (FCM) analysis  
FCM analysis was performed on an EPICS XL-MCL (Beckman-Coulter Corporation, 
Hialeah, FL, USA) flow cytometer. At least twenty thousand cells were analyzed per sample 
at low flow rate. An acquisition protocol was defined to measure forward scatter (FSC), side 
scatter (SSC), green fluorescence and red fluorescence on a logarithmic scale. Each sample 
was collected for 30 s at the slowest flow rate to minimize the coincidental appearance of free 
yeasts and macrophages in the laser beam. A FSC threshold was set to gate out debris. 
Macrophages and free yeast cells were discriminated by combined measurements of FSC and 
SSC. Macrophages were gated in R1 area and free yeast cells in R2 area. The control with 
macrophages alone was used to define the R1 gates.  
The percentage of yeast particles interacting with macrophages was calculated from 
dot plot analysis of Sytox Green fluorescence intensity vs. PI fluorescence intensity of R1-
gated events by using Flowing software. The percentage of macrophages with attached yeast 
particles (MYA) was calculated using the next formula, following the red fluorescence signal:  MYA	  =	  (MR*100/MAF),	  
 
where MR is the mean red fluorescence (calculated by number of events in quadrant Q4), 
gated in R1, MAF is the total number of events gated in R1. The percentage of macrophages 
with ingested and attached yeast particles (MYAI) was assessed as follows:  MYAI	  =MRG*100/MAF	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where MRG is the mean green and red fluorescence (calculated by number of events in 
quadrant Q3), gated in R1. The percentage of macrophages with only ingested yeast particles 
(MYI) was assessed as follows:  MYI	  =MG*100/MAF	  
where MG is the mean green fluorescence (calculated by number of events in quadrant Q2) 
gated in R1. The percentage of phagocytosis, macrophages with ingested yeast particles 
(MYI), was assessed as follows:  MYF	  =	  MYI	  +	  MYA	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3. RESULTS AND DISCUSSION  
 
3.1. Analyses of labeled yeast cells and quenching effect  
The challenge in developing an in vitro method to assess phagocytosis of yeast cells 
based on flow cytometry (FCM) relies on the difficulty to distinguish between internalized 
and non-internalized yeasts, and on the stability of the fluorochrome within the hostile 
environment of the phagolysosome both reducing the accuracy of phagocytosis 
measurements [6]. In this view, these two characteristics were analyzed with several 
fluorochrome combinations in order to assess their utility for phagocytosis measurements by 
FCM.  
One way to distinguish between internalized and non-internalized yeasts is by taking 
advantage of the quenching effect of some dyes over the emitted fluorescence of another dye. 
So, first we tested the ability of TB or PI in quenching FITC fluorescence on labeled yeast 
cells. We observed that TB, although not completely, was able to quench FITC fluorescence, 
as described in previous studies [8, 9] but FITC fluorescence is no longer detected upon 
incubation at a lower pH (Figure 1A), as previously reported [10]. PI was not able to quench 
FITC fluorescence (supplementary information Figure 1A). Thus, both combinations FITC/PI 
and FITC/TB were discarded for phagocytosis measurements by FCM. The quenching effect 
of TB over CFW-stained yeast cells was also tested and results confirmed previous data that 
TB quenches CFW fluorescence [4] but, CFW fluorescence is significantly reduced at lower 
pH (Figure 1B). Once again, PI failed as a quenching dye, being unable to quench CFW 
fluorescence (Figure 1B).  
Traditionally, studies focusing on phagocytes–yeast interaction use live yeast cells, 
however, it was already establish that the innate immune cells recognize and respond to cell 
wall PAMPs in both, live or dead cells. The major difference described is in the efficiency of 
phagocytosis but this difference is only relevant after yeast multiplication takes place [4]. 
However, inactivating treatments based on heat killing by boiling result in the release of 
matricial cell wall surface components [11], which are extremely important for phagocyte 
recognition. On the contrary, inactivating treatments based on fixation of the cell wall 
components conserve the PAMPs in such a way that enables antibody recognition [12]. In 
this sense, in the present study yeast cells were inactivated by a fixation method that does not 
alter the fungal cell wall structure.  
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Figure 1: Analysis of yeast cells labeling, quenching effect and fluorochrome stability at low pH. The effect of 
TB, PI, or medium pH in the fluorescence of: A) FITC labeled yeast cells, B) CFW labeled yeast cells. The 
scale bar represents 7.5 µm.  
 
The use of dead yeast cells allowed the exploitation of viability fluorescent dyes such 
as Sytox Green for yeast labeling, avoiding the surface exposure of the dyes. Sytox Green is a 
high affinity nuclear stain that penetrates cells and intercalates with nucleic acids, staining the 
cell. The ability of TB or PI to quench the Sytox Green-stained yeast cells was also assessed 
(Figure 2). As can be observed in the figure, TB incompletely quenches Sytox Green 
fluorescence, however the quenching effect over Sytox Green labeled yeasts is remarkably 
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evident when PI is used. Additionally, no significant reduction of fluorescence was observed 
when Sytox Green labeled yeast cells were incubated at pH 3.9 (Figure 2). 
 
 
Figure 2: Analysis of yeast cells labeling, quenching effect, and fluorochrome stability at low pH. Effect of TB, 
PI, or medium pH in the fluorescence of Sytox Green labeled yeast cells. The scale bar represents 7.5 µm.  
 
 
Since Sytox Green/PI combination is more adequate for flow cytometry analyses than 
Sytox Green/TB, the quenching effect and pH stability of the Sytox Green/PI protocol were 
confirmed by FCM. Non-stained yeast cells were gated (Figure 3A) and used to calibrate 
yeast auto-fluorescence in the cytometer (Figure 3B). After incubation with Sytox Green, 
99.97% of the yeast cells are labeled, validating Sytox Green label efficiency (Figure 3C). 
The incubation of Sytox Green labeled cells with PI shifted the fluorescence of 99.25% of the 
cells to PI positive, while only 0.75% remained Sytox Green positive (Figure 3D), 
confirming our previous results of an almost complete quenching of the Sytox Green 
fluorescence.  
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Figure 3: FCM analysis of PI quenching effect over Sytox Green labeled yeast cells. (A) Gated non-stained 
yeast cells used for (B) auto-fluorescence calibration. (C) Sytox Green labeled yeasts showing green 
fluorescence (Q1) and (D) Sytox Green/PI double-stained yeast cells showing red florescence (Q4).  
 
The mean fluorescence (MFI) of Sytox Green yeast cells incubated at pH 3.9 showed 
a slight decrease in intensity but yeast cells remained Sytox Green stained, supporting our 
previous observations (Figure 4). 
In order to evaluate the efficiency of Sytox Green/PI protocol in a phagocytosis assay, 
fixed C. albicans cells stained with Sytox Green were incubated with macrophages for 30 
min and then stained with PI. The murine macrophage-like cell line J774A.1 was selected for 
this study, since it is widely used in phagocytic studies and no significant differences 
regarding the ability to engulf yeast cells are described, in comparison with primary 
phagocytic culture, at least within the time point used in our study [2]. 
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Figure 4: FCM analysis of fluorescence stability at low pH in Sytox Green labeled yeast cells. Histogram 
overlay of Sytox Green Medium Fluorescence Intensity (MFI) of non-labeled yeast cells (1), labeled yeast cells 
at pH of 7.5 (2), and labeled yeast cells at pH of 3.9 (3). 
 
The confocal microscopy analysis after phagocytosis revealed, as expected, that 
without fluorescence distinction of internalized from non-internalized yeast cells is imprecise 
(Figure 5Ai). The PI quenching effect of the non-internalized yeast cells (Figure 5Aiii), and 
the integrity of the Sytox Green fluorescence of C. albicans cells inside live macrophages 
(Figure 5Aii) are clearly visible and critical for the accurate distinction. In order to confirm 
that Sytox Green labeled yeast cells were indeed inside macrophages, an ortho-stack 3D 
visualization of the cells is represented in Figure 5B (supplementary information Movie S1). 
In view of these results, the presented protocol will enable differentiation of: (i) non labeled 
phagocytes, representing phagocytes with no interaction with yeast cells; (ii) Sytox Green 
labeled phagocytes, representing phagocytes that have only internalized yeast cells; (iii) PI 
labeled phagocytes, representing phagocytes that have only attached yeast cells; and (iv) 
Sytox Green and PI labeled phagocytes, representing phagocytes that have both internalized 
and attached yeast cells.  
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Figure 5: Confocal phagocytosis analysis. (A) Confocal microscopy image of J774A.1 macrophage with 
internalized and adhered yeast cells showing the PI quenching effect on yeast cells after phagocytosis. 
Intracellular yeast remains Sytox Green fluorescent after 30 min of incubation and extracellular yeast cells are 
PI stained. i) Nomarski image, ii) Sytox Green fluorescence, iii) PI fluorescence and iv) Merged image.  
(B) Z-stack images were analyzed to confirm internalization. The scale bar represents 5 µm.  
 
3.2. FCM analysis of the phagocytosis assay with different Candida species  
In order to test this new FCM phagocytosis protocol, assays were performed using 
different Candida species: C. albicans, C. glabrata, C. bracarensis, C. parapsilosis,  
C. orthopsilosis, and C. krusei. The % of phagocytes with internalized yeast cells, the % of 
phagocytes that have both internalized and attached yeast cells, and the % of phagocytes that 
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have only attached yeast cells were calculated. Before incubation with yeast cells 
macrophage auto-fluorescence was calibrated with a suspension of non-stained macrophages. 
Then, PI stained macrophages were evaluated and two populations clearly distinguishable, 
one representing dead macrophages (PI positive), which was not analyzed, and the other, the 
live macrophages, designated as R1 (P1 negative) (Figure 6A). The non stained R1 
macrophages were indeed PI negative and were further analyzed in a second dot plot, by 
plotting Sytox Green fluorescence against PI fluorescence. The majority of the cells (97.39%) 
gated in a quadrant (Q2) were used to define the limits of Sytox Green and PI negative cells 
(Figure 6B). The other quadrants will gate the distinct phagocytes–yeast interactions: 
phagocytes that have only internalized yeast cells (Q1), phagocytes representing phagocytes 
that have both internalized and attached yeast cells (Q3), and phagocytes that have only 
attached yeast cells (Q4). In a first approach, C. albicans FCM assessed phagocytosis was 
performed to test the protocol. Dot plot of macrophages after incubation with the yeast cells 
showed an additional population, the free yeast cells (R2), that were not analyzed (Figure 
5C). In order to quantify C. albicans phagocytosis, the R1 cell population was selected and 
the fluorescence intensity of Sytox Green vs. PI analyzed, by using the previously defined 
gate limits (Figure 5D). Four distinct phagocytes–yeast interactions could be quantified: in 
Q1 the phagocytes that have only internalized yeast cells (MYI, 57.6%); in Q2 the phagocytes 
with no interaction with yeast cells (MYNO, 42.7%); in Q3 the phagocytes with both 
internalized and attached yeast cells (MYAI, 8.7%); and in Q4 the phagocytes with only 
attached yeast cells (MYA, 1.50%). These results confirmed that the new fluorochrome 
combination is suitable for flow cytometry phagocytosis assays of fixed yeast cells. 
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Figure 6: Macrophage Candida spp. phagocytosis assay by flow cytometry. (A) Dot plot of macrophage cells 
alone stained with PI that were used to gate live cells (R1) and (B) calibrate auto- fluorescence. (C) Dot plot of 
macrophages after 30 min of incubation with yeast cells, showing a clear distinction between live macrophages 
(R1) and yeast cells (R2). (D) Analysis of R1 population after phagocytosis allows the identification of 
macrophages without yeast interaction (MYNO) in quadrant Q2; macrophages with ingested yeast cells (MYI) in 
quadrant Q1; macrophages with ingested and adhered yeast cells (MYAI) in quadrant Q3, and macrophages with 
only adhered cells (MYA) in quadrant Q4.  
 
Following this confirmation, the protocol was extended to evaluate phagocytosis 
quantified by the new protocol in different Candida species. As expected, different species 
presented different ratios of macrophage ingestion and/or adhered yeast cells (Figure 7).  
C. orthopsilosis was the species with the higher percentage of ingested/adhered cells 
followed by C. krusei, C. bracarensis and C. parapsilosis, while C. glabrata and C. albicans 
were the species with the lower percentage. These results are in accordance with several 
studies that demonstrated that the immune cells respond differently. These results are in 
accordance with several studies that demonstrated that the immune cells respond differently 
to individual Candida species in part, due to differences in cell wall PAMP components and 
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organization [13-18]. It was also described that phagocytosis was more efficient using  
C. parapsilosis as a target than C. albicans yeasts [19]. C. krusei was more phagocytized than  
C. albicans or C. glabrata [20], and C. orthopsilosis was less resistant to phagocytic host 
defenses than C. parapsilosis [21].  
 
 
Figure 7: Phagocytosis assay with cells from different Candida species. Analysis of the interactions of J774A.1 
macrophages with formol/ethanol (1:9) killed Candida spp. cells after 30 min of incubation. The light gray bars 
(MYNO) represent the % of macrophages with no interaction with yeast cells; The gray bars (MYI) macrophages 
with internalized yeast cells; white bars (MYAI) macrophages with internalized and adhered yeast cells and the 
black bars (MYA) macrophages with only adhered cells. The gray bar together with the white bar represents the 
% of phagocytosis. Each bar is the average of two independent experiments. The significance of the results 
between the different species is indicated in this figure (*P<0.05, **P<0.01).  
 
 For methodology comparison, confocal microscopy images were taken and analyzed 
to assess the percentage of macrophages with internalized C. albicans, C. parapsilosis and  
C. orthopsilosis yeast cells. At least 500 macrophages were counted in each slide and results 
confirmed that C. orthopsilosis is easily internalized followed by C. parapsilosis and by  
C. albicans (Figure 8). The percentages of internalization were slightly lower than those 
observed with FCM, probably due to the fact that the number of macrophages counted was 
10 times lower than those assessed by flow cytometry.  
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Figure 8: Quantification of macrophage Candida spp. phagocytosis by fluorescence microscopy. Macrophages 
were incubated with Sytox green stained yeast cells for 30 minutes, at 37°C and 5% CO2. After incubation 
macrophages and associated yeasts were incubated with Propidium iodide (PI) for 5 minutes at RT. Cells were 
then analyzed by fluorescence microscopy, images taken and the number of macrophages with internalized 
yeast counted manually using ImageJ cell counter software. Each bar is the average of two experiments ± 
standard error. 
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4. CONCLUSION 	  
In conclusion, we proposed a new, fast and simple method to study the interaction 
between phagocytes and Candida spp. yeast cells and to quantify phagocytosis. The method 
is based on the quenching effect of PI over Sytox Green fluorescence and allows a clear 
distinction between internalized and non-internalized yeast cells with the advantage of 
maintaining Sytox Green fluorescence upon internalization of the yeast by phagocytic cells. 
Using only these two fluorochromes we could accurately distinguish and quantify various 
parameters simultaneously, in a single infection experiment: i) phagocyte survival and ii) the 
association of phagocytes to fungal cells: phagocytes that have only internalized yeast cells, 
phagocytes that have only attached yeast cells, and phagocytes that have both, internalized 
and attached yeast cells. In addition, this method proved to be efficient for evaluation of 
differences in the phagocytosis of distinct Candida species. Although the comparative 
virulence among different Candida species is not entirely dependent on its recognition and 
internalization by phagocytes, the innate immune system plays an important role in 
controlling Candida infections, and this technique may help to elucidate some PAMPs 
characteristics that may be involved in the virulence process. Contrary to microscopy, which 
may be too cumbersome for analyzing a large number of strains, this method allows the high-
throughput screening of yeast strains from different species, including mutants. Such studies 
would significantly enhance our understanding of the molecular mechanisms involved in the 
interaction between yeasts and host phagocytes.  
 
Supplementary data to this chapter can be found online at: 
https://www.dropbox.com/s/vlg3beikjde18qq/Movie%20S1.avi?dl=0 
Movie S1: Video microscopy of the confocal Z-stack microscopy sections of J774A.1 
macrophage yeast phagocytosis, showing that the extracellular yeast cells are PI stained while 
the phagocytized yeast remain Sytox Green fluorescent even after 30 min of  incubation 
(AVI).  
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ABSTRACT 
 
The introduction of a helper lipid into cationic liposomes formulation is essential for 
liposomal membrane stabilization and for minimization of cationic lipids cytotoxicity 
associated. The purpose of this study was to investigate the role of monooleoyl-rac-glycerol 
(monoolein, MO) content in DODAB:MO liposomes. The introduction of MO leads to an 
increase in the mean size and in PDI values, except for DODAB:MO (1:2) liposomes were 
the liposomes exhibited a more homogenous population with a mean size of 139 ± 14.0 nm. 
In addition, an increase in MO content decreased the cytotoxic effect associated with 
DODAB and improved internalization efficiency. Accordingly, we demonstrated that 
DODAB:MO liposomes loaded with BSA (BSA LNPs) benefit with an increase in MO molar 
fraction in terms of colloidal stability, cellular viability and uptake. In addition, incorporation 
of BSA into DODAB:MO liposomes leads to a reorganization of the liposomal bilayer, 
forming rigid rich DODAB domains separated from fluids rich MO domains. In terms of 
macrophage uptake both empty liposomes and BSA LNPs were internalized by endocytosis 
and BSA uptake per cell was increased upon BSA loading in DODAB:MO liposomes. 
Finally, and according with the previous characteristics we choose DODAB:MO (1:2) and 
demonstrated its adjuvant ability in activating antigen presenting cells by enhancing the 
expression of three activation markers, CD86 and CD80 co-stimulatory molecules and MHC 
class II molecules.  
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1. INTRODUCTION 
 
Cationic liposomes have been used extensively as drug and vaccine delivery systems 
[1, 2]. The cationic surfactant dioctadecyldimethylammonium bromide (DODAB) is a 
synthetic amphiphilic molecule composed of a hydrophilic positively charged 
dimethylammonium group (head) attached to two hydrophobic 18-carbon alkyl chains (tail). 
In aqueous buffers, DODAB molecules self-assemble into closed liposomal vesicular bilayers 
[3].  Being a cationic molecule, DODAB induces dose-dependent cytotoxicity requiring dose 
minimization for administration in vivo. The introduction of a helper lipid to formulate drugs 
or vaccines at reduced charged lipid doses is essential for minimization of the cytotoxic effect 
associated with cationic lipids [4-6]. Moreover, in salt solutions, such as phosphate buffer 
saline (PBS), DODAB liposomes can instantaneously aggregate due to insufficient 
electrostatic repulsion forces [7]. 
Monooleoyl-rac-glycerol (monoolein, MO) was first proposed as helper lipid in a 
DODAB liposomal formulation for use as non-viral transfection system [3]. MO has the 
ability to exist in several different phases, with one-, two- and three- dimensional periodicity, 
such as the lamellar (Lα), inverted micelles (L2), hexagonal (H2), and bicontinuous cubic 
phases, under rather easily accessible temperature and pressure conditions [8, 9].  
Phase scan imaging shows that DODAB liposomal formulations benefit from the 
structural richness of MO content, revealing that with higher MO proportion are dominated 
by densely packed cubic-oriented structures [10]. This enhancement in the structural 
complexity of DODAB liposomes can be used for tailored design of protein delivery systems. 
Encapsulation of macromolecules, proteins and other drugs into developed systems is 
of great interest for pharmaceutics and biotechnology due to its capability to use such 
systems as micro- and nanocarriers, not only for controlled drug delivery but also for use as 
adjuvants in vaccination strategies [11, 12]. Subunit proteins or synthetic peptides are 
normally used for the development of immunoprotective strategies. Unfortunately, their 
effective implementation is limited, due to their poor immunogenicity, when administered 
without a carrier for the targeted delivery of antigens to immune competent cells [13, 14]. 
Therefore, understanding the behavior of the empty delivery system as well as the interaction 
between the antigen and the delivery system is highly necessary, since this would allow for 
optimization of the efficacy, stability and safety of new formulations.  
In this study, we investigate the role of MO in the improvement of DODAB liposomes 
as antigen delivery systems. Bovine serum albumin (BSA) was used as model protein in 
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order to assess the effect of MO on the colloidal stability of the liposomal BSA loaded 
nanoparticles (BSA LNPs), cell viability and internalization efficiency. Finally, we validated 
the use of DODAB:MO liposomes as carriers with the ability to enhance antigen activation of 
antigen presenting cells (APCs).  
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2. MATERIALS AND METHODS 	  
2.1. Materials 
Dioctadecyldimethylammonium bromide (DODAB) was purchased from Tokyo 
Kasei (Japan). 1-monooleoyl-rac-glycerol (MO), Hanks’ balanced salt solution (HBSS), 
Trypan Blue, BSA-FITC conjugate, BSA were supplied by Sigma–Aldrich (St. Louis, MO, 
USA). Dulbecco's Modified Eagle's medium (DMEM) was supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Valbiotech), 2 mM L-glutamine, 1 mM sodium 
pyruvate, and 10 mM HEPES (all from Sigma–Aldrich (St. Louis, MO, USA). Wheat Germ 
Agglutinin (WGA) Alexa Fluor® 633 Conjugate (λem=647nm) was provided by Alfagene 
(Carcavelos, Portugal), Rhodamine DHPE (Lissamine™ λem=580nm) and ethanol (high 
spectral purity) was purchased from Uvasol (Leicester, United Kingdom). Dulbecco’s 
Modified Eagle’s Medium (DMEM) was supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM L-glutamine, (all from Sigma-Aldrich), HEPES-Buffer solution 
pH=7.5 supplied by VWR Internacional (Radnor, PA, USA). 
 
2.2.  Extraction of complex fungal antigens from cell wall surface of C. albicans 
C. albicans strain SC5314, kindly provided by Prof. Joachim Morschhauser 
(Wurzburg, Germany), was obtained from a 2 day YPD agar (2% D-glucose, 1% Difco yeast 
extract, 2% peptone and 2% agar) (w/v) culture incubated at 26 °C. The following procedures 
used for antigen extraction were all performed in a sterile environment using apyrogenic 
solutions. The fungal antigens were released from whole intact cells by DTT treatment as 
described previously [15]. 
 
2.3. Preparation and characterization of liposomes 
2.3.1 Preparation of Liposomes by the Lipid-Film Method 
DODAB:MO based liposomes were prepared using the lipid-film hydration method 
[16]. Five different MO molar fractions (χMO) were used: 0.2 (DOBAB:MO molar ratio 
4:1), 0.330 (DOBAB:MO molar ratio 2:1), 0.5 (DOBAB:MO molar ratio 1:1), 0.66 
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(DOBAB:MO molar ratio 1:2) and 0.8 (DOBAB:MO molar ratio 1:4). The χMO is given by 
the following eq. [10]:  
 𝜒MO = MO
DODAB + MO
 
 
Briefly, DODAB and MO were dissolved in ethanol and mixed in a round-bottom 
flask, followed by removal of the solvent by rotary evaporation at 55 ºC. Liposomes formed 
after hydration of the lipid film with 25 mM HEPES buffer pH 7.5 at 55 ºC as previously 
described [15]. The dispersion was then placed in a bath sonicator during 2 min. The 
liposomal stock dispersion was prepared at a 4 mM total lipid concentration. For liposomal 
BSA loaded nanoparticles (BSA LNPs) formation (protein to lipid ratio of 0,376 mol/mol) 
equal volumes of liposomal stock dispersion and 0.75mM BSA stock solution were co-
incubated at 55 ºC for 1 h. Empty liposomes were always used at 2 mM, after addition of 
equal volumes of 25 mM HEPES buffer pH 7.5 to the liposomal stock dispersion. For the 
studies with the CWSP, the same preparation method was used and similar concentrations of 
antigen and empty liposomes were used (protein to lipid ratio of 0,376 mol/mol). 
 
2.3.2 Size, Polydispersity Index and ζ -Potential  
The ζ-potential and the mean size of all formulations were determined by dynamic 
light scattering (DLS) at 25 ºC with a Malvern ZetaSizer Nano ZS particle analyzer. The 
Malvern Dispersion Technology Software (DTS) was used with multiple narrow mode (high-
resolution) data processing, and mean size (nm), polydispersity index (PDI) and error values 
were determined. The liposomes surface charge was measured indirectly by ζ-potential 
analysis, using electrophoretic light scattering (ELS) at 25 ºC. DTS with monomodal mode 
data processing was used to determine average ζ-potential (mV) and error values. All 
characterization was undertaken in triplicate.  
 
2.3.3 Differential Scanning Calorimetry (DSC) 
DSC was used to determine the gel-to-liquid crystalline phase transition temperature 
(Tm) of the liposomes or liposomal nanoparticles in suspension. These measurements were 
performed on a VP-DSC (MicroCal, Northampton, MA) calorimeter equipped with 0.542 mL 
twin cells for the reference and sample solutions. The formulations were prepared as 
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described in section 2.3.1 and total lipid concentration was maintained at 2 mM for all 
measurements, which were performed at the scan rate of 1 °C/min and temperature range of 
5−55°C. The Tm was determined as the temperature at which the excess heat capacity, Cp, 
was at its maximum. The change in enthalpy (ΔH) was determined by integrating the area 
under the baseline-corrected Cp curve obtained for each sample.  
 
2.3.4  Cryo-SEM analysis  
The morphology of the liposomes was evaluated by cryogenic scanning electron 
microscopy (cryo-SEM) using a High resolution Scanning Electron Microscope with X- Ray 
Microanalysis (JEOL JSM 6301F/ Oxford INCA Energy 350/ Gatan Alto 2500). Aliquots of 
4 µl of empty liposomes (total lipid concentration of 2 mM) were placed into carbon film 
grids, rapidly cooled (plunging into sub-cooled nitrogen – slush nitrogen) and transferred 
under vacuum to the cold stage of the preparation chamber. The samples were fractured, 
sublimated (‘etched’) for 120 seconds at -90 °C and coated with Au/Pd by sputtering for 40 
seconds. Samples were transferred into the SEM chamber and studied at a temperature of -
150°C. Micrographs were captured at an acceleration voltage of 15 kV and a working 
distance of 15 mm with a secondary electron in the lens detector. 
 
2.4. “In vitro” analyses  
The in vitro studies were performed using the murine macrophage cell line  
RAW 264.7. The cell line was maintained in complete medium, DMEM supplemented with 
10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and 10 mM HEPES, at 37°C in a 5% 
CO2 atmosphere. After confluent growth, macrophage cells were recovered, washed and re-
suspended in complete medium to the desired cell concentration.  
 
2.4.1 Cytotoxicity analysis 
RAW 264.7 macrophages were plated onto 96-well tissue culture plates (Falcon) at 
1x105 cells/well and incubated to adhere overnight at 37ºC in a humidified atmosphere of 5 
% CO2. Three different concentrations of empty liposomes (40 µM, 80 µM or 160 µM) were 
evaluated. In addition, using the same protein to lipid ratio (0.376 mol/mol), three different 
concentrations of BSA LNPs were used (15:40; 30:80; 60:160, protein:lipid, µM: µM). 
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Cell viability was assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) assay and Lactate Dehydrogenase (LDH) assay after  
24 h of incubation, according to the manufacturer’s instructions.  
MTT is a water-soluble tetrazolium salt, which is converted to an insoluble purple 
formazan by cleavage of the tetrazolium ring by succinate dehydrogenase within the 
mitochondria. Enzymatic activity was quantified after solubilization of MTT formazan with 
DMSO:ethanol (1:1) solution and absorbance measured at 570 nm. Untreated cells were used 
as a control of viability (100%) and cells treated with DMEM:DMSO (4:1) as a control of 
cytotoxicity (100%) as previously described [17].  
The membrane cell integrity was analyzed using the LDH leakage assay, quantified 
by measuring the lactate dehydrogenase activity in the extracellular medium as previously 
described [18]. Briefly, the extracellular enzyme activity was assessed at 30 ºC on a 
microplate reader (Spectra Max 340PC), by following for 3 min, the rate of conversion of 
reduced nicotinamide adenine dinucleotide (0.28 mM NADH) to oxidized nicotinamide 
adenine dinucleotide (NAD+), at 340 nm. Pyruvate 0.32 mM (in phosphate buffer, pH 7.4) 
was used as substrate. Data were expressed as percentage of the control (cells without 
treatment, 100% cellular viability) from at least two independent experiments.  
 
2.4.2 Cellular Uptake 
Cellular uptake of liposomes, at 37 °C or at 4 ºC (at 4 ºC cells were also incubated 
with 10 mM of sodium azide to the medium) was quantified by flow cytometry. For analyses 
of empty liposomes internalization Rhodamine DHPE (at a molar ratio of 1:200) was 
incorporated into the DODAB:MO liposomes during the preparation phase. RAW 264.7 cells 
were seeded into 24-multiwell plates at a density of 5 × 105 cells per well in complete cell 
culture medium. Immediately before liposome addition, cells were washed and medium 
replaced. Cells were incubated with Rhodamine DHPE labeled empty liposomes (final 
concentration of 40 µM) or BSA-FITC LNPs (15:40 protein:lipid (µM: µM)). After 40 min 
incubation, cells were placed on ice and washed with PBS 1X and scrapped in FCM Buffer 
(2%FBS, 10 mM sodium azide in 25% PBS 1X). Before analysis, 0,6% of Trypan Blue (0.36 
ng/ml) was added to the samples in order to quench the fluorescence of non-internalized 
liposomes. A control without cells, only with the formulations alone, was analyzed for 
validation of Trypan Blue quenching.  
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For confocal microscopy analyses, Rhodamine DHPE (at a molar ratio of 1:200) was 
incorporated into DODAB:MO liposomes during the preparation phase. Macrophages were 
plated in a microscopy chamber plate (Ibidi) at 3×105 cells/well and left to adhere overnight 
at 37 ºC in a humidiﬁed atmosphere of 5% CO2. Immediately prior to incubation with labeled 
liposomes, RAW 264.7 macrophages were labeled with Wheat Germ Agglutinin Alexa 
Fluor® 633 Conjugate (2.5 µg/ml) for 10 min and then washed twice with HBSS. The 
microscopy chamber plate was then placed in the integrated chamber (37 ºC, 5% CO2) of the 
LSM 780 Carl Zeiss Microscope and 8 µl of empty labeled liposomes (total lipid 
concentration of 888µg /ml) were added to the adhered macrophages. A z-stack image after 
40 min were obtained and images were analyzed using ZEN 2012 lite software (ZEISS). 
 
2.4.3 ROS production 
RAW 264.7 macrophages were plated onto 24-well tissue culture plates (Falcon) at 
5×105 cells/well, incubated with empty liposomes (final concentration 80 µM) during 1h. 
Using Superoxide Detection Kit from Enzo Life Sciences (NY, USA) superoxide production 
was assessed in live cells using flow cytometry according to manufacture instructions. 
 
2.5. Stimulation of Bone Marrow Dendritic Cells (BMDCs)   
Bone marrow cells were collected from femurs and tibias of BALB/c mice by 
flushing with cold RPMI 1640 (Sigma). Cells (1×106/mL) were cultured in 6-well plates in 
RPMI medium supplemented with 15% (v/v) J558-cell supernatant, 10% FBS (PAA), 
penicillin (100 U.I./mL)-streptomycin (100 µg/ml) (Sigma), and L- Glutamine (2 mM) 
(Sigma) and incubated at 37 ºC and 5% CO2. Half of the medium was renewed every two 
days. At day 6, BMDCs were detached and distributed in 96-well round bottom plates 
adjusted at a concentration of 2×105 cells/well in supplemented RPMI medium. Immediately 
after being seeded, cells were stimulated with: empty liposomes (final concentration 160 
µM); BSA (final concentration 160 µM); BSA LNPs (final concentration 60:160 protein: 
lipid molar ratio (µM: µM)); fungal antigens (at the same final concentration used for free 
BSA); fungal antigens LNPs (at the same final concentration used for BSA LNPs). LPS 
(1µg/ml) (Sigma) and unstimulated cells were used as positive and negative controls of 
activation, respectively. For the assessment of cell surface markers, after stimulation the 
BMDCs were  collected from the culture plates, washed twice in Hanks’s Balanced Salt 
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Solution (Sigma) and incubated with specific cell surface antibodies. The  following 
monoclonal antibodies (mAbs), at previously determined optimal dilutions, for 
immunofluorescence cytometry [19] were used: fluorescein isothiocyanate (FITC) hamster 
anti-mouse CD11c (HL3), PE anti-mouse CD80 (B7-1) (16-10A1); PE anti-mouse CD86 
(B7-2) (GL1); PE anti-mouse I-Ad/I-Ed-MHC class II (clone 2G9); all from BD (Biosciences 
Pharmingen, San Diego, CA).  The analyzed cell samples were always pre-incubated with 
anti-FcγR mAb  before the antibody incubation to prevent non-specific antibody binding. All 
cytometric measurements were performed in an EPICS XL flow cytometer using the 
EXPO32ADC software (Beckman Coulter). The collected data files were converted using 
FACS CONVERT, v1.0 (Becton Dickinson) and analyzed using CELL QUEST software, 
v3.2.1f1 (Becton Dickinson).  
 
2.6. Statistical analyses 
Data were analyzed using analysis of variance (ANOVA) followed by the Bonferroni 
test to compare the mean values of different groups, using GraphPad Prism 5 software 
(GraphPad Software, Inc., La Jolla, CA). Unless otherwise stated, results shown are from 
three independent experiments with three replicates. Differences were considered significant 
when the p value was less than 0.05. 
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3. RESULTS AND DISCUSSION 	  
3.1. The effect of χMO in DODAB:MO empty liposomes  
3.1.1 Characterization of empty liposomes 
The physicochemical properties of DODAB liposomes after MO incorporation at 
different molar fractions were study by dynamic light scattering (DLS), electrophoretic light 
scattering (ELS) and differential scanning calorimetry (DSC). Five different DODAB:MO 
liposome formulations were used, DOBAB:MO molar ratios 4:1, 2:1, 1:1, 1:2 and 1:4. The 
average size of these liposomes, prepared by the thin film method followed by a sonication 
step was relatively small, all formulations presented sizes smaller than 500 nm, except 
DODAB:MO 1:4 liposomes, that presented a mean size of 2880 ± 699 nm,	 a significant 
increase (P<0.0001) in comparison with all other molar ratios (Figure 1). The values for 
polydispersity index (PDI) ranged from 1.0 ± 0.01 for DODAB:MO 1:4 liposomes to  
0.2 ± 0.06 relatively for DODAB:MO 1:2 liposomes (Figure 1).  
 
 
Figure 1: Effect of χMO in DODAB:MO liposomes  mean size (bars), PDI (spherical symbols) and ζ-potential 
(bars). Significant differences in the mean size and in the ζ-potential between the different ratios are represented 
above the lines by: *P<0.05, **P<0.01 and ***P<0.001. All values shown are the average values from three 
independent experiments ± SD 
 
All MO-based liposomes tested have a high net positive charge (> +55mV) clearly 
resulting from the cationic nature of DODAB. DODAB:MO (1:2) liposomes presented the 
lowest surface charge (+55.9 ± 3.2 mV) and DODAB:MO (1:4) liposomes presenting the 
highest surface charge (+78.2 ± 8.2 mV) (Figure 1). 
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 In previous studies, we established that, for χMO < 0.5, MO is distributed in the 
lamellar phase of DODAB and bilayer-based structures dominate, whereas for χMO > 0.5, 
DODAB and MO self-assembled into lamellar and bicontinuous inverted cubic mesophases 
[10, 20]. This implies a lipid phase separation and could explain the high  
ζ-potential values observed for DODAB:MO (1:4) molar ratio. 
Overall, an increase in the amount of MO until DODAB:MO (1:1) leads to an 
increase in the mean size and in PDI values, except for DODAB:MO (1:2) liposomes were 
the liposomes exhibited a more homogenous population with a mean size of 139 ± 14.0 nm. 
 
3.1.2 The effect of χMO in DODAB:MO liposomes cytotoxicity, uptake and ROS 
production by macrophages.  
One of the main concerns in the design of any cellular delivery system is their 
associated cytotoxicity. In this sense, the effect of MO content on the metabolic activity of 
RAW 264.7 cells after being exposed to three different concentrations of each of the five 
DODAB:MO liposome formulations, was evaluated using the MTT assay, while the impact 
on membrane integrity was evaluated using the LDH assay, after 24 h of co-incubation.  
As represented in Figure 2, a slight decrease in cell metabolic activity is observed 
with increasing concentration of liposomes, particularly for the formulations where MO was 
present at lower percentages (<50%). However, DODAB:MO (1:2) and DODAB:MO (1:4) 
liposomes were well tolerated at all concentrations, showing viability values above 95 %. 
Cells treated with 160 µM DODAB:MO (4:1) liposomes showed only 73.9 ± 14.9 % of 
viability, significantly lower than values observed with all other DODAB:MO molar ratios 
(P<0.01, Figure 2). However, the membrane integrity was maintained when cells were 
incubation with liposomes with all other molar ratios, which confirmed the capacity of MO to 
lower the cytotoxicity associated with DODAB [21].  
Phagocytes generate ROS by using superoxide-generating NADPH oxidase (NOX) 
family proteins, which play pivotal roles in host defense against bacterial and fungal 
pathogens [22]. After 1 hour of incubation, ROS was evident in macrophages incubated with 
all liposomal formulations, but the percentage of ROS producing cells was not significantly 
different between the liposomal preparations, ranged from 44 ± 0.8% for DODAB:MO (1:2) 
liposomes to 59 ± 1.5% for DODAB:MO (4:1) liposomes (Figure 3). Only with incubation 
with DODAB:MO (1:2) the percentage of ROS producing cells was slightly lower (P<0.05) 
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Of note is the fact that this ROS production does not seem to affect cell viability although it 
can be considered a marker of cell activation. 
 
 
Figure 2: Viability of RAW 264.7 cells after 24 h incubation with DODAB:MO liposomes at different χMO. 
Viability was assessed using the MTT (in the top) and LDH (in the bottom) assay after 24 h incubation. The 
liposomes were diluted in the culture medium at the final concentrations of 40, 80 and 160 µM. Bars indicate 
the mean ± SD of two independent experiments. Significant differences between the different molar ratios are 
represented by (*) above the line, differences with the former concentration are represented by (*) above the 
bar: (*P<0.5, **P < 0.01, ***P < 0.001, ****P< 0.0001) 
 
 
Figure 3: Percentage of cells producing ROS after 1 h incubation with DODAB:MO liposomes at different  
χMO. The liposomes were diluted in cell culture medium at a final concentration of 80 µM. Bars indicate the 
mean ± SD of two independent experiments. UC: unstimulated cells. Significant differences between the 
different molar ratios and control-unstimulated cells are represented by (*) above the bar: (*P<0.5, **P<0.01, 
***P <0.001). 
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In order to elucidate the effect of MO in cellular uptake, cells were incubated with 
Rhodamine DHPE labeled empty liposomes at either 37 °C or 4 °C. Incubations at 4 ºC were 
preformed in the presence of sodium azide in medium (which helps inhibition of the energy-
dependent uptake by endocytosis). At 4 ºC, and comparing with the results observed at 37 ºC, 
a decrease in intracellular fluorescent intensity was observed for all DODAB:MO molar 
ratios tested (Figure 4A), which indicates that the uptake DODAB:MO liposomes is energy-
dependent. The fact that cationic liposomes are taken up by active endocytosis has been 
reported in other studies [23-25]. At a physiological temperature, the ability of cellular uptake 
of DODAB:MO liposomes was dependent of the MO content. As shown in Figure 4A, the 
percentage of positive cells was higher for DODAB:MO (1:1) and (1:2) (P>0.01) in 
comparison to the other molar ratios. The amount of internalized liposomes per cell (MFI) 
was higher for DODAB:MO (1:1) (P> 0.0001) in comparison to the other molar ratios 
(Figure 4A).  
As shown in Figure 4A, at 37 ºC the percentage of fluorescently labeled cells 
(positive cells) tends to increase with increasing the amount of MO. The percentage of 
positive cells was higher for DODAB:MO (1:1) and (1:2) (P>0.01) in comparison with the 
DODAB:MO (4:1) and (2:1). Additionally, the amount of internalized liposomes per cell 
(MFI) increased from DODAB:MO (4:1) to (1:1), diminishing again from (1:2) to (1:4). This 
result indicates that at a physiological temperature, increasing the MO content favors cellular 
uptake of DODAB:MO liposomes, at least until molar ratio of 1:2. 
In order to confirm endocytosis, internalization of DODAB:MO liposomes was 
visualized by confocal microscopy (Figure 4B). DODAB:MO (1:2) liposomes were chosen 
as evidence, since according to their good colloidal stability, efficient internalization and lack 
of cytotoxic effects, liposomes with this DODAB:MO molar ratio are suitable for the 
construction of an antigen delivery system. After 40 min of incubation, most of the 
Rhodamine (Rho)-labeled liposomes were seen accumulated throughout the cytoplasm, the 
transport endosome region and in the Golgi area next to the nucleus, which itself does not 
reveal any fluorescence signal (Figure 4B). Superimposition of Rho with Alexa Fluor 633 
fluorescence was observed and localized liposomes within membrane-rich regions, i.e., in the 
cytoplasmic area and in the cellular extensions as expected in an endocytic process [26]. 
Figure 4C displays the view at the mid-point of cell thickness confirming that most of the 
Rho fluorescence is concentrated intracellularly in certain areas. Figure 4D Cryo-SEM 
micrographs showed that DODAB:MO (1:2) liposomes are spherical smaller-sized 
liposomes. 
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Figure 4: Cellular uptake of DODAB:MO liposomes after 40 min of incubation. A) Percentage of cellular 
uptake (in the top) and the mean fluorescence intensity (MFI) (in the bottom), at 37ºC and 4ºC, at different χMO 
B) Confocal images of Rho-DODAB:MO (1:2) liposomes cellular  uptake at 37ºC: i. Rhodamine fluorescence 
ii. Alexa Fluor 633 fluorescence and iii. superimposition of Rhodamine and Alexa Fluor 633 fluorescence. C) A 
mid-point thickness view (X68, Y44, Z24) of the cell, indicated by a yellow rectangle in (Biii), (z). Z-axis 
rotations of a single transverse slice through two sections of the cell: view in the x-0-z plane (x) and view in the 
y-0-z plane (y). D) Cryo-SEM Representative image of DODAB:MO (1:2) liposomes morphology. Bars 
indicate the mean ± SD of two independent experiments. Significant differences between the different molar 
ratios and control-unstimulated cells are represent by (*) above the bar: (*P<0.5, **P<0.01, ***P<0.001, 
****P<0.0001)  
 
3.2. The effect of χMO in protein loaded DODAB:MO liposomes  
3.2.1 Characterization of BSA LNPs 
Cationic liposomes have the ability to adsorb oppositely charged antigens and to 
encapsulate hydrophobic and hydrophilic antigens due to their amphiphilic nature [21]. The 
model protein chosen in this study was Bovine Serum Albumin (BSA), a medium-weight 
protein (MW = 66 kDa) consisting of 580 amino acid residues. BSA is negatively charged 
with an isoelectric point of 5.3 at pH 7.4 [27]. The binding mode of the lipid–protein 
interaction can be determined from the effect of the protein on the gel-to-liquid crystalline 
lipid phase transition [28]. Dynamic light scattering (DLS), electrophoretic light scattering 
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(ELS) and differential scanning calorimetry (DSC) were used in order to study the interaction 
of BSA with the DODAB:MO liposomes with different MO content, after BSA 
incorporation. Figure 5 shows the mean size, PDI and the surface charge of DODAB:MO 
liposomes in the presence of BSA (BSA LNPs). Curiously, the adsorption of BSA to all 
DODAB:MO liposomes made no significant difference to the ζ-potential of the empty 
liposomes (Figure 5). Regarding BSA LNPs mean sizes and PDI, although these values 
decreased in comparison with empty liposomes, the decreases were only significant for 1:4 
BSA LNPs (P<0.0001). In fact, for DODAB:MO (1:4) liposomes the incorporation of BSA 
enhanced its colloidal stability, since both mean size (< 350 nm) and PDI (<0.4) drastically 
decrease. With the incorporation of BSA, the effect of the MO in increasing the mean size 
was no longer observed. 
 
 
Figure 5: Effect of χMO in BSA LNPs mean size (bars), PDI (spherical symbols) and ζ-potential (bars). 
Significant differences in the mean size in comparison with DODAB:MO (1:2) molar ratio are represented by: 
*P<0.05, **P<0.01. All values shown are the average values from three independent experiments ± SD.   
 
DODAB:MO (1:2) BSA LNPs, which compromises the most promising molar ratio 
so far, exhibited the lowest mean size (135 ± 12.4 nm) and the lowest PDI value (0.18 ± 
0.03).  
MO dispersions present no melting transition since they do not contain bilayer 
aggregates and are instead two-phase dispersions of a bicontinuous cubic phase in a very 
diluted solution [29]. It is well known that DODAB presents a pre-transition temperature (Tp) 
due to the tilting of the DODAB chains prior to the melting temperature which occurs at 44.4 
°C, when the gel-phase dominated by ordered alkyl chain conformations melts into a high-
temperature fluid-phase characterized by disordered alkyl chain conformations [10, 20, 30].  
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The effect of MO on the thermal behavior of the mixture of DODAB:MO was 
previously described using DSC [10]. The gel-to-liquid crystalline phase transition is 
characterized by a number of thermodynamic parameters, such as the phase transition 
temperature (Tm) and the enthalpy of the calorimetric event (ΔH) and, in some cases, a pre-
transition temperature is also observed. In the present study, the effect of BSA in the thermal 
behavior of DODAB:MO liposomes, at different χMO, was studied by DSC (Figure 6 and 
Table 1).  
 
  
Table 1: The effect of BSA in the gel-to-Liquid Crystalline Transition Temperature (Tm) and variation in 
Enthalpy (ΔHm) of DODAB:MO liposomes, as assessed by DSC in the Heating Mode. 
* Empty liposomes values present in the table were previously reported [10]. 
 
Table 1 shows, in detail, the gel-to-liquid crystalline phase transition properties of 
DODAB:MO liposomes, at different χMO, in the presence of BSA. The properties of empty 
liposomes with similar χMO, were described in previous studies [10, 20] and are also present 
in Table 1 for comparison. 
For all DODAB:MO molar ratios, BSA induced great changes in the enthalpy and Tm 
suggesting the occurrence of strong interactions between BSA with the lipid bilayer. The Tm 
increased and the ΔH decreased in comparison with empty liposomes (Figure 6 and Table 1). 
Tm was nevertheless still detected even for the highest molar fraction of MO (DODAB:MO 
(1:4)), indicating the presence of some rigid bilayers at higher MO content  
The increase in Tm values indicates that the incorporation of BSA leads to the 
reorganization of the bilayer with the separation of a MO rich domain (more fluid) from the 
DODAB rich domain (more rigid). Furthermore, a decrease in ΔT1/2, as observed by a 
reduction of the peak diameter, suggests that BSA incorporation speeds the phage transition 
probably due to the formation of DODAB rich domains. In fact, the effect of proteins on the 
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transition temperature and shape of the DSC peaks can also provide information on the 
miscibility of lipids and proteins. In accordance with these results, the proteins well mixed 
with the gel phase, displayed an upward shift of thermogram broadening the high-
temperature side [31]. Consequently, for the same BSA LNPs, the Tp found in pure DODAB 
appears at higher temperatures. Interestingly, for BSA LNPs formulations with excess of 
DODAB, DODAB:MO (4:1), equal molar fraction DODAB:MO (1:1) or  excess of MO, 
DODAB:MO (1:4) the appearance of a second pre-transition peak (Tp*) is observed.  
These results suggest that at these χMO, we may have the same phase separation 
leading to co-existence of DODAB-rich and MO-rich domains. In fact, for empty 
DODAB:MO (1:4) liposomes no transition peak was observed [10] suggesting the presence 
of some BSA LNPs-MO rich (fluid) and also the convergence of DODAB-rich domains upon 
protein interaction, which could explain the reappearance of the peak. In fact, it was already 
reported that specific interactions between a protein/peptide with lipid molecules could 
induce the formation of domains within lipid membranes and the appearance of shoulders or 
double peaks in the DSC [32, 33]. In DODAB:MO (2:1) and (1:2) BSA LNPs, the Tp found 
in pure DODAB is reduced for lower values, although no Tp exists for the corresponding 
empty liposomes [10]. This again suggests that a phase separation occurs between DODAB 
and MO molecules upon BSA interaction.  
The decrease in enthalpy suggests that in BSA/cationic lipid interaction may occur 
two competing effects: charge-neutralization interaction at the bilayer surface, due to 
electrostatic forces which cause the packing and stabilization of the gel-state bilayer, and a 
hydrophobic interaction caused by a partial insertion of BSA into the lipid bilayer core. DLS 
studies reveal that BSA incorporation lead to slight decreased in mean size and PDI of LNPS 
than can be associated with the packing and stabilization effect.  
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Figure 6: The effect of BSA on the DSC thermograms of DODAB:MO liposomes, at different  χMO, obtained 
in the heating mode, at scan rate 1 °C/ min. The left Y-axis indicates differential heat capacity values for the 
BSA NLPs (black) and the right Y-axis indicates differential heat capacity values for the empty liposomes 
(blue) as previously described [10]. 
 
Moreover, BSA incorporation in the bilayers can restrain the swing of surrounding 
DODAB molecules preventing their contribution to the phase transition decreasing enthalpy 
[34]. The same authors also suggested that hydrophobic interaction between BSA and 
liposomal bilayer membrane is likely to be between the ‘domain III’ and/or ‘hydrophobic 
hole’ of BSA and the hydrocarbon region of liposomal bilayer membranes [34]. In fact, 
different studies suggested that the presence of substances that insert, or even only penetrate 
to some extent into the hydrophobic core of the bilayer promote a decrease in cooperativity 
(ΔH decreases) [35, 36].  
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3.2.2 The effect of χMO in liposomal BSA nanoparticles (BSA LNPs) cytotoxicity 
and BSA uptake. 
The cytotoxicity of the BSA LNPs was evaluated on the metabolic activity of RAW 
264.7 cells after being exposed to three different concentrations of each of the five 
DODAB:MO molar ratios, using the MTT assay, while the impact on membrane integrity 
was evaluated using the LDH assay, after 24h of co-incubation.   
In general, cell viability after incubation with BSA LNPs was above 93%, indicating 
no cytotoxic effect (Figure 7). However, contrary to what was observed for empty liposomes, 
the clear dependence of cell viability on the content of MO was not observed.  
 
 
Figure 7: Viability of RAW 264.7 cells after 24 h incubation with BSA LNPs at different χMO. Viability was 
assessed using the MTT (in the top) and LDH (in the bottom). The liposomes were diluted in the cells medium 
and the final concentration is indicated by means of protein to lipid molar ratio. Free BSA was used at the same 
concentrations. The bars indicate the mean ± SD of two independent experiments. Significant differences 
between the different molar ratios are represented by (*) above the line, differences with the former 
concentration are represented by (*) above the bar: (*P<0.5, **P<0.01, ***P<0.001, ****P<0.0001) 
 
The only formulation with a higher cytotoxic effect was DODAB:MO (4:1) BSA 
LNPs at the higher concentration, that seems to affect cell membrane integrity (Figure 7). 
Nevertheless, comparing all result from this analysis, cell viability was higher than 90% for 
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DODAB:MO (1:2) and (1:4) BSA LNPs, supporting the tolerability of the cells towards 
liposomes that incorporated higher proportions of MO. 
In order to evaluate the effect of MO presence in BSA internalization, DODAB:MO 
(1:2) BSA LNPs were chosen, due to the characteristics described previously, and for 
comparison, the inverted χMO: DODAB:MO (2:1) BSA LNPs was also included in this 
analysis. After 40 min of exposure at 37ºC to FITC–BSA LNPs or FITC–BSA solution, the 
percentage of FITC positive cells was significantly higher (P<0.05) for FITC–BSA solution 
and for DODAB:MO (1:2) BSA LNPs in comparison  to cells incubated with DODAB:MO 
(2:1) BSA LNPs (Figure 8). In contrast, the mean fluorescence intensity (MFI), that indicates 
the amount of FITC-BSA internalized per cell, was higher when BSA was loaded in 
DODAB:MO (2:1) (P<0.0001) or (1:2) (P<0.001) liposomes, increasing from 120 ± 5.0  for 
the free BSA to 152 ± 5.6 for DODAB:MO (1:2) reaching 243 ± 7.0 for DODAB:MO (2:1) 
liposomes. These results are in agreement with several studies pointing out that cationic 
liposomes bound avidly to murine antigen presenting cells (APCs) and consequently mediate 
enhanced cellular adsorption and uptake of antigens [25, 37].  
 
 
Figure 8: Effect of χMO in the cellular uptake of BSA LNPs after 40 min of incubation at 37 ºC and 4 ºC. 
Percentage of cellular uptake (left) and the mean fluorescence intensity (MFI) (right). The bars indicate the 
mean ± SD of two independent experiments. Significant differences are represented by (*) above the line: 
(*P<0.5, **P<0.01, ***P<0.001, ****P<0.0001) 
 
Considering the results obtained, DODAB:MO (1:2) liposomes prove to be superior 
when successfully delivered the FITC-BSA to 95.2 ± 1.2% of the cells in contrast to 76 ± 
4.6% reached by DODAB:MO (2:1) BSA LNPs, leading to a more homogeneous and 
efficient delivery. This result is in agreement with our previous indication that empty 
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liposomes with a higher amount of MO favors cellular uptake. The same tendency was 
observed, for these two χMO in DODAB:MO liposomes in a Small interfering RNA (siRNA) 
transfection assay , in a different strategy [20]. These observations suggest that differences in 
the structural organization of the liposomes due to different χMO can interfere with the 
internalization efficiency. 
Exposure to FITC–BSA LNPs or FITC–BSA solution at 4 ºC, resulted in negligible 
increase in FITC fluorescence above cellular auto-fluorescence, indicating that fluorescence 
associated with the cells at 37 ºC is a result of active uptake rather than superficial adhesion, 
similar to what was observed for empty liposomes. Moreover, the uptake pathway for 
particles internalization is mainly determined by the particle size [38]. The BSA LNPs used 
in this study, as previously mentioned, exhibit sizes larger than 50 nm and smaller than 500 
nm, which is the exact range defined for macrophage particle uptake to occur mainly via 
endocytosis (including clathrin-, caveolae-mediated, non-mediated endocytosis etc) [38]. 
 
3.2.3 Activation of Bone marrow dendritic cells (BMDCs)  
Dendritic cells (DCs) constitute the most important class of antigen presenting cells 
(APCs) of the immune system and the activation of these cells seems to play a major role in 
the initiation of the adaptive immune response. In fact, DCs are responsible for capturing, 
processing and presenting antigens, through MHC pathways, to CD4+ and CD8+ T 
lymphocytes [39, 40].  
After showing that that DODAB:MO (1:2) liposomes enhanced BSA internalization 
by macrophages, and in order to test if this efficiency was associated with a functional 
enhancement of APCs activation, DODAB:MO (1:2) BSA LNPs were incubated for 24 h 
with BMDCs and the of activation  markers were assessed by measuring surface expression 
of co-stimulatory  (CD80 and CD86) and MHC class II molecules. As it can be seen in Figure 
9A, the loading of BSA in liposomes did not cause any effect in BMDCs activation. In fact, 
several studies have demonstrated that dendritic cells are remarkably potent at initiating and 
directing adaptive immune responses but only when the antigen is captured in the presence of 
microbial products or inflammatory stimuli, being tolerant in the absence of these signals [41, 
42].  
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Figure 9: BMDCs isolated from BALB/c mice were stimulated in vitro with empty liposomes A) BSA LNPs or 
free BSA for; B) fungal antigens (F.A.) LNPs or free fungal. All at DODAB:MO (1:2) molar ratio during 24 h. 
BMDCs were gated on CD11c+ cells and analyzed for expression of co-stimulatory and MHC class II 
molecules. Bars represent the mean ± SD of mean fluorescence intensity (MFI) from two independent 
experiments. U.C.: unstimulated cells. Only significant differences between fungal antigens loaded in LNPs and 
free antigens are represent by (#), between the two time points at the same concentration by (*) above the bars 
and between concentration by (*) above the line: **P<0.01; ***P<0.001 and ****P<0.0001. U.C.: unstimulated 
cells  
 
In order to clarify if DODAB:MO liposomes could enhance the immunogenicity of 
microbial antigens, the same liposomes, DODAB:MO (1:2) liposomes were loaded with 
complex fungal antigens (F.A.). Complex F.A. were obtained from C. albicans cell wall, 
which due to its outer location is readily recognized by the host immune cells, triggering and 
modulating the anti-Candida host immune responses, and therefore constitutes the most 
important pathogen-associated molecular patterns (PAMPs) of C. albicans [43, 44]. These 
complex fungal antigens display a mean size of 88.7 ± 5.1 nm and a PDI of 0.63 ± 0.01, 
characterized by DLS. Fungal antigens DODAB:MO (1:2) LNPs present a mean size of  
223 ± 37 nm and a PDI of 0.19 ± 0.015, relatively similar to BSA LNPs. After 24 h of 
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incubation with BMDCs a pronounced improvement in the activation promoted by the free 
fungal antigens is achieved for both activation markers and MHC class II molecules with 
their incorporation in DODAB:MO (1:2) liposomes (P<0.0001) (Figure 9B).  
This improvement in the activation suggests that after being captured by DCs the 
LNPs collapse within the intracellular acidic compartments, releasing the fungal antigens 
intracellularly in a way that enabled processing by the MHC class II dependent pathway. 
Furthermore, expression of activation markers (  CD80 and CD86) represents important 
surface molecules for T cell activation [45]. The fact LNPs enhance their expression indicates 
that DODAB:MO liposomes can have tremendous potential as adjuvant delivery systems in 
development of new vaccines. 
Consistent with the current study, other proposed delivery systems have been shown 
to have an adjuvant activity for DCs activation, such as layered double  hydroxides  [46], 
salidroside (a component from Rhodiola rosea L plant) liposome formulations [47], 
polyanhydride nanoparticles[48], poly (D,L-lactic-co-glycolic acid) (PLGA) nanoparticles 
with entrapped with monophosphoryl lipid A (MPL) [49], cationized gelatin nanoparticles 
(GNPs) [50]. 
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4. CONCLUSION 	  
Based on presented findings we therefore established that an increase in MO content 
is important for the improvement of DODAB:MO liposomes colloidal stability and in 
contrary a decrease in MO content affects cell viability and internalization efficiency. BSA 
incorporation in DODAB:MO liposomes leads to a reorganization of the liposomal bilayer 
with the separation of a MO rich domain (more fluid) from the DODAB rich domain (more 
rigid). Moreover, according to the obtained results we show that both empty liposomes and 
BSA LNPs are internalized in an energy depend process and BSA uptake per cell is increased 
upon BSA loading in DODAB:MO liposomes. Finally, according we the previous 
characteristics we selected the more suitable molar fraction of MO and showed that 
DODAB:MO (1:2 molar ratio) liposomes can be used, in the future, as delivery system to 
promote vaccine delivery in immune cells, since they not only act as nanocarries but also as 
antigen adjuvants that induced significantly more effective APC activation than free 
microbial antigens. 
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ABSTRACT  
 
We describe the preparation and characterization of DODAB:MO-based liposomes 
and demonstrate their adjuvant potential and use in antigen delivery. Liposomes loaded with 
C. albicans proteins assembled as stable negatively charged spherical liposomal nanoparticles 
(LNPs) with a mean size of 280 nm. High adsorption efficiency (91.0 ± 9.0%) is attained 
with high lipid concentrations. The LNPs were non-toxic, avidly taken up by macrophage 
cells and accumulated in membrane rich regions with an internalization time of 20 min. 
Immunized mice displayed strong humoral and cell-mediated immune responses, producing 
antibodies (IgGs) against specific cell wall proteins, Cht3p and Xog1p. DODAB:MO-based 
liposomes loaded with C. albicans proteins have an excellent immunogenic potential and can 
be explored for the development of an immunoprotective strategy against Candida infections. 
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1. INTRODUCTION 
 
Delivery systems are frequently used in vaccine formulations to ensure efficient 
antigen delivery and induction of an adequate immune response. In fact, delivery systems 
have been applied in marketed vaccines for over 70 years to protect and carry antigens as 
well as to act as adjuvants for molecules with low immunogenicity [1, 2]. Currently, many 
options for delivery systems are available, including liposomes, polymer-based micro- and 
nanoparticles, virosomes, immune stimulating complexes (ISCOMS) and many more [3-6]. 
Of these, liposomes can also act as immunological adjuvants [7] and are the most widely 
investigated delivery system for phagocyte-targeted therapies [8, 9]. Liposomes offer a 
flexible system for manipulation and enable the preparation of vesicles with varying 
lamellarities, physical characteristics, adsorption efficiencies, and antigen encapsulation 
abilities [3]. In addition, liposomes are biodegradable and biocompatible and may be 
functionalized to provide cell targeting specificity and antigen protection [10, 11]. 
Cationic liposomes have been used extensively as drug and vaccine delivery systems 
[12, 13]. Various types of cationic lipids may be used in the preparation of liposomes, 
varying in the charge of the hydrophilic head group, the number and/or length of fatty acid 
chains (tail) and/or their degree of saturation. The cationic surfactant 
dioctadecyldimethylammonium bromide (DODAB) is a synthetic amphiphilic lipid 
composed of a hydrophilic positively charged dimethylammonium group (head) attached to 
two hydrophobic 18-carbon alkyl chains (tail). In aqueous buffers, DODAB molecules self-
assembles into closed liposomal vesicular bilayers [14]. DODAB cationic vesicles have been 
used as carriers in drug delivery [15, 16] as well as adjuvants for vaccination, displaying 
higher colloid stability than alum and better efficacy in inducting higher cellular immune 
responses [17-19]. However, cationic liposomes alone may be associated with in vivo 
cytotoxicity [18, 20] and, in salt solutions, such as phosphate buffer saline (PBS), can 
instantaneously aggregate due to insufficient electrostatic repulsion forces [21]. To overcome 
these problems, several stabilizers including trehalose 6,6’-dibehenate (TDB) [12], and silica 
[19] have been used to increase DODAB liposomes colloidal stability, minimize cytotoxicity 
by dilution effect and increase adjuvant efficacy. In previous studies, we have demonstrated 
that monooleoyl-rac-glycerol (monoolein, MO) could also be used as a stabilizer as it 
conferred fluidity to the DODAB system by favoring lipid chain mobility [22]. In fact, we 
have successfully used DODAB:MO as a mammalian cell transfection system and as a 
system for in vitro gene silencing [16, 23]. MO is particularly interesting because it exhibits 
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two inverted bicontinuous cubic phases and as a result forms non-lamellar vesicles with 
negative curvature [24]. This characteristic decreases the structural rigidity of DODAB 
vesicles causing an increase in the lateral mobility of the lipid chain which in turn improves 
the fusion of the liposomes with cell membranes [16]. Tuning MO content in DODAB:MO 
formulations is also very advantageous in terms of formulation development for drug/protein 
delivery purposes, since MO has been described as an enhancer of proteins solubilization 
[25-28]. 
Fungal cell wall protein antigens constitute excellent candidates for vaccine 
development as the cell wall is a unique microbial feature with an important role in antigen 
presentation and immunomodulation [29]. Currently, several vaccine strategies against 
Candida have been investigated, using several cell wall antigens varying from proteins 
carriers conjugated with laminarin [30, 31] or mannoproteins conjugates [32] to recombinant 
cell surface proteins or peptides, such as Hyr1p [33], or the surface adhesins family of 
proteins (Als proteins) [34-36]. These studies administered these antigens with several 
adjuvants or carriers such as complete Freund’s adjuvant (CFA), aluminum hydroxide gel or 
MPL (lipid A; monophosphoryl) [37-39]. Other studies also reported the used of β-
mercaptoethanol (β -ME) extracts containing Candida cell wall proteins mixed with Ribi 
Adjuvant System [40]. However, despite the extensive investigation, more studies are needed 
to develop a safe and efficient a vaccine against Candida infections.  
In the present study, we developed and explored a DODAB:MO lipid based delivery 
system loaded with dithiothreitol (DTT) extracted C. albicans cell wall surface proteins 
(CWSP) and determined its immunogenicity for future use against deleterious fungal 
infections.  
 
 
 
 
 
 
 
 
 
CHAPTER V 
________________________________________________________________________________________________________________ 
 
	  140	  
2. MATERIAL AND METHODS 
 
2.1. Materials 
Dioctadecyldimethylammonium bromide (DODAB) was purchased from Tokyo 
Kasei (Japan). 1-monooleoyl-rac-glycerol (MO), Hanks’ balanced salt solution (HBSS), 
glutaraldehyde, propidium iodide (PI) and DTT were supplied by Sigma–Aldrich (St. Louis, 
MO, USA). Wheat Germ Agglutinin Alexa Fluor® 633 Conjugate (λem=647nm) was 
provided by Alfagene (Carcavelos, Portugal), Rhodamine DHPE (Lissamine™ λem=580nm) 
and Tris-HCI Buffer by Invitrogen/Molecular Probes (Eugene, OR, USA) and ethanol (high 
spectral purity) was purchased from Uvasol (Leicester, United Kingdom). Dulbecco’s 
Modified Eagle’s Medium (DMEM) was supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM L-glutamine, (all from Sigma-Aldrich), HEPES-Buffer solution 
pH=7.5 supplied by VWR Internacional (Radnor, PA, USA) and 1mM sodium pyruvate by 
Merck (Frankfurt, Germany).  
 
2.2. Extraction of yeast cell wall surface proteins  
C. albicans strain SC5314, kindly provided by Prof. Joachim Morschhauser 
(Wurzburg, Germany), was obtained from a 2 day YPD agar (2 % D-glucose, 1% Difco yeast 
extract, 2% peptone and 2% agar) (w/v) culture incubated at 26 °C. The following procedures 
used for CWSP extraction were all performed in a sterile environment using apyrogenic 
solutions. The CWSP were released from whole intact cells by DTT treatment as described 
previously [41] with some modifications. Briefly, yeast cells were grown in YPD medium at 
26 °C, 180 ×g, to the start of the stationary growth phase. Cells were then harvested by 
fugation and washed twice with 50 mM-Tris–HCl pH 7.5 buffer. Subsequently, cells were 
resuspended in the same buffer supplemented with 2 mM dithiothreitol (DTT), shaken 
vigorously for 2 h at 4 °C and centrifuged at 7943g for 15min. The yeast pellet obtained was 
used for assessment of membrane integrity while the yeast CWSP in the supernatant were 
concentrated and retained. Membrane integrity was assessed by incubating cells with PI (6 
µg/ml) and analysis by flow cytometry (EPICS XL-MCL, Beckman-Coulter Corporation). 
Supernatant proteins were concentrated with a 3 kDa Amicon centrifugal filter supplied by 
Millipore (Madrid, Spain) at 4 °C, washed with 25 mM HEPES-buffer solution pH=7.5 and 
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quantified by means of the Bradford assay [42]. The concentrated proteins obtained were 
stored at -80 °C in aliquots of 100 µg/ml. 
 
2.3. Western Blot 
Extracted proteins were subjected to 12% SDS-polyacrylamide gel electrophoresis 
and transferred to polyvinylidene fluoride membranes (hybond-P; Amersham). The 
membranes were blocked with 3% BSA in Tris-saline buffer (w/v) containing 0.05% Tween 
(v/v) for 2 h at room temperature. Membranes were then incubated overnight at 4 ºC with a 
pool of antisera (1:250) from immunized mice. Bound antibodies were detected with goat 
anti-mouse Igs AP conjugate and membranes were developed using the conventional method 
with nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indolylphosphate (BCIP) (Roche) in 
100 mM Tris, 100 mM NaCl, and 5 mM MgCl2, pH 9.5. A broad range SDS-PAGE 
molecular weight (MW) marker (15-250 kDa) was used (Bio-Rad).  
 
2.4. Identification of the proteins 
The protein bands, excised from the gel, were destained, reduced, alkylated and 
digested with trypsin (Promega, 6.7ng/µl) overnight at 37 ºC. The tryptic peptides were 
desalted and concentrated using POROS R2 (Applied Biosystems) and eluted directly onto 
the MALDI plate using 0.6µl of 5mg/ml CHCA (alpha-cyano-4-hydroxycinnamic acid, 
Sigma) in 50% (v/v) acetonitrile and 5% (v/v) formic acid. The data was acquired in positive 
reflector MS and MS/MS modes using a 4800plus MALDI-TOF/TOF (AB Sciex) mass 
spectrometer and using 4000 Series Explorer Software v.3.5.3 (Applied Biosystems). 
External calibration was performed using Pepmix1 (Laser BioLabs). The twenty-fifth most 
intense precursor ions from the MS spectra were selected for MS/MS analysis. The MS/MS 
data were analyzed using Protein Pilot Software v. 4.5 (ABSciex) with the Mascot search 
engine (MOWSE algorithm). The search parameters were as follows: monoisotopic peptide 
mass values were considered, maximum precursor mass tolerance (MS) of 50 ppm and a 
maximum fragment mass tolerance (MS/MS) of 0.3 Da. The searches were performed against 
SwissProt database with or without taxonomic restriction for Fungi. A maximum of two 
missed cleavage was allowed. Carboxyamidomethylation of cysteines and oxidation of 
methionines, were set as fixed and variable modifications, respectively. 
CHAPTER V 
________________________________________________________________________________________________________________ 
 
	  142	  
Protein identification was only accepted when significant protein homology scores 
were obtained (P<0.05) and at least one peptide was fragmented with a significant individual 
ion score (P<0.05). This data was obtained at the Mass Spectrometry Unit (UniMS), at 
ITQB/iBET, Oeiras, Portugal. 
 
2.5. Preparation and characterization of CWSP-loaded liposomes 
DODAB:MO based liposomes were prepared using the lipid-film hydration method as 
previously described [43]. DODAB and MO, at a DODAB molar fraction (χDODAB) of 
0.33, were dissolved in ethanol and mixed in a round-bottom flask. The χDODAB is given 
by the following equation [25]: 
 𝜒DODAB = DODAB
DODAB + MO
  
 
The solvent was removed by rotary evaporation at 55 ºC and liposomes formed after 
hydration of the lipid film with 25 mM HEPES pH 7.5 at 55 ºC. The dispersion was then 
placed in a bath sonicator during 2 min .The liposomal stock dispersion was prepared at a 
total lipid concentration of 1774 µg/ml. Using 5 µg/ml of CWSP, seven different 
formulations containing different protein/lipid ratio (w/w), 0.006, 0.011, 0.014, 0.028, 0.056 
and 0.113 were prepared (Table 1). The formulations were then incubated for 1h at 55 ºC. 
The z-average diameter of all formulations was determined by dynamic light scattering at 25 
ºC with a Malvern ZetaSizer Nano ZS particle analyzer. The Malvern Dispersion Technology 
Software (DTS) was used with multiple narrow mode (high-resolution) data processing, and 
mean size (nm), polydispersity index (PDI) and error values were determined. The liposomal 
nanoparticle (LNP) surface charge was measured indirectly by ζ-potential analysis at 25 ºC 
using DTS with mono-modal mode data processing to determine average ζ-potential (mV) 
and error values. For several studies, an up-scale of some formulations, using 50 µg/ml of 
protein, was necessary but in all cases the protein-to-lipid weight ratios was maintained as 
described in Table 1. 
 
2.5.1 Quantification of protein adsorption to liposomes  
The prepared formulations were pelleted by ultracentrifugation (100,000g for 1 h), the 
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pellet submitted to TCA protein precipitation (Thermo Scientific Pierce), and the 
concentration of CWSP determined using the BCA Protein Assay Kit (Thermo Scientific 
Pierce) according to the manufacturer’s instructions. The empty liposomes were used as 
negative control in order to exclude lipid interference in the protein quantification method. 
 
2.5.2 Cryo-SEM analysis of liposomes 
The morphology of the liposomes was evaluated by cryogenic scanning electron 
microscopy (cryo-SEM) using a High resolution Scanning Electron Microscope with X-Ray 
Microanalysis (JEOL JSM 6301F/ Oxford INCA Energy 350/ Gatan Alto 2500). Aliquots of 
4 µl of empty liposomes (total lipid concentration of 888 µg/ml) or 4 µl of formulation ADS1 
LNPs (50 µg/ml of CWSP and 888 µg/ml of lipids, CWSP:Lipid weight ratio of 0.056) were 
placed into carbon film grids, rapidly cooled (plunging into sub-cooled nitrogen – slush 
nitrogen) and transferred under vacuum to the cold stage of the preparation chamber. The 
samples were fractured, sublimated (‘etched’) for 120 seconds at -90 °C and coated with 
Au/Pd by sputtering for 40 seconds. Samples were transferred into the SEM chamber and 
studied at a temperature of -150°C.Micrographs were captured at an acceleration voltage of 
15 kV and a working distance of 15 mm with a secondary electron in lens detector. 
 
Table 1: Total lipid and of antigen concentrations for the different protein to lipid weight ratios. 
 
Equal volumes of CWSP were added to the liposomes dispersions and the final concentrations of the 
formulations are presented. For some experiments, the concentration of total lipid and of CWSP was increased 
but protein to lipid ratio was maintained. 
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2.6. Macrophage studies  
The in vitro studies were performed using the murine macrophage cell line J774A.1 
as previously described [44]. This cell line was cultured in complete DMEM at 37°C in a 5% 
CO2 atmosphere. After confluent growth, macrophage cells were recovered, washed and re-
suspended in complete DMEM to the desired final concentration. 
 
2.6.1 Cytotoxicity analysis  
Macrophages were plated onto 96-well tissue culture plates (Falcon) at 3x105 
cells/well and incubated to adhere overnight at 37 ºC in a humidiﬁed atmosphere of 5% CO2. 
Different concentrations of empty liposomes, CWSP alone and two LNPs, ADS1 
(CWSP:Lipid weight ratio of 0.056) and ADS2 (CWSP:Lipid weight ratio of 0.376), were 
added to the cells. Cell viability was analyzed by the 3-(4,5-dimethyl- thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [45] following 24 h and 48 h incubation with the 
different formulations, at different concentrations. MTT formazan was solubilized by adding 
DMSO:ethanol (1:1) solution and absorbance measured at 570 nm. Untreated cells were used 
as a control of viability (100%) and cells treated with DMEM:DMSO (4:1) as a control of 
cytotoxicity (100%). Results were expressed as percentage of viability according to the 
following equation: 
 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 % = 𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙  𝑣𝑎𝑙𝑢𝑒   𝑎𝑣𝑒𝑟𝑎𝑔𝑒 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙  𝑜𝑓  𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦  (𝑎𝑣𝑒𝑟𝑎𝑔𝑒)  C𝑜𝑛𝑡𝑟𝑜𝑙  𝑜𝑓  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦   𝑎𝑣𝑒𝑟𝑎𝑔𝑒 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙  𝑜𝑓  𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦  (𝑎𝑣𝑒𝑟𝑎𝑔𝑒)   ×  100 
 
2.6.2 Microscopy analysis of internalized liposomes  
For confocal microscopy, Rhodamine DHPE was incorporated into the DODAB:MO 
liposome (at a molar ratio of 1:200) during the preparation phase, as described in section 2.3. 
Labeled liposomes were then pelleted by ultracentrifugation (100,000g for 1 h) to remove 
unbound dye and resuspended in the same buffer volume. This labeled liposome stock 
dispersion was used to prepare the various protein to lipids weight ratios formulations, as 
described in section 2.3. Macrophages were plated in a microscopy chamber plate (Ibidi) at 
3×105 cells/well and left to adhere overnight at 37 ºC in a humidiﬁed atmosphere of 5% CO2. 
Immediately prior to incubation with liposomes, the macrophages were labeled with Wheat 
Germ Agglutinin Alexa Fluor® 633 Conjugate (2.5 µg/ml) for 10 min and then washed twice 
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with HBSS. The microscopy chamber plate was then placed in the integrated chamber (37 ºC, 
5% CO2) of the LSM 780 Carl Zeiss Microscope and 8 µl of DODAB:MO (1:2) empty 
labeled liposomes (total lipid concentration of 888 µg /ml) and 8 µl of labeled ADS1 or 
ADS2 LNPs were added to the adhered macrophages. A time-lapse imaging video and a z-
stack image after 75 min were obtained and images were analyzed using ZEN 2012 lite 
software (ZEISS). 
For scanning electron microscopy (SEM), macrophages were plated at 5×105 
cells/well onto 24-well tissue culture plates (Falcon) containing clean sterile glass coverslips 
(Ø13 mm) and left to adhere overnight at 37 ºC in a humidiﬁed atmosphere of 5% CO2. 8 µl 
of DODAB:MO (1:2) empty liposomes (total lipid concentration of 888 µg/ml), 8 µl of 
ADS1 or ADS2 LNPs were added to the adhered macrophages. After 30 min, cells were 
washed with 1× PBS and fixed according to Hoess et al [46] with some modifications. 
Briefly, cells were fixed with 2% glutaraldehyde in PBS (v/v) for 2h at 4 ºC and dehydrated 
through a series of 10 min incubations in increasing ethanol concentrations (10, 30, 50, 70, 90 
and 100%). Desiccation was carried out with two mixtures of hexamethyldisilazane:ethanol 
(1:2, 2:1) (v/v) and pure hexamethyldisilazane for 3 min each followed by air-drying. Glass 
coverslips were mounted onto aluminium stubs, sputter-coated with gold and observed with 
an S-360 scanning electron microscope (Leo, Cambridge, USA). 
 
2.6.3 Cytokine production  
Macrophages were plated onto 96-well tissue culture plates (Falcon) at 3×105 
cells/well, incubated with the prepared lipid formulations and the release of pro-inflammatory 
cytokine TNF-α was quantified after 2, 6 and 24 h of incubation. The Mouse TNFα Elisa Kit 
(Thermo Scientific) (Sensitivity: 9 pg/mL) was used according to the manufacturer’s 
instructions. Macrophages incubated with 1µg/ml LPS were used as a positive control and 
macrophages alone as a negative control. 
 
2.7. Immunization procedures 
Female BALB/c mice, 8 to 10 weeks old, were purchased from Charles River (Barcelona, 
Spain) and kept under specific-pathogen-free conditions at the Animal Facility of the 
Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. All procedures involving 
mice were performed according to the European Convention for the Protection of Vertebrate 
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Animals used for Experimental and other Scientific Purposes (ETS 123), the 86/609/EEC 
directive and Portuguese rules (DL 129/92).  
 
2.7.1 Immunization protocol 
Eight BALB/c mice per group, total of 4 groups, were injected subcutaneously three 
times with a 2-week intervening period, with 200µl of one of the following preparations: 
CWSP alone (50 µg/ml); DODAB:MO (1:2) empty liposomes (total lipid concentration of 
888 µg/ml), ADS1 or ADS2. Following the last immunization, serum was collected by retro-
orbital bleeding and mice humanely terminated by placing them in a closed chamber filled 
with CO2. Spleens were aseptically removed and total splenocytes obtained by 
homogenization of the tissue in HBSS buffer. 
 
2.7.2 Quantification of CWSP Specific Antibody Isotypes 
Specific anti-CWSP immunoglobulins in the collected serum were quantified by an 
enzyme-linked immunosorbent assay (ELISA) according to Ferreirinha et al. [47]. Briefly, 
polystyrene microtiter plates (Nunc, Roskilde, Denmark) were coated with 5 µg/ml of CWSP 
and incubated overnight. Wells were then saturated for 1 h at room temperature with 1% 
BSA in PBS (w/v) and serial dilutions of the serum samples were plated and incubated for 2 
h at room temperature. After washing, alkaline phosphatase-coupled monoclonal goat anti-
mouse IgG1 and IgG2a (Southern Biotechnology Associates, Birmingham, AL) were added 
and incubated for 30 min at room temperature. After washing, the bound antibodies were 
detected by development with a substrate solution containing p-nitrophenyl phosphate 
(Sigma) during 30 min, and the reaction stopped by addition of 0.1 M EDTA, pH 8. The 
absorbance was measured at 405 nm, subtracting for each well the value of the absorbance at 
570 nm. The antibody titers were expressed as the reciprocal of the highest dilution with an 
absorbance 2X higher than the value of the control (no serum added). 
 
2.7.3 Analysis of Cytokine Production 
Splenocytes isolated from mice were washed, re-suspended in RPMI 1640-FCS and 
seeded at 1×106 cells/ml in 96-well flat-bottom plates (Nunc). Spleen cells were stimulated ex 
vivo for 6 days with CWSP (5 µg/ml) at 37 °C in 5% CO2. The culture supernatants were 
collected and IFN-γ (Sensitivity: 2 pg/mL), IL-17 (Sensitivity: 5 pg/mL), IL-10 (Sensitivity: 
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5.22 pg/mL) and IL-4 (Sensitivity: 2 pg/mL) levels quantified with Duo-Set ELISA kits (all 
from R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. 
 
2.7.4 Proliferation of Splenocytes ex Vivo  
After ex-vivo stimulation with 5µg/mL CWSP, splenocytes were incubated with 
polystyrene monodisperse microparticles (Fluka) and the number of splenocytes determined 
by Flow Cytometry ((Beckman-Coulter Corporation, Hialeah, FL, USA) according to the 
manufacturer’s instructions. CD3 was used as a positive control for proliferation. 
 
2.8. Statistical Analyses 
Data were analyzed using analysis of variance (ANOVA) followed by the Bonferroni 
test to compare the mean values of different groups, using GraphPad Prism 5 software 
(GraphPad Software, Inc., La Jolla, CA). Unless otherwise stated, results shown are from 
three independent experiments with three replicates. Differences were considered significant 
when the p value was less than 0.05. 
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3. RESULTS 
 
3.1. Characterization of CWSP-loaded liposomes 
In previous studies, we observed that DODAB:MO formulations with an enriched 
MO content assembled mainly as vesicles with lamellar structures containing inverted non-
lamellar structures. This morphology is observed probably because MO is preferentially 
localized in the interior of the lipidic structures, due to its natural negative curvature [16, 23]. 
These structures will offer a high surface area that may be advantageous for 
entrapping/adsorbing antigens for vaccine development.  
In the present study, we used liposomes based on DODAB and MO with a χDODAB 
of 0.33 to prepare antigen delivery systems (ADS) and evaluated the adjuvant potential of 
this lipid formulation. C. albicans CWSP obtained by using the reducing agent DTT were 
selected as antigens for the DODAB:MO delivery systems. Flow cytometry analysis of  
C. albicans cells after the extraction treatment confirmed the membrane integrity of yeast 
cells (>99% PI negative) (Figure 1), thereby ensuring that the majority of the extracted 
proteins are derived from the surface of the yeast cell and that cytoplasmic protein 
contamination is low.  
 
 
Figure 1: (A) Flow cytometry evaluation of membrane integrity of C. albicans. Cells were stained with the 
propidium iodide (PI), a membrane impermeant dye, before (I) and after (II) treatment with DTT used for 
CWSP extraction. Membrane disrupted, by heat, C. albicans cells were used as a negative control (III). In the 
histograms, PI stained cells percentage is indicated and gated in H-2. Histograms are a representative example 
from one of three independent experiments (mean ± SD). No less than 20 000 cells were analyzed per condition. 
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This method yielded 3 ± 0.04 µg of proteins/g of cell dry weight and DLS and  
ζ-potential measurements suggested polydisperse (PDI) (0.63 ± 0.01), negatively charged  
(-14 ± 0.70 mV) proteins with a mean size of 88.76 ± 5.1. The DLS size distributions of the 
extracted CWSP and can be found in supplementary information (Figure 2). 
 
 
Figure 2: DLS size distributions of CWSP. The mean size, PDI and populations size are indicated. The DLS 
image is a representative result of three independent experiments (mean ± SEM). 
 
DODAB:MO liposomes were relatively polydisperse, PDI ~ 0.39 ± 0.01, with a main 
(95 ± 6%) population size of around 245 ± 18 nm and were highly positively charged (+52 ± 
2.4 mV). Since the protein-to-lipid weight ratio is highly decisive for the aggregation 
behavior of the liposomes [48], seven different formulations were prepared and characterized. 
Figure 3 includes a schematic representation of the possible protein-to-lipid interactions 
observed at different protein-lipid weight ratios. Analyses of the mean size and ζ- potential of 
these formulations indicated that at protein/lipid weight ratios below 0.014, an increase in the 
liposomal nanoparticle (LNP) size and heterogeneity is observed in comparison with the 
naked liposomes (Figure 3). The mean size of the LNPs at the lowest protein/lipid ratio 
(0.006) was approximately 200 nm, similar to the empty liposomes, what confirms a small 
adsorption of the protein at this point. The PDI of these LNPs revealed however a more 
polydisperse population in comparison with the naked vesicles, which can be explained by 
the presence of a high amount of liposomes competing for the proteins. However, at 
protein/lipid ratio from 0.006 to 0.014, the mean size of the LNPs increased significantly, 
from 207.2 ± 49.8 nm to 4143 ± 1903 nm, and this increase was characterized by aggregation 
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at room temperature (data not shown). It is also important to mention that the increase in 
mean size and PDI was accompanied by a decrease in ζ-potential from 51.1 ± 1.02 mV 
(naked liposomes) to 22.7 ± 1.1 mV (at weight ratio 0.014).  
 
 
Figure 3: Representative mean size, PDI and ζ-potential of DODAB:MO LNPs at different protein-to-lipid 
weight ratios. At the bottom, a schematic representation of the possible interactions between proteins and 
liposomes: (I) empty liposomes, (II) at low protein to lipid weight ratios, liposomes and proteins interact 
forming unstable aggregates, (III) at intermediate protein to lipid weight ratios, liposomes adsorb more proteins, 
forming a protein corona around the liposomal surface that stabilizes liposomes and reduces liposome-to-
liposome interactions, and (IV) at high, protein to lipid weight ratios, liposomes with a protein corona are 
formed and free proteins remain in solution. Significant differences between the different formulations and the 
empty liposomes are: *⁄P<0.05, and ***P<0.001. All values shown are the average values from three 
independent experiments ± SEM.  
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In contrast, a LNP size reduction is observed at protein/lipid weight ratios of 0.028 
and above, ranging from 1157 ± 143.5 nm to 223.1 ± 23.1 nm. In addition, at these 
protein/lipid ratios the ζ-potential became negative, ranging from -17.95 ± 0.07 mV to -24.03 
± 0.14 mV. This is a clear indication that, by decreasing the concentration of lipids the 
positive charge of this LNPs is shielded by the negative residues of the adsorbed proteins and 
the vesicles become negatively charged. The DLS size distributions of DODAB:MO 
liposomes at the different protein/lipid weight ratios are represented in Figure 4.  
The morphology of the liposomal structures was determined by Cryo-SEM (Figure 5) 
and demonstrated that the DODAB:MO microstructure is clearly dominated by spherical 
vesicles of variable sizes, as already observed by DLS assays. Large vesicles (≥ 500 nm) 
were also detected, in some of which it is possible to observe smaller vesicles inside. It was 
also observed that the vesicles with a protein-to-lipid weight ratio of 0.056 had a mean 
particle size of around 350 nm, showing that the addition of proteins did not changed the 
main morphology; it only reduced the mean size of the LNPs. 
Based on physicochemical properties (Figure 3), negatively charged LNPs with mean 
sizes around 200 nm, and acceptable PDI values were selected. The LNPs with a protein/lipid 
weight ratio of 0.056, designated as ADS1 (antigen delivery system 1), and the LNPs with a 
protein/lipid ratio of 0.376, designated as ADS2 (antigen delivery system 2) were selected. 
These were the LNPs with the highest (833 µg/ml) and lowest (125 µg/ml) lipid 
concentrations, respectively, that meet the criteria defined. 
After selecting the formulations, the protein adsorption was quantified. ADS1 and 
ADS2 LNPs presented different degrees of antigen adsorption efficiency: 91.0 ± 9.0% for the 
former and 16.5 ± 4.5% for the latter, showing that an increase in the protein/lipid ratio 
reduced the protein adsorption. In order to confirm this trend the adsorption efficiency of the 
protein/lipid weight ratio 0.113 was quantified and, as expected, an intermediate value of 
45.2 ± 4.9% was obtained. 
 
CHAPTER V 
________________________________________________________________________________________________________________ 
 
	  152	  
 
Figure 4: DLS size distributions of DODAB:MO liposomes at different protein-to-lipid weight ratios. The 
mean size, PDI and main population size are indicated. The DLS image is a representative result of three 
independent experiments (mean ± SEM). 
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Figure 5: Representative image of DODAB:MO liposomes morphology observed by Cryo-SEM.  
I) Liposomes alone (36 µg/ml of total lipid) with the insert showing an open liposome and, II) liposomes (final 
concentration 36 µg/ml of total lipid) after incubation with the antigenic proteins (final concentration 2 µg/ml).  
 
3.2. In vitro activation of phagocytic cells 
Before evaluating the immunostimulatory potential of the formulations their 
associated cytotoxicity was considered. Figure 6 shows cell viability values above 81% for 
all formulations and lipid concentrations upon 24 and 48 h of co-incubation, indicating that 
the CWSP and ADSs systems are not cytotoxic to these cells.  
 
 
Figure 6. The effect of different concentrations of empty liposomes, CWSP, ADS1 or ADS2, on the viability of 
J774A.1 cells. Viability was assessed using the MTT assay after 24 h and 48 h incubation. The liposomes, 
CWSP and the ADSs were diluted in the cells medium and the final concentration is indicated in the x-axis. 
Results indicate the mean ± SEM of three independent experiments. Significant differences between the two 
time points, 24 h and 48 h of incubation, are indicated: (**P<0.01, ***P<0.001).  
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We also characterized macrophage morphology after one hour of incubation with the 
different formulations by scanning electron microscopy (SEM) and found these to be similar 
to that of the control cells (Figure 7), in agreement with the toxicity results. 
 
 
Figure 7: Representative SEM photomicrographs of macrophage cell morphology untreated (A); after 1 h 
incubation with empty liposomes (36 µg/ml) (B); after 1 h incubation with ADS1 (2:36 µg/ml; CWSP:Lipid ) 
(C) or ADS2 (2:6 µg /ml; CWSP:Lipid)  (D) . 
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ADS1 LNPs uptake by J447 cells was monitored for 70 min by confocal microscopy 
in order to determine uptake by macrophages (Figure 8A). A gradual intracellular 
accumulation of rhodamine labeled LNPs was observed with time, showing that ADS1 is 
efficiently taken up by macrophages (Supplementary data Movie S1).  
 
 
 
Figure 8: A representative confocal microscopy image of ADS1 uptake, by J774A.1 cells. (A) Uptake as a 
function of incubation time over 75 min. Rhodamine labeled ADS1 (red) superimposed with Alexa Fluor® 633 
Conjugate labeled macrophages (blue). B) A mid-point thickness view (22.8 µm x 20.7 µm x 0.7 µm) of the cell, 
indicated by a rectangle in (A), shows rhodamine fluorescence superimposed with Alexa Fluor® 633 Conjugate 
fluorescence (z). Z-axis rotations of a single transverse slice through two sections of the cell: view in the x-0-z 
plane (x) and view in the y-0-z plane (y) are also presented. 
 
Interestingly, an image viewed at the mid-point of cell thickness shows that most of 
the rhodamine fluorescence did not spread uniformly and seemed to concentrate intra-
cellularly in discrete sites (Figure 8B). Rhodamine fluorescence appears to be distributed 
throughout the cytoplasm, the transport endosome region and in the Golgi area next to the 
nucleus, which itself does not reveal any fluorescence signal. By analyzing co-localization 
with Alexa Fluor 633 the fluorescence was observed to be within membrane-rich regions, i.e., 
in the cytoplasmic area and in the cellular extensions (Figure 8A - arrow head), resembling 
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the pattern seen after endocytosis described previously [49]. The internalization of a labeled 
ADS1 was estimated to be around 20 min, in agreement with other studies that assessed 
endocytosis of a liposome to occur within 30 min (Figure 9) [49, 50]. 
 
 
Figure 9: Representative confocal microscopy image of a time-resolved magnification of Rhodamine 
labeled ADS1, indicated by the yellow arrow in Figure 8A, penetrating a J774A.1 cell during 35 min. 
(38.66 µm x 42.61µm). 
 
Secretion of pro-inflammatory cytokines, namely TNF-α, by the macrophages was 
quantified by ELISA after co-incubation with the different formulations (Figure 10). 
Untreated cells and cells stimulated with liposomes alone produced residual or no TNF-α. 
CWSP significantly (P<0.01) potentiated the production of TNF-α in a time dependent 
manner in comparison with lipids alone. ADS2 LNPs also induced TNF-α production as 
expected since free CWSP are also present in this formulation, but the levels were 
significantly lower than for CWSP (P<0.05). ADS1 LNPs however failed to enhance the 
basal levels of TNF-α production. 
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Figure 10: Production of TNF-α by J774A.1 cells after incubation with CWSP (2 µg/ml), liposomes alone  
(36 µg/ml), ADS1 (2:36 µg/ml; CWSP:Lipid), ADS2 (2:6 µg/ml; CWSP:Lipid), or LPS (1 µg/ml) for 2, 6 and 
24 h.  Results indicate the mean ± SEM of three measurements and represent three independent experiments. 
Significant differences between ADSs and the CWSP are shown above the symbol / and significant differences 
between the ADSs are shown below /: *P<0.05, **P<0.01, and ****P<0.0001. 
 
3.3. Immunological characterization of CWSP-loaded liposomes 
The potential of the ADSs to act as adjuvant/antigen delivery vehicles in vivo, was 
analyzed by determining both humoral and cell mediated immune responses elicited by the 
loaded CWSP. The humoral response was analyzed by quantification of CWSP-specific IgG1 
and IgG2a antibody production, after immunization with ADS1, ADS2, CWSP alone or 
empty liposomes (Figure 11). Immunization with ADS2 induced similar levels of IgGs as 
immunization with the proteins alone (P>0.05). On the contrary, the IgG response of mice 
immunized with ADS1 was significantly higher (P<0.05) than the response observed with 
proteins alone. 
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Figure 11: Anti-CWSP specific IgG1 and IgG2a responses in serum of mice immunized with 200 µl of the 
following: CWSP alone (50 µg/ml), ADS1 (50:888 µg/ml; CWSP:Lipid), ADS2 (50:133 µg/ml; CWSP:Lipid), 
or empty liposomes (888 µg/ml). The antibody titers are expressed as the reciprocal highest dilution with an 
absorbance 2X higher than the value of the control (no serum added). Each point represents an individual 
mouse. Horizontal lines correspond to the mean value in each group. Results are representative of two 
independent experiments. Significant differences between the ADSs LNPs and the CWSP are shown above the 
symbol / and significant differences between the ADSs LNPs are shown below /: *P<0.05, **P<0.01 and 
***P<0.001.  
 
Comparing the two systems, immunization with ADS1 resulted in significantly higher 
levels of IgG1 and IgG2a than immunization with ADS2 (P<0.05). IgG1 was the 
predominantly produced isotype as the ratio of IgG1:IgG2a in mice immunized with the 
CWSP was 21.4. However, in mice immunized with ADS1, the IgG1:IgG2a ratio was three 
times lower as compared to the one detected when using free-proteins, indicating that 
immunization with ADS1 shifted the immune response to a Th1-type (P<0.05) in comparison 
with mice immunized with the CWSP alone. 
Cell mediated immune responses to CWSP delivered by the prepared liposomes were 
evaluated by splenocytes proliferation analysis and subsequent quantification of cytokine 
secretion after antigen re-stimulation. Results showed that, after re-stimulation, splenocytes 
from all groups of mice, except from mice immunized with empty liposomes, exhibited a 
higher (P<0.05) proliferative response in comparison with the respective non re-stimulated 
controls (Figure 12).  
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Figure 12: Splenocytes proliferation after re-stimulation with CWSP (5 µg/ml) after 6 days incubation. Controls 
are cells incubated in the same conditions without re-stimulation and CD3 was used as a positive control for 
proliferation. Each point represents an individual mouse. Results are representative of two independent 
experiments. Significant differences between control and re-stimulated cells are indicated above the bars and 
differences between the groups are indicated above the horizontal line: *P<0.05, **P<0.01. 
 
Splenocytes from mice immunized with ADS1 showed the highest levels of 
proliferation and only these presented a significant proliferation (P<0.05) in comparison with 
cells from CWSP immunized mice. Quantification of IFN-γ and IL-17 was performed after 
re-stimulation with CWSP as indicators of a Th1 or Th17-type polarized response, 
respectively, while IL-4 and IL-10 were used as indicators of a Th2 pathway. Re-stimulated 
splenocytes derived from mice immunized with ADS1 or ADS2 secreted IFN-γ and IL-17A, 
while splenocytes from mice immunized with CWSP or liposomes alone failed to do so 
(Figure 13). Importantly, the levels of these cytokines were much higher in mice immunized 
with ADS1 (380.0 pg/ml of IFN-γ and 124.0 pg/ml of IL-17A) than with ADS2 (41.6 pg/ml 
of IFN-γ and 2.0 pg/ml of IL-17A) (P<0.05). 
The production of IL-4 and IL-10 was investigated as an indicator of Th2 
polarization. Low levels of IL-4 were detected in splenocytes of mice immunized with ADS1 
(31 pg/ml) and ADS2 (11.6 pg/ml) while residual or no production was observed in mice 
immunized with CWSP or liposomes alone. IL-10 levels were similar in all groups (between 
55.1 and 99.6 pg/ml) except for the group of mice injected with lipids alone where only 
residual levels were observed (1.7 pg/ml).  
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Figure 13: Cytokine production from CWSP re-stimulated splenocytes derived from mice immunized with 200 
µl of the following: CWSP alone (50 µg/ml), ADS1 (50:888 µg/ml; CWSP:Lipid), ADS2 (50:133 µg/ml; 
CWSP:Lipid), or empty liposomes (888 µg/ml). Bars denote mean cytokine levels, and error bars denote SD of 
8 mice per group. Results are representative of two independent experiments. Significant differences between 
the systems and the CWSP are shown above the symbol / and significant differences between systems are 
shown below the symbol /: *P<0.05, **P<0.01 and ***P<0.001.  
 
As expected, no significant differences were observed regarding levels of IL-4 or  
IL-10 between mice immunized with CWSP and ADS2. Comparing both ADSs LNPs, the 
levels of IL-4 and IL-10 secreted by splenocytes of mice immunized with ADS1 were higher 
than of mice immunized with ADS2 (P<0.01). 
 
3.4. Analysis of antibody specificities by Western blotting 
In order to determine whether the different ADS LNPs were similarly capable of 
delivering proteins, immunoblotting assays were performed by combining the CWSP proteins 
as antigens with the serum from immunized mice. Reactivity of serum obtained from mice 
immunized with CWSP revealed the presence of antibodies specific for protein bands located 
at a molecular weight of circa 60 kDa, for a protein band of approximately 40 kDa and for 
others less intensely, between 10 and 15 kDa (Figure 14). 
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Figure 14:  Western blot analysis of the C. albicans cell wall surface proteins (CWSP) used in the preparation 
of the LNPs. Proteins were separated on 12% SDS-PAGE, (between the black arrows a profile with increased 
resolution of the low molecular weight proteins is shown) (A), and transferred onto a PVDF membrane to be 
probed with serum from mice immunized with CWSP, ADS1, ADS2 or liposomes alone (B). 
 
Curiously, serum from mice immunized with ADS1 contained antibodies mainly 
reactive with a protein (or proteins) with a molecular weight of approximately 200 kDa, 
while serum from mice immunized with ADS2 mainly contained antibodies specific for this 
protein but also for proteins with a molecular weight of ~ 60 kDa, as observed for the serum 
of mice immunized with CWSP. The reactivity detected with serum of mice immunized with 
ADS2 is in agreement with the fact that, with this lipid formulation, only 16% of the proteins 
are entrapped and most is free, as in mice immunized with CWSP alone. Protein sequence 
analysis revealed that the protein that was mainly identified by antibodies induced by ADS1 
was Cht3p (60.0 kDa) (Figure 14, band 1), the major chitinase that has been reported to be 
present at C. albicans cell wall [51]. In contrast, the protein identified by serum of mice 
immunized with CWSP with a molecular weight circa 40 kDa was Xog1p (50 kDa) identified 
as exo-1, 3-beta-glucanase (Figure 14, band 3), which has also been identified at C. albicans 
cell wall [52]. Unfortunately, the other protein identified by the serum of CWSP immunized 
mice with a molecular weight ~ 60 kDa (Figure 14, band 2) could not be identified by the 
method applied due to the presence of several proteins in that molecular weight range. 
Nevertheless it is clear that the ADS1 favors the induction of antibodies against Cht3p, a 
protein with none or very low reactivity to be delivered alone. 
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4. DISCUSSION 
 
In this study, we evaluated “in vivo” for the first time the ability of DODAB:MO 
liposomes to act simultaneously as protein delivery vehicles and immunoadjuvants. In 
previous studies, we observed that the introduction of MO in DODAB based liposomes at a 
molar fraction lower than 0.5, allowed the liposomes to assemble mainly into spherical 
densely packed nanoparticles [25]. These DODAB:MO based liposomes offer a high surface 
area that may be advantageous for adsorbing antigens for vaccine development. Therefore in 
the present study, we used these liposomes to prepare antigen delivery systems (ADS) with 
C. albicans cell wall surface proteins (CWSP) as antigens and evaluated their adjuvant 
potential. Indeed, the surface of C. albicans is a signiﬁcant source of candidal antigens [53] 
and previous studies have shown that the major cell wall components that elicit a response 
from the host immune system are proteins and mannoproteins, in which both the 
carbohydrate and protein moieties are able to trigger the response [54-56]. 
The characterization of the prepared formulations revealed interesting features for 
these LNPs. At low protein/lipid weight ratios (<0.014; higher lipid concentrations) an 
increase in the LNPs mean size and heterogeneity is observed, in comparison with the naked 
liposomes, accompanied by a decrease in ζ-potential. This can be explained stepwise 
considering the decreasing effect of liposomes concentration for a fixed amount of protein. 
For the lowest protein/lipid weight ratio (0.006) there is the highest amount of cationic 
liposomes, and hence the ζ-potential presents positive values although slightly smaller 
comparing to the naked vesicles of DODAB:MO, indicating the beginning of some charge 
shielding made by the protein negatively charged residues. This charge neutralization may 
reduce the repulsion of the liposomes that tend to aggregate and thus the increase in size and 
PDI is due to the formation of aggregates of different sizes. In addition, the protein adsorbed 
at the surface might behave as linker between some positively charged LNPs promoting the 
aggregation, as represented in the schematic drawing proposed (Figure 3II). At ratio of 0.028 
and above (lower lipid concentrations) the LNPs are now negatively charged, the size is 
reducing stabilizing at a protein/lipid ratio of 0.056 with lower PDI and colloidal stability. 
This stabilization of liposomes against aggregation may be due to the adsorption of a protein 
layer around the surface of the liposomes and could result in a progressive coating of the 
cationic head groups of the liposomes with the negatively charged CWSP and thereby 
forming a protein corona as already suggested by other authors [48, 57, 58]. In fact, one of 
the main advantages of using positively charged liposomes lies on its ability to adsorb 
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oppositely charged antigens. Furthermore, complexation of liposomes with the CWSP might 
also occur by the hydrophobic effect since some of these proteins might exhibit a substantial 
proportion of hydrophobic alpha-helix domains as secondary structures, which will be prone 
to interact with hydrophobic borders of the DODAB:MO layers. In fact, the main protein 
recognized by the serum of mice immunized with ADS1, the Cht3, is indicated as a probable 
unstable protein, considering the method of Guruprasad et al. [59].  
In a previous work we characterized the DODAB:MO liposome system used in this 
study by Cryo-TEM and  showed the presence of larger and smaller vesicles with some 
internal structures [25]. Indeed, cryo-SEM performed in this work confirmed spherical 
vesicles of variable sizes, and in some, smaller vesicles inside, in accordance with Cryo-TEM 
observations. In addition, Cryo-SEM showed that the addition of proteins doesn’t change the 
main morphology of the liposomes but instead stabilizes the LNPs to a more uniform size. 
One of the advantages of using liposomes is the possibility of quantitative evaluation 
of CWSP adsorption by means of ultracentrifugation to separate free from adsorbed proteins. 
ADS1 showed an adsorption efficiency of more than 90% and ADS2 around 17% with ADS1 
being thus an excellent vehicle for CWSP adsorption. We also observed that from the 50 
µg/ml of CWSP initially added, the amount of protein effectively adsorbed into ADS1 and 
ADS2 equals 45.5 and 8.25 µg/ml, respectively, resulting in an effective ratio of protein/lipid 
of 0.05 for ADS1 and 0.06 for ADS2, when taking into account the amount of lipid used to 
prepare the LNPs. Since ADS1 and ADS2 present similar LNPs sizes it appears that the 
stabilizing protein corona is achieved at a protein/lipid ratio of around 0.05 - 0.06 and that 
addition of more liposomes doesn’t significantly increased the proteins absorbed, instead, the 
formulations aggregate and precipitation ensues. As expected, at an intermediate weight ratio 
of 0.113 approximately 45% of CWSP added were adsorbed confirming the optimal ratio for 
protein corona formation. A schematic representation of the possible LNPs structures, based 
on electrostatic interactions with the CWSP, is presented in figure 3. 
The immunostimulatory potential of these DODAB:MO based formulations was 
evaluated but firstly their cytotoxic effect was examined. Cationic liposomes are well known 
for their toxicity in comparison to neutral or anionic liposomes and DODAB liposomes were 
previously shown to be cytotoxic to macrophage cultures at concentrations ≥ 50 µg/ml [60]. 
However, since the concentration of DODAB needed for the preparation of the formulations, 
used in this study, is reduced by the introduction of MO, the cytotoxic effects associated to 
high doses of DODAB were avoided and all formulations showed viabilities above 80%. 
Indeed, cationic liposomes cytotoxic effects are well-described [61] and that is why the 
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interest in neutral and anionic liposomes is increasing [62]. However, the adsorption of 
CWSP masked the cationic charge of liposomes and that might be the reason why 
pronounced toxicity was avoided when ADS where incubated with the cells. Moreover, the 
negative charge of ADSs didn’t interfere with cell uptake. In fact, ADS1 was avidly 
internalized by macrophages as observed by the gradually intracellular accumulation of 
rhodamine labeled ADS1, stained with Alexa Fluor 633, in discrete sites membrane-rich 
regions. This pattern of internalization is similar to endocytosis pattern observed in other 
studies [49, 50] and was estimated to occur within 20 min, in agreement with other studies 
that assessed endocytosis of a liposome within 30 min [49, 50]. The mean size of the two 
LNPs selected may also contribute for adequate cell uptake since size range for optimal 
uptake of antigens and elicitation of a cellular response by dendritic cells have been 
determined to be below 500 nm [18, 63].  
After confirmation of internalization, it was important to evaluate if the LNPs were 
able to activate macrophages. Our studies indicated that only, ADS2 and the CWSP were 
able to induce the production of the pro-inflammatory cytokine, TNF-α, in J774A.1 cells. 
Only residual TNF-α was obtained upon incubation of these cells with ADS1 or liposomes 
alone. Several studies have already reported that the cell wall components of C. albicans 
have the capacity to induce the release of pro-inflammatory cytokines upon incubation with 
phagocytic cells [64-67]. The fact that ADS1, contrary to ADS2, fails to stimulate these cells 
is probably due to all CWSP being entrapped/protected and unavailable to activate, whereas 
free non-encapsulated CWSP (approx.83%) are believed to be present in ADS2. Therefore, as 
discussed previously, the phagocytic cells rapidly internalize ADS1, but fail to activate TNF-
α secretion. Similarly to these observations, it was previously described that a C. albicans 
recombinant mannoprotein was transported into the compartments of endosomes and 
lysosomes, degraded and loaded on major histocompatibility molecules without stimulating 
pro-inflammatory cytokines production [68]. The lack of evident TNF-α production could be 
an interesting feature of that delivery system by preventing deleterious side effects that could 
result from excessive inflammation still allowing antigen-delivery and the generation of an 
immune response [69]. 
Due to the results of the studies on the activation of macrophages it was thus 
important to evaluate whether the liposomes were able to activate the immune system in vivo 
and generate humoral and cellular responses. As expected, immunization with CWSP and 
ADS2 induced similar levels of IgGs, while immunization with ADS1 induced significantly 
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higher levels of IgGs than immunization with ADS2 (P<0.05). The ratio of IgG1:IgG2a in 
mice immunized with the CWSP was 21.4, suggesting a Th2-type immune response was 
generated. However, in mice immunized with ADS1, this ratio was three times lower in 
comparison with the one detected when using free-proteins, indicating that immunization 
with ADS1, promoted a shifted in the Th1/Th2 balance towards the Th1 type (P<0.05), as 
observed in previous studies with DODAB based liposomes [12]. These results show that 
increasing the amount of DODAB:MO liposomes used to incorporate the CWSP (ADS1) is 
effective in enhancing not only the levels of CWSP-IgGs but also the balance towards a Th1-
type response, which is known to be protective in C. albicans infections [70]. In accordance 
with this, splenocytes of ADS1 immunized mice produced higher levels of IFN-γ and Il-17 
than splenocytes from mice immunized with the other formulations after re-stimulation with 
the proteins. These are important indicators of T-cell activation and protective immunity and 
numerous vaccine studies have shown their importance in C. albicans vaccine efficacy [71-
74]. Finally, activation of a cell-mediated immune response was also shown by the 
observation of splenocytes proliferation after specific re-stimulation (P<0.05). 
An important feature of using different formulations to deliver proteins is the 
evaluation of whether the antibodies induced by the different liposomes/CWSP are reactive 
against the same proteins. In our work, immunoblotting using CWSP as antigens revealed 
major differences in the serum CWSP-specific antibodies produced by the different groups of 
immunized mice. Serum from ADS1 immunized mice showed a pattern of CWSP-specific 
antibodies that hybridized mainly with a high molecular weight protein identified as Cht3p 
(C. albicans cell wall chitinase). Although the molecular weight estimated in our analysis 
was of around 150 -200 kDa, the molecular weight of this protein has been estimated to be 
around 60.0 kDa. This discrepancy is probably due to glycosylation of the protein, indeed it 
has been described that CHT3 has four N-glycosylation sites (Asn-Xaa-Ser/Thr) and several 
sites for 0-mannosylation [75]. In contrast, serum from mice immunized with CWSP alone 
presented antibodies against proteins around 60 kDa (not identified) and the 50 kDa Xog1p 
(C. albicans exo-1,3-beta-glucanase). Curiously, ADS2 showed a pattern of hybridization 
that appears to include the range of proteins that hybridize with serum from mice immunized 
with CWSP alone and with ADS1. The differences in the hybridization patterns between the 
ADS1 and ADS2 are in agreement with the fact that ADS2 entraps only 16% of the CWSP 
while most is free, as in mice immunized with CWSP alone and ADS1 entraps 91% of the 
CWSP, presenting a different pattern. The major difference between Xog1p and Cht3p, 
besides the molecular weight, is the fact that Cht3p is unstable in vitro. These results reveal 
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interesting features for these liposomal formulations, showing that these liposomes not only 
enhance the immune response against proteins from the pathogenic yeast C. albicans but also 
adsorb and efficiently deliver a protein considered to be unstable in vitro, that otherwise was 
not efficiently delivered. 
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5. CONCLUSIONS 
 
In this study, we prepared and evaluated “in vivo” for the first time the ability of 
DODAB:MO liposomes to act simultaneously as protein delivery vehicles and 
immunoadjuvants. The selected LNPs were stable, non-cytotoxic, avidly taken up by 
macrophages and showed a good adjuvant activity, inducing both strong antibody responses 
and cell-mediated immunity. In contrast to immunization with CWSP alone, these systems 
induced high levels of IL-17 and IFN-γ but low levels of IL-10, indicating polarization 
towards a Th1-type immune response and confirming their immunoadjuvant potential. 
Additionally, these systems favored the induction of antibodies against proteins different to 
those induced by CWSP alone, with mainly a protein(s), probably glycosylated, of high 
molecular weight being observed. The advantage of these liposomes may be associated with 
the fact that, as particulate carriers, they entrap and therefore protect the specific protein(s) 
against degradation.  
 
Supplementary data to this chapter can be found online at 
https://www.dropbox.com/s/39xq9jsvvn4yun3/Movie%20S1%20%281%29.avi?dl=0 
Movie S1: Video microscopy of ADS1 uptake by J774A.1 cells as a function of incubation 
time over 75 min. 
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ABSTRACT 
 
Here, we evaluate the potential of a liposomal antigen delivery system (ADS) 
containing C. albicans cell wall surface proteins in mediate protection against systemic 
candidiasis. Firstly, we show that loading of the CWSP in DODAB:MO liposomes enhances 
and prologues the activation of dendritic cells indicating that entrapped antigen is slowly and 
sustained released when trapped in DODAB:MO liposomes. Then we immunized mice with 
free CWSP, ADS1, ADS2 or empty liposomes. The efficacy of various formulations in 
protecting mice against a lethal dose of C. albicans was determined assessing mice survival 
rate and kidney fungal burden. Mice immunized with ADS1 significantly extended survival 
time in comparison to mice immunized with either free CWSP or buffer.  
Mice vaccinated with ADS1 LNPs developed a strong humoral response with specific 
antibodies that enhanced phagocytosis of C. albicans cells. In addition, this mice group 
developed a protective and specific Th1/Th17 response with higher frequencies of splenic 
CD4+IL-4+ cells and higher levels of IL-17/IL-10/IL-4 in CWSP re-stimulated splenocytes in 
comparison with mice immunized with free CWSP. 
In this study we demonstrate that DODAB:MO liposomes enhance C. albicans 
antigens immunogenicity and that adjuvant potential was crucial in protecting mice against a 
systemic candidiasis 
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1. INTRODUCTION 
 
Vaccines are routinely used to protect against pathogens. They generally contain 
antigens that mimic the disease-causing microorganism, including weakened or killed forms 
of the target microbe, its surface or secreted molecules. Nevertheless, the use of attenuated 
pathogens raises several safety issues due to possible reversion of the phenotype, and the use 
of single molecules may be insufficient because of antigen modifications. To overcome some 
of these issues, subunit vaccines, composed of nonliving or split pathogens, are being 
developed as immunoprotective strategies. Their effective implementation is however greatly 
limited by their poor immunogenicity when administered without adjuvant [1, 2]. Therefore, 
selecting an appropriate adjuvant or delivery system is as important as selecting the antigen 
candidates. For this purpose, cationic liposomes are interesting adjuvants that also serve as 
carriers for the targeted delivery of antigens to immune cells. These liposomes are used both 
as immunoadjuvants to induce cell mediated immunity or humoral immune responses to 
various antigens but also as delivery systems for drugs, DNA or peptides [3, 4]. In fact, 
cationic liposomes have the ability to tightly bind negatively charged  antigen, rendering 
soluble antigens into a particulate form thereby lengthening their in vivo half-life [5, 6]. 
Formulating protein antigens into nanoparticles has emerged as one of the most promising 
strategies to trigger an immune response to vaccine antigens [4-8]. Cationic liposomes 
composed by surfactant dioctadecyldimethylammonium bromide (DODAB) have been used 
as carriers in drug delivery [7, 8] as well as adjuvants for vaccination, displaying higher 
colloidal stability than alum and better efficacy in inducing cellular immune responses [9-11].  
Previously, we have demonstrated that monooleoyl-rac-glycerol (monoolein, MO), 
when used as helper lipid with DODAB, can act as a stabilizer, conferring fluidity to the 
DODAB nanoparticle liposomes by favoring lipid chain mobility [12]. In fact, we have 
successfully used DODAB:MO as a mammalian cell transfection system and as a system for 
in vitro gene silencing [8, 13]. In particular, we demonstrated that liposomes formed by 
DODAB and MO at DODAB:MO (1:2) molar ratio, assembled mainly as positively spherical 
bilamellar vesicles with some internal structures [14].  
Candida albicans is an important complex opportunistic human pathogen causing 
infections that range from superficial mucosal lesions to life-threatening systemic diseases 
[15].  It is by far the most common cause of fungal invasive infections and, despite the 
availability of new antifungal agents, candidemia is the fourth most common bloodstream 
infection in hospitalized patients both in the United States and in many European countries 
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[16-18]. Consequently, antifungal vaccines are currently considered one of the most 
appealing and cost effective strategies and many laboratories are focused on the development 
of a vaccine against Candida infections [16, 19-21]. In a recent report, we described the 
development of two liposomal nanoparticle (LNPs) antigen delivery systems (ADS), ADS1 
and ADS2, composed of DODAB:MO liposomes loaded with C. albicans cell wall surface 
proteins (CWSP) as antigens. These ADSs assembled as stable negatively charged spherical 
nanoparticles with an average particle size of approximately 280 nm. Their size mimicking 
that of natural pathogens allowed internalization and antigen presentation. Immunization with 
these systems resulted in an evident enhancement in both antibody responses and cell-
mediated immunity when compared with freely administered CWSP [22]. 
In this work, we confirmed that the designed LNP vaccine is effective against 
systemic candidiasis. Moreover, we examined the ability of these liposomes to load and 
retain CWSP, their ability to deliver the antigens and enhance activation of dendritic cells, 
key antigen presenting cells. Moreover, in vivo immunization studies confirmed that these 
LNPs are protective against lethal systemic C. albicans infection, by inducing Th1/Th17 cell-
mediated and humoral immunity. This study indicates that a liposomal nanoparticle based 
immunization with complex and heterogeneous proteins is a promising approach to improve 
vaccination efficacy. 
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2. MATERIAL AND METHODS 
 
2.1. Materials 
Dioctadecyldimethylammonium bromide (DODAB) was purchased from Tokyo 
Kasei (Japan). 1-monooleoyl-rac-glycerol (MO); Hanks’ balanced salt solution (HBSS); 
glutaraldehyde; propidium iodide (PI) and DTT were supplied by Sigma–Aldrich (St. Louis, 
MO, USA). Tris-HCl Buffer was provided by Invitrogen/Molecular Probes (Eugene, OR, 
USA) and ethanol (high spectral purity) was purchased from Uvasol (Leicester, United 
Kingdom). Dulbecco’s Modified Eagle’s Medium (DMEM) was supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, (all from Sigma-Aldrich); 
HEPES-Buffer solution pH 7.5 was provided by VWR International (Radnor, PA, USA) and 
1 mM sodium pyruvate by Merck (Frankfurt, Germany).  
 
2.2. Candida albicans and culture conditions 
For cell wall surface proteins extraction, C. albicans strain SC5314 was used. For 
infection experiments C. albicans 124A clinical isolate was used. All strains were maintained 
as frozen stocks in 30% glycerol at -80°C. When needed, yeasts were obtained from a 2 day 
YPD agar plate (2% D-glucose, 1% Difco yeast extract, 2% peptone and 2% agar) (w/v) 
incubated at 30 °C.  
 
2.3. Extraction of yeast cell wall surface proteins 
All procedures used for CWSP extraction was performed in a sterile environment and 
using apyrogenic solutions. The CWSP were released from whole intact cells by DTT 
treatment as described previously [22]. The concentrated proteins obtained were stored at  
-80°C in aliquots of 100 µg/ml. 
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2.4. Preparation and characterization of CWSP-loaded liposomes 
DODAB:MO based liposomes were prepared using the lipid-film hydration method 
[23]. Briefly, DODAB and MO, at a DODAB molar fraction (χDODAB) of 0.33, were 
dissolved in ethanol and mixed in a round-bottom flask. The solvent was removed by rotary 
evaporation, at a temperature 10 ºC above the main phase transition of DODAB 
(Tm ≈ 44 ºC), and liposomes formed after hydration of the lipid film with 25 mM HEPES pH 
7.5 at 55 ºC. The dispersion was then placed in a bath sonicator during 2 min. 
Two liposomal stock dispersions were prepared, stock 1, used for ADS1, at a total 
lipid concentration of 1774 µg/ml and stock 2, used for ADS2, at a total lipid concentration 
of 266 µg/ml. For the ADSs assembling, equal volumes of CWSP were added to respective 
stock dispersions post lipid-film hydration. For both ADSs the final concentration of CWSP 
was 50µg/ml. For ADS1, the final total lipid concentration was 888 µg/ml and for ADS2 was 
133 µg/ml. The empty liposomes were always used at a final total lipid concentration of 888 
µg/ml (Table 1). These formulations were then incubated for 1 hour, at 55 ºC, to ensure 
CWSP adsorption followed by a brief sonication step in a bath sonicator. 
 
2.4.1 Quantification of protein retention 
The liposomes were prepared as previously described and stored at 4 ºC. Protein 
retention was evaluated at different time points, 0, 3, 24, 48 and 72 h. The prepared 
formulations were pelleted by ultracentrifugation (100,000g for 1 hour), the pellet submitted 
to TCA protein precipitation (Thermo Scientific Pierce), and the proteins quantified with the 
BCA Protein Assay Kit (Thermo Scientific Pierce), according to the manufacturer’s 
instructions. The empty liposomes were used as negative control in order to exclude lipid 
interference in the protein quantification method. 
 
2.5. Stimulation of Bone Marrow Dendritic Cells (BMDCs) 
Bone marrow cells were collected from femurs and tibias of BALB/c mice by 
flushing with cold RPMI 1640 (Sigma). Cells (1×106/mL) were cultured in 6-well plates in 
RPMI supplemented with 15% (v/v) J558-cell supernatant, 10% FBS (PAA), penicillin (100 
U.I./mL)-streptomycin (100 µg/ml) (Sigma), and L-Glutamine (2 mM) (Sigma) and 
incubated at 37 ºC and 5% CO2. Half of the medium was renewed every two days. At day 6, 
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BMDCs were detached and distributed in 96-well round bottom plates adjusted at a 
concentration of 2×105 cells/well in supplemented RPMI medium. Immediately after being 
seeded cells were stimulated with 10 µl (removed from the stock preparations indicated in 
Table 1) of CWPS (0.5 µg), ADS1 (0.5 µg of CWSP loaded in 8.8 µg of total lipid), ADS2 
(0.5 µg of CWSP loaded in 1.33 µg of total lipid) or empty liposomes (8.8 µg of total lipid) in 
a final volume of 200 µl. LPS (1µg/ml) (Sigma) and un-stimulated cells were used as positive 
and negative controls of activation, respectively. After 6 or 24 h, the culture supernatants 
were removed and stored at -80 ºC. For the assessment of cell surface markers, after 
stimulation, the BMDC were collected from the culture plates, washed twice in Hanks’s 
Balanced Salt  Solution (Sigma) and incubated with specific cell surface antibodies. The 
following monoclonal antibodies (mAbs), along with the respective isotype controls were 
used (at previously determined optimal dilutions) [24] for  immunofluorescence cytometry: 
fluorescein isothiocyanate (FITC) hamster anti-mouse CD11c (HL3), PE anti-mouse CD80 
(B7-1) (16-10A1); PE anti-mouse CD86 (B7-2) (GL1) ; PE anti-mouse I-Ad/I-Ed (clone 
2G9); all from BD Biosciences Pharmingen, San Diego, CA. The analyzed cell samples were 
always pre-incubated with anti-FcγR mAb before the antibody incubation to prevent non-
specific antibody binding. All cytometric measurements were performed in an EPICS XL 
flow cytometer using the EXPO32ADC software (Beckman Coulter). The collected data files 
were converted using FACS CONVERT, v1.0 (Becton Dickinson) and analyzed using CELL 
QUEST software, v3.2.1f1 (Becton Dickinson).  
The concentrations of IL-23, IL-12 and TNF-α in cell culture supernatants were 
quantified with the respective Mouse ELISA Ready-Set-Go kit (eBioscience, San Diego, CA) 
while IL-10 was quantified using the Mouse IL-10 DuoSet ELISA development system 
(R&D Systems, Minneapolis, MN); according to the manufacturer’s instructions.  
 
2.6. Cellular delivery of proteins by ADSs LNPs 
Confocal microscopy was performed as described in our previous study [22]. Briefly, 
macrophages (RAW 264.7 cell line) were plated in 6-well chamber plates (Ibidi) 3 x 105 
cells/well and left to adhere overnight at 37 °C in a humidified atmosphere of 5% CO2. Prior 
to LNPs preparation, DODAB:MO liposomes were labeled with Rhodamine (Rho) DHPE. 
Previous to incubation with Rho-DHPE labeled LNPs, macrophages were labeled with Wheat 
Germ Agglutinin Alexa Fluor 633 Conjugate. Labeled macrophages were then incubated 
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with labeled LNPs, the microscopy chamber plate placed in the integrated chamber (37 °C, 
5% CO2) of LSM 780 Carl Zeiss and a mid-point cells thickness view images and z-stack 
images were obtained after 60 min and analyzed using ZEN 2012 lite software (ZEISS). 
 
2.7. Immunization procedures 
Female BALB/c mice, 8 to 10 weeks old, were purchased from Charles River 
(Barcelona, Spain) and kept under specific-pathogen-free conditions at the Animal Facility of 
the Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. All procedures involving 
mice were performed according to the European Convention for the Protection of Vertebrate 
Animals used for Experimental and other Scientific Purposes (ETS 123), the 86/609/EEC 
directive and Portuguese rules (DL 129/92).  
Nineteen BALB/c mice per group, in a total of 5 groups, were injected 
subcutaneously three times with a 2-week intervening period, with 200µl of one of the 
following preparations: CWSP alone (50 µg/ml); DODAB:MO empty liposomes (888 
µg/ml), ADS1 (50:888 µg/ml; CWSP:Lipid) or ADS2 (50:133 µg/ml; CWSP:Lipid).  
 
2.8. C. albicans hematogenously disseminated infections 
For the survival experiment, three weeks after the last immunization, eight female 
BALB/c mice per group were infected intravenously (i.v.) with 1 x 105 C. albicans yeast-
form cells. C. albicans inoculum for infection was grown in a shaking incubator for 14 h at 
30 °C in Winge medium (0.2% glucose, 0.3% yeast extract). Yeast cells were harvested, 
washed twice with sterile, apyrogenic phosphate- buffered saline (PBS), counted in a 
hemocytometer, and resuspended at the appropriate concentrations. Inocula were always 
confirmed by CFU (colony forming units) counts on YPD agar plates at 37°C for up to 48 h. 
Infected mice were weighed and monitored twice daily to evaluate the progress of 
hematological disseminated candidemia. Moribund mice were humanely terminated, and 
their deaths recorded as occurring on the following day.  
 
2.8.1 Kidney fungal burden 
For the determination of organ fungal-burden, four mice per group were similarly 
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immunized and infected. Three and seven days C. albicans infection mice were sacrificed 
and both kidneys aseptically removed. The organs were weighed, homogenized in Hanks’s 
Balanced Salt Solution (Sigma), and quantitatively cultured on YPD agar at 37°C. The results 
are expressed as log CFU per gram of tissue.  
 
2.9. Splenocytes intracytoplasmic cytokines determination 
For the determination of immunological parameters, four mice per group were 
similarly immunized and infected and spleens from days 0 (before infection), 3 and 7 post-
infection were aseptically removed, homogenized in Hanks’ balanced salt solution (Sigma) 
and red blood cells lysed with 0.15 M ammonium chloride. The remaining cells were counted 
and plated in round-bottom 96-well plates (Nunc, 1 x106 cells) in RPMI-1640 compete 
medium [RPMI-1640 (Sigma) supplemented with 10% fetal calf serum (PAA Laboratories), 
HEPES (10 mM), penicillin (200 IU/ml), streptomycin (200 g/ml) (all from Sigma) and 2-
mercaptoethanol (0.1 mM) (Merk)]. Cells were incubated in a humidified atmosphere with 
5% CO2 at 37° for 5 hour under stimulation with 20 ng/ml PMA (Sigma), 200 ng/ ml 
ionomycin (Merk) and 10 ng/ml brefeldin A (Epicentre Biotechologies, Madison, WI). Then, 
cells were recovered and non-specific antibody binding was prevented by the pre-incubation 
with anti-FcγR mAb followed by incubation with anti-CD4 peridinin-chlorophyll protein-
cychrome 5.5 (PerCP-Cy5.5)-conjugate (clone RM4- 5). Following extracellular CD4 
staining cells were washed, fixed in 2% formaldehyde, washed again and permeabilized with 
0.05% saponin (Sigma) in PBS solution. Intra-cytoplasmic staining was carried out with anti-
interferon-γ (IFN-γ) FITC-conjugate (clone XMG1.2) (Biolegend) and anti-IL-10 
phycoerythrin-conjugate (clone JES5-16E3) (BD Biosciences) or with anti-IL-4 
phycoerythrin-conjugate (clone BVD4-1D11) (BD Biosciences) and anti-IL-17A FITC 
conjugate (clone TC11-18H10.1) (Biolegend). Antibody-labeled cells were analyzed in an 
EPICS XL flow cytometer using the EXPO32ADC software (Beckman Coulter). At least 150 
000 events were acquired per sample. The collected data files were converted using FACS 
CONVERT, v1.0 (Becton Dickinson) and analyzed using CELL QUEST software, v3.2.1f1 
(Becton Dickinson).  
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2.10. “ex vivo” splenocytes cytokine detection 
To assess in vitro cytokine production by CWSP-stimulated spleen cells, 5 ml aliquots 
of cell suspensions prepared as described above for intra-cytoplasmic staining, were layered 
onto 2.5 ml of a polysucrose-sodium ditrizoate solution (Histopaque 1083®, Sigma) and 
centrifuged at 800g for 20 min at room temperature. Mononuclear cells collected from the 
medium–Histopaque interface were collected, washed, suspended in RPMI-1640 complete 
medium, plated (5x 105/well) in round-bottom 96-well plates, and stimulated with CWSP 
(final concentration of 20 µg/ml) for 3 days at 37° and 5% CO2. The concentrations of IFN- 
γ, IL-4 and IL-17 in cell culture supernatants were quantified with the respective Mouse 
ELISA Ready-Set-Go kit (eBioscience, San Diego, CA) while IL-10 was quantified using the 
Mouse IL-10 DuoSet ELISA development system (R&D Systems, Minneapolis, MN); 
according to the manufacturer’s instructions.  
 
2.11. Phagocytosis of C. albicans opsonized cells 
Phagocytosis analyses was assessed by flow cytometry as described by Carneiro, et al 
[25]. Briefly, fixed C. albicans cells were labeled with Sytox Green and opsonized (treated 
with 20% mice serum during 30 min at 37 °C) from mice immunized thrice with CWSP, 
ADS1, ADS2 or empty liposomes, then washed twice with PBS and resuspended in 
incomplete DMEM. RAW 264.7 macrophage were incubated with labeled yeast suspensions 
at MOI of 1M:5Y for 30 min, at 37 °C and 5% CO2. After incubation plates were kept on ice 
to stop phagocytosis, and wells rinsed twice with PBS to remove unbound yeasts. 
Macrophages and associated yeasts were then incubated with PI at a final concentration of 6 
µg/ml, for 5 min at RT. The percentage of macrophages with internalized cells as well as the 
percentage of macrophages with adherent cells was determined as previously described [25] . 
 
2.12. Statistical Analyses. 
Data was analyzed using analysis of variance (ANOVA) followed by the Bonferroni 
test to compare the mean values of different groups, using GraphPad Prism 5 software 
(GraphPad Software, Inc., La Jolla, CA).  Unless otherwise stated, results shown are from 
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three independent experiments with three replicates. Differences were considered significant 
when the P value was less than 0.05. 
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3. RESULTS 
 
3.1. Characterization of ADS LNPs, quantification of protein retention and delivery 
ADSs are liposomal nanoparticles (LNPs) prepared from DODAB:MO liposomes 
loaded with C. albicans cell wall surface antigens (CWSP) as previously described [22]. The 
ADS1 LNPs had a size around 223 ± 37 nm with a polydispersity index (PDI) of 0.19 ± 
0.015, while ADS2 LNPs had a similar size, 255 ± 46 nm, but were more polydisperse, 0.25 
± 0.017 (Table 1). These LNPs were negatively charged, with ADS1 presenting a ζ-potential 
value of -18.3 ± 1.5 mV and ADS2 a ζ-potential value of -21.8 ± 1.5 mV, while DODAB:MO 
empty liposomes exhibited a ζ-potential value of  54.6 ± 3.2  mV, showing that antigenic 
proteins (CWSP) are surface adsorbed to liposomes. 
 
Table 1: Composition, mean size and ζ-potential of ADSs liposomal nanoparticles.  
DODAB:MO liposomes were mixed with CWSP for 1 hour to prepare ADS1 and ADS2 and mean size and  
ζ-potential were measured by dynamic light scattering on a ZetaSizer NanoZS. PDI: polydispersity index. 
 
Owing to the complexity of Candida cell wall antigens and their surface localization, 
we now focused on the stability over time of the proteins associated with the liposomes when 
stored at 4 ºC. Immediately after LNPs assembling (time 0), ADS1 presents 91 ± 12% of the 
proteins adsorbed while ADS2 shows only 25 ± 12% (Fig. 1). Although at 48h approximately 
12,6% of CWSP was released from the surface of ADS1 liposomes, no significant change is 
observed over 72h after preparation. Thus, in this study, both systems, ADS1 and ADS2, 
were always used within 48h after preparation to ensure the % of CWSP absorbed. This 
result highlights the fact that the interactions between DODAB:MO liposomes and CWSP 
proteins are strong and protein adsorption on to ADS1 or ADS2 LNPs is stable, at least over 
a range of 72h after liposomes preparation and storage at 4 ºC.  
 ADS1 ADS2 CWSP 
Empty 
liposomes 
Total lipid (µg/ml) 888 133 - 888 
CWSP added 
(µg/ml) 50 50 50 - 
Mean size (nm) 223±37 255±46 88.7±5.1 176.8±23 
PDI 0.19±0.015 0.25±0.017 0.63±0.01 0.24±0.08 
ζ-potential(mv) -18.3±1.5 -21.8±1.4 -14±0.7 54.6±3.2 !
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Figure 1: Percentage of CWSP retention in ADSs liposomal nanoparticles (LNPs)(ADS1 and ADS2) over time. 
LNPs were prepared, stored at 4 ºC, and retention of CWSP (antigen) was monitored during 72 h after 
preparation. Results represent percentage retention of initial antigen added (50 µg/ml for both ADSs). All values 
shown are the average values from two independent experiments with two replicates mean ± SD. 
 
In our previous study we have shown that the prepared LNPs were non-toxic and 
avidly internalized by J774A.1 macrophages, indicating that LNPs are able to efficiently 
deliver antigens into this macrophages cell line [22]. In this study we confirmed that after 60 
min of incubation, ADS1 also effectively delivered CWSP into the RAW 264.7 macrophage 
by confocal microscopy (Figure 2). 
 
 
Figure 2: Cellular uptake of empty liposomes and ADS1 LNPs after 1 h min of incubation.  Representation of a 
mid-point thickness view (X68, Y44, Z24 ) (z). Z-axis rotations of a single transverse slice through two sections 
of the cell: view in the x-0-z plane (x) and view in the y-0-z plane (y). The scale bar represents 10 nm. 
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3.2. Immunostimulatory efficiency of ADSs LNPs on dendritic cells 
The activation of antigen presenting cells (APCs), such as dendritic cells (DCs) and 
macrophages, is one of the fundamental steps towards an effective in vivo immune response. 
Thus, it is important to evaluate the ability of these LNPs vaccine formulations to activate 
APCs in vitro. Therefore, BMDCs activation was assessed by measuring surface expression 
of co-stimulatory CD80 and CD86) and MHC class II molecules, and by quantifying pro-
inflammatory cytokines TNF-α, IL-12 and IL-23 and anti-inflammatory cytokine IL-10 from 
the culture supernatants, after incubation with the LNPs. 
Figure 3A shows that after 6 h cells stimulated with CWSP and LNPs already 
significantly enhanced the expression of all surface activation markers analyzed (P<0.05) in 
comparison with un-stimulated cells or cells stimulated with empty liposomes. At this time 
point, the LNPs enhanced activation promoted by free antigenic proteins but only regarding 
CD80 expression (P<0.01). However, after 24 h of incubation a remarked enhancement in the 
activation promoted by the free CWSP is achieved with ADS1 (P<0.0001, Figure 3A). 
CWSP and ADS2 failed to boost the activation and the effect achieved at 6h was even 
reduced after 24 h. 
The BMDCs stimulated with either CWSP or ADS2 produced similar levels of TNF-α 
and IL-12 as those stimulated with LPS, a strong activator of the innate immune system and a 
potent inducer of inflammation [26]. These cells also produced significantly higher amounts 
of IL-23 and IL-10 (P<0.01) when compared with stimulation by ADS1 or empty liposomes 
(Figure 3B). After 24 h the levels of all these cytokines were maintained or even enhanced. 
On the contrary, stimulation with ADS1 led to intermediate levels of all cytokines, between 
the free proteins/ADS2 and liposomes alone (Figure 3B). 
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Figure 3: BMDCs activation by ADSs LNPs. BMDCs isolated from BALB/c mice were stimulated in vitro 
with CWSP, ADS1, ADS2 or Liposomes for 6 or 24 h. (A) BMDCs were gated on CD11c+cells and analyzed 
for expression of co-stimulatory (CD80, CD86) and MHC class II molecules. (B) Cytokine production with the 
indicated stimulus is represented. As references, un-stimulated cell (UC) and cells stimulated with LPS are also 
represented. Bars represent the mean ± SD of mean fluorescence intensity (MFI) from two independent 
experiments Only significant differences obtain in comparison with the free CWSP (#) and between the two 
time points for the same stimulus are presented: **P<0.01; ***P<0.001 and ****P<0.0001 
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These results suggests that both LNPs activate DCs but ADS2 and the antigens alone 
appear to be as inflammatory as LPS, while ADS1 activated not only reasonable amounts of 
cytokines but also significantly enhanced expression of co-stimulatory surface proteins. 
 
3.3. ADSs LNPs vaccination protects against a lethal C. albicans infection 
In order to evaluate the protective effect of LNPs vaccine against a candidemia, s.c. 
vaccinated and control mice were challenged with a lethal dose of C. albicans cells from a 
clinical strain obtained from a systemic infection (strain 124A, [27]), two weeks after the last 
immunization (a scheme of the immunization protocol is represented in Figure 4A). Mice 
survival was monitored over 50 days.  
Infection progressed similarly in all immunized and control groups until the first week 
after infection, when mice immunized with HEPES-buffer began to die. As expected, mice 
from this control group were the first to succumb to Candida infection, followed by mice 
immunized with CWSP (Figure 4B).  
ADS1 immunized mice presented a significant extended overall survival time 
(undefined) compared to mice immunized with CWSP (21 days, P=0.020) or with HEPES-
Buffer (18 days, P=0.012). At the end of the experimental period, 62.5% of the mice 
immunized with ADS1 survived the infection while none of the CWSP immunized mice 
survived. All mice immunized with ADS2 expired at the end of the experience but presented 
a survival time of 30 days, between immunization with CSWP (P=0.096) and ADS1 
(P=0.031). 
Kidney fungal burden was evaluated and only mice immunized with ADS1 LNPs 
were able to significantly reduce (P<0.01) fungal burden from day three to seven post 
infection (Figure 4C). Vaccination of mice with ADS2 LNPs or CWSP also reduced fungal 
burden, even if without statistical significance. Although immunization with ADS1 resulted 
in significant reduction in CFUs, the fungal burden at day seven was still comparable to those 
observed in mice immunized with CWSP and ADS2. 
These results demonstrate that the ADS1 LNPs vaccine protects against lethal 
infection even using a C. albicans strain different from the origin of the isolated antigens, and 
that protection correlated with a significant reduction in fungal burden but not total CFU 
counts. 
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Figure 4: Mice protection after ADS LNPs vaccination. Naive BALB/c mice were immunized s.c. with CWSP, 
ADS1, ADS2 or empty Liposomes, boosted 2 times, with an intervening interval of 2 weeks, and infected 
intravenously (i.v.) with 1 x 105 C. albicans yeast-form cells, 21 days after the last s.c. immunization. At days 0, 
3 and 7 after infection mice were sacrificed for immunological studies (A) Scheme of the immunization 
protocol. (B) Survival rates of immunized mice. Eight mice per group were used. (C) Kidney fungal burden of 
mice sacrificed at 3 and 7 days after C. albicans infection. Data are displayed as mean ± SD of four mice used 
per group. Only significant differences obtain in comparison with the free CWSP (#), and between the two time 
points for the same stimulus (*) are represented: (**P<0.01, ***P<0.001). 
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3.4. Production of antigen specific antibodies in vivo 
Serum IgG titers of BALB/c mice vaccinated with ADSs LNPs or CWSP alone were 
quantified before and after infection. Before infection, immunization with ADS2 or with free 
CWSP induced similar levels of both anti-CWSP IgG1 and IgG2a. Only ADS1 induced a 
significant increase in serum anti-CWSP antibody titers in comparison with all other groups 
(P<0.05, Figure 5).  
 
Figure 5: CWSP-specific IgGs antibody titers. Specific anti-CWSP IgG1 and IgG2a were quantified in mice 
immunized s.c. with CWSP, ADS1, ADS2 or empty Liposomes. Antibody titers were measured by ELISA 
using sera collected 21 days after the last s.c. immunization (before infection) and 3 and 7 days post-intravenous 
(i.v.) infection with 1 x 105 C. albicans yeast-form cells. Data are representative of at least three independent 
experiments. The statistical significance between the different groups is indicated above the lines: *P<0.05. 
CHAPTER VI 
________________________________________________________________________________________________________________ 
 
	  198	  
After infection, a significant reduction in anti-CWSP IgGs was observed, at both time 
points and for all groups of mice.The efficacy of sera from immunized mice in enhancing the 
phagocytosis of C. albicans cells was tested in vitro by flow cytometry, with a methodology 
that enables the discrimination of yeast cells that are internalized from yeast cells that are 
only adhered to phagocytes [25]. It is clear that C. albicans cell pre-treated with serum from 
mice immunized with LNPs were significantly better internalized/adhered by macrophages 
than yeast cells incubated with serum from mice immunized with empty liposomes (P<0.01), 
in which no anti-CWSP IgGs were detected (Figure 6). This indicates that the enhancement 
in the percentage of internalized/adhered cells by macrophages may be associated to the 
presence of anti-CWSP IgGs. The same trend was observed when comparing cells incubated 
with serum from mice immunized with LNPs or with CWSP alone (P<0.001).  
 
 
 
Figure 6: Antibody opsonization enhances macrophage-mediated internalization of C. albicans yeast cells. 
Serum from mice immunized with CWSP, ADS1, ADS2 or empty liposomes were used to opsonize the yeast 
cells before interaction with RAW264.7 (A) Phagocytosis was measured after 30 min of incubation, by flow 
cytometry. M(IA) represent the percentage of macrophages cells with internalized (Sytox Green positive 
fluorescence) and internalized/adhered yeast cells (Sytox Green/IP positive fluorescence); M(A), percentage of 
macrophage cells with only adhered yeast cells (IP positive fluorescence). Control represents non-opsonized 
yeast cells. (B) Representative image of internalized (Sytox Green positive, *) and adhered (IP positive, #) yeast 
cells. Bars represent mean ± SD. Significant differences between sera from ADSs and the liposomes immunized 
mice are represented above the lines and significant differences between sera from ADSs and the CWSP 
immunized mice are represented as #: *P<0.05;  **P<0.01, ****P<0.0001. 
 
Although serum from CWSP immunized mice contained anti-CWSP IgGs, no 
differences in the percentage of internalized/adhered yeast were observed for yeast cells 
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treated with this serum in comparison with cells treated with serum from mice immunized 
with empty liposomes. This result indicates that serum from CWSP immunized mice is not 
efficient in inducing cell opsonization. 
According to these results, mice immunized with LNPs presented a significant 
increase in serum anti-CWSP antibody titers before infection that markedly enhanced ex vivo 
phagocytosis of C. albicans yeast cells. Immunization with ADS1 LNPs resulted in superior 
protection, indicating that protection seems to be correlated with opsonizing antibody titers 
before infection. 
 
3.5. Splenocytes stimulation and intracellular cytokine quantification 
 Cell-mediated immune response is essential for the control of C. albicans and 
Th1/Th17 cytokines are critical for coordinating protective immunity against the fungus. 
Thus, to determine whether immunization with LNPs could induce cellular immunity, Th1 
(IFN- γ), Th2 (IL-4), Treg (IL-10) and Th17 (IL-17) cytokines were analyzed in the 
supernatant of CWSP-re-stimulated splenocytes from immunized mice. The frequencies of 
splenic CD4+ T cells producing these cytokines were also assessed. 
Before infection, CWSP re-stimulated splenocytes from mice immunized with ADSs 
LNPs produced higher levels of IFN-γ and IL-17 (P<0.05) in comparison with re-stimulated 
splenocytes from mice immunized with CWSP or liposomes (Figure 7). Although low, levels 
of IL-4 and IL-10 were detectable in splenocytes from mice immunized with the LNPs but, at 
this time point, no significant differences between groups were observed. After C. albicans 
i.v. infection, the levels of IFN-γ increased significantly for all groups of mice, at the acute 
phase (3 days post-infection), decreasing again by day seven to levels similar to those before 
infection, except for mice immunized with empty liposomes (P<0.0001) (Figure 7). The same 
pattern was observed for IL-4, but at day seven post-infection its levels remained higher than 
before infection for the LNPs. Only LNPs were capable of inducing significant levels of IL-
17, and mice immunized with ADS1 showed the highest levels at three days post-infection 
(P<0.001), diminishing at day seven, albeit being the only group that retained significant 
levels of this cytokine (Figure 7). 
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Figure 7: Cytokine production after splenocytes re-stimulation with CWSP. Splenocytes from mice s.c. 
immunized with CWSP, ADS1, ADS2 or liposomes were isolated 21 days after the last s.c. immunization 
(before infection) and 3 and 7 days post-intravenous (i.v.) infection with 1 x 105 C. albicans yeast-form cells. 
Re-stimulation with CWSP (20 µg/ml) was performed for 3 days and IFN- γ, IL-17, IL-4 and IL-10 quantified 
by ELISA. Bars represent mean ± SD of four mice used per group. Only significant differences obtain in 
comparison with the free CWSP (#), significant differences between the two time points for the same group of 
immunized mice and significant differences between ADSs are represented: **P<0.01; ***P<0.001 and 
****P<0.0001.  
 
Moreover, mice immunized with LNPs presented the highest levels of Treg IL-10, at 
day 3 post-infection, while for all other groups the levels of this cytokine diminished. At day 
seven post-infection, levels of Treg IL-10 continued to increase only in ADS1 immunized 
mice, being significantly higher compared to all other groups (P<0.05). 
The frequency of splenic CD4+ T cells producing IFN-γ increased for all groups at 
day 3 post-infection, in comparison with values observed before infection. At day seven, for 
mice immunized with CWSP, ADS1 and ADS2, the levels of CD4+ T cells producing IFN-γ 
were significantly diminished (Figure 8A) to levels similar to those observed before infection 
(P<0.05), as observed in figure 7. A significant increase in the frequency of CD4+ cells 
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secreting IL-4 (P<0.001) and IL-10 (P<0.01) was observed for mice immunized with LNPs at 
the acute phase of infection, in comparison with mice immunized with the free proteins or 
empty liposomes, remaining relatively high at day seven post-infection, particularly for 
ADS1 immunized mice (Figure 8A). Of note is the fact that mice immunized with ADS1 
enhanced the frequency of CD4+ cells expressing IL-17 at day three post-infection (P<0.05) 
in comparison with mice immunized with CWSP and empty liposomes (Figure 8B). As 
expected, these results are in accordance with the cytokine profile observed analyzing total 
splenocytes. 
These results indicate that immunization with LNPs primed lymphocytes to produce 
pro-inflammatory Th1/Th17 cytokines particularly at the acute phase of inflammation and 
that prove to be decisive for the recovery and protection of mice infected with C. albicans. 
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Figure 8: A) Frequency of IFN-γ+, IL-17+, IL-10+, or  IL-4+ cells in splenic CD4+ T cells from mice s.c. 
immunized with CWSP, ADS1, ADS2 or liposomes, isolated 21 days after the last s.c. immunization (before 
infection) and 3 and 7 days post-intravenous (i.v.) infection with 1 x 105 C. albicans yeast-form cells (B) 
Representative examples of flow cytometry analysis of intracellular IFN-γ+, IL-17+, IL-10+, or  IL-4+ expression 
on gated splenic CD4+ T cells after 3 days of infection, as indicated. Numbers inside dot plot regions represent 
means ± SD. Only significant differences obtain in comparison with the free CWSP (#), significant differences 
between the two time points for the same group of immunized mice and significant differences between ADSs 
are represented: **P<0.01; ***P<0.001 and ****P<0.0001.  
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4. DISCUSSION 	  
The surge of Candida species infections coupled to higher resistance rates to 
antifungal drugs resulted in a tremendous increase in the prevalence of systemic candidiasis 
in hospitalized patients over the past two decades [28-31].  Hence, it is of paramount interest 
to develop a new prophylactic immunointervention against systemic candidiasis. In a 
previous study, we have shown the potential of DODAB:MO liposomes loaded with C. 
albicans CWSP (ADSs LNPs) in improving the immunogenicity of Candida antigens and 
therefore suggested that these liposomes could act as promising delivery systems for use in 
vaccination against C. albicans [22].  In this study, CWSP were also chosen as antigens since 
they ensure the diversity and complexity of C. albicans surface antigens. In fact, the proteins 
present in the fungal cell wall constitute excellent candidates for vaccine development as the 
cell wall plays a unique and important role in antigen presentation and immunomodulation 
[32]. In addition, the combination of antigens that are related to key C. albicans virulence 
attributes or biological functions may induce additive or synergistic immune responses and 
therefore reduce the probability of fungal immune evasion [33].  
The LNPs have been prepared as two vaccine formulations, ADS1 and ADS2, 
differing only in the total lipid concentration used for CWSP adsorption. ADS1 is composed 
by approximately 7 times more total lipid than ADS2 and, as a consequence, it retains 91 ± 
12% of the protein added, while ADS2 only 25 ± 12%, as previously reported [22]. Its 
characterization confirmed the LNPs mean sizes to be approximately 223 and 255 nm for 
ADS1 and ADS2 respectively, and that the antigenic proteins are adsorbed to the cationic 
liposomes, as shown by ζ-potential values. Furthermore, the electrostatic interactions 
between the cationic liposomes and the anionic proteins are strong enough to retain the 
antigens at the LNPs surface for at least 3 days after preparation. Importantly, the quantity of 
antigens loaded in the LNPs is dependent of the total lipid concentration, but the stability of 
the core proteins at their surface is not. 
DCs constitute an important class of antigen presenting cells (APCs) of the immune 
system and are involved in antigen capturing, processing and subsequent presentation to 
antigen-specific T cells [26, 34]. DC maturation in vitro is characterized by up-regulation of 
MHC II and the co-stimulatory molecules CD80 and CD86 [35]. Un-stimulated cells CD11c+ 
revealed moderate expression levels of CD80, CD86 and MHC-II molecules as shown by the 
mean fluorescence intensity (MFI) in the flow cytometry analysis. Incubation with the four 
different stimulus, CWSP, ADS1, ADS2 and empty liposomes reveal that only ADS1 was 
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able to significantly elevate the levels of expression of the three activation markers, in 
comparison cells exposed to the same concentration of free CWSP. This enhancement was 
only achieved after 24 h and interestingly at this time point the activation promoted by the 
CWSP significantly decreased, as opposed to the significant stimulation obtained with ADS1. 
This kinetic suggests that the delivery of CWSP in the liposomes not only enhances but also 
prolongs the cells activation by slow and sustained release of the entrapped antigen. Thus, the 
particulate nature of the ADS1 strongly improves the uptake  of the entrapped antigen by 
DCs and their subsequent presentation to responder cells. In fact, the ability of cationic lipids 
to improve antigen immunogenicity is well recognized [36-38].  The fact that ADS2 fails to 
promote the same pattern is probably related to the lower lipid concentration used in this 
system, which results in just about 20% of CSWP entrapment, behaving similarly as the free 
CWSP. 
IL-12 and IL-23 are members of a family of pro-inflammatory heterodimeric 
cytokines that can promote a Th1/Th17 response, inducing IFN-γ expression in CD4+ T cells 
and maintaining Th17 effector function, respectively [39, 40]. In contrast, IL-10 might be 
required to limit host damage under circumstances of strong inflammation [41] and can also 
be associated with a Th2 polarization [42]. The cytokine profile obtained by stimulating 
CD11c+ cells with ADS2 and free CWSP revealed a response similar to LPS, which could be 
considered as an exacerbated pro-inflammation. On the contrary, ADS1 seems to control that 
high inflammatory response once these cytokines were present but in significantly reduced 
levels. Furthermore, the higher levels of IL-23 and TNF-α and lower levels of IL-10 and 1L-
12 suggest a Th17 polarization. In accordance with previous reports [26], incubation with 
empty liposomes led to production of insignificant levels of all cytokines, which indicates 
that the strong pro-inflammatory response was probably due to the presence of high 
concentrations of free proteins in the incubation solution, with CWSP and ADS2 stimuli. In 
fact, C. albicans cell wall proteins have been considered pro-inflammatory [43, 44]. The 
results observed with these LNPs, particularly with ADS1, encourage us to test if protection 
of mice from a lethal C. albicans systemic infection could be achieved. 
In fact, after a lethal dose of C. albicans, only mice immunized with ADS1 LNPs 
showed a significant extended survival time compared to mice immunized with either free 
CWSP or buffer (P<0.05), and in fact more than 60% of mice immunized with ADS1 
survived. Currently, scientific interest has grown towards the development of nanoparticles 
for use as adjuvants and delivery of antigens for vaccine development [45-49]. Other studies, 
using DODAB liposomes with monophosphoryl lipid A (MPL) or with trehalose 6,6'-
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dibehenate (TDB) were used as adjuvants, also resulted in a protective immune response 
towards Chlamydia infection [50]. Similarly, in another study, the combination of DODAB 
with a major antigen of Paracoccidioides brasiliensis resulted in the lowest numbers of 
viable yeast cells in mice infected with P. brasiliensis in comparison with the use of other 
adjuvants such as aluminum hydroxide, CFA or flagellin [51]. 
Of note is the fact that only 10 µg of antigen were used per immunization in the 
present strategy, which is a small quantity in comparison to other studies describing the 
enhanced protection provide by liposomes with entrapped candida antigens [52, 53], 
supporting the high adjuvant potential of DODAB:MO liposomes. It is described that fungal 
CFU in mice kidneys increase progressively during fatal infection and decrease during 
nonfatal infection [54]. Consistently, the decrease of kidney fungal burden, observed at day 7, 
was only achieved in ADS1 immunized mice, which correlates with the survival of this 
group. This decrease in fungal burden with ADS1 immunization can be correlated with the 
fact that mice vaccinated with LNPs developed a strong humoral response with specific 
antibodies able to enhance phagocytosis of C. albicans cells. Serum from mice immunized 
with empty liposomes also enhanced yeast internalization, which could be accounted for both 
the presence of complement proteins and/or unspecific antibodies. The fact that serum from 
mice immunized with LNPs lead to a higher phagocytic activity than serum from mice 
immunized with empty liposomes, indicates that specific antibodies against CWSP play a 
major role in C. albicans recognition and internalization. This result is in agreement with 
studies that show that antibodies against C. albicans cell surface components favor 
internalization and killing of the fungus [55-57]. However, incubation with serum from 
CWSP immunized mice, which contains sufficient levels of anti-CWSP IgGs, was unable to 
enhance internalization/adhesion as did the serum form LNPs immunized mice. This result 
highlights the fact that not all antibodies have the same efficiency in the effector function of 
opsonizing/enhancing phagocytosis [58]. Indeed, in our previous study we have shown that 
the cell wall proteins identified by serum from CWSP immunized mice are different from the 
proteins identified by ADSs [22].  
Mice vaccinated with ADS1 LNPs developed a protective and specific Th1/Th17 
response with higher frequencies of splenic CD4+IL-4+ cells and higher levels of  
IL-17/IL-10/IL-4 in re-stimulated splenocytes in comparison with mice immunized with free 
CWSP. In fact, Th1 cells secrete IFN-γ but not IL-4, and the immune response is described 
by intense phagocytic activity while Th17 cells response is characterized by enhancement of 
neutrophil recruitment through secretion of IL-17 cytokine [59, 60]. Conversely, Th2 cells 
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secrete IL-4 but not IFN-γ suppressing the phagocytic activity [33]. Indeed, at day 3, the 
inflammatory response is high for all immunized mice, but it is at this time point that LNPs 
immunized mice show the highest amount of the anti-inflammatory cytokine IL-10. Actually, 
it is known that a vaccine that elicits by itself an inflammatory reaction might damage the 
host when the infectious agent is encountered, and IL-10 may act as a homeostatic host-
driven response to keep inflammation under control [41, 61]. Moreover, a vaccine that 
elicited some Th2-type regulatory cytokines could provide a more balanced response [62]. 
Furthermore, although Th1/Th17 cells have been shown to be important in the development 
of protective host responses against C. albicans infection [60, 63] it is the balance between 
pro- and anti-inflammatory signaling that defines a successful fungal control [52, 64]. In the 
case of mice immunized with ADS1, the generation of Th1/Th17 and Th2 mix immune 
responses supports the idea that DODAB:MO liposomes contribute to more balanced 
immune responses against Candida infections that ultimately culminate in extended survival 
of mice when compared with mice immunized with free CWSP. These results reveal once 
more the adjuvant potential of DODAB:MO liposomes, suggesting that a decreased in their 
concentration could be fatal once ADS2 fails in enhancing CWSP immunogenicity. 
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5. CONCLUSION 	  
This study demonstrated that DODAB:MO ADSs liposomal nanoparticles not only 
efficiently deliver antigens to activate BMDCs but also represents a promising new antigen 
vaccine delivery system. The in vivo results showed that a dose as low as 10 µg of antigenic 
proteins elicited significant humoral and cellular immune responses in BALB/c mice, 
conferring protection against a lethal C. albicans systemic infection.  
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1. CONCLUDING REMARKS 	  
Subunit vaccines, composed of nonliving or split pathogens, are being developed as 
immunoprotective strategies. Their effective implementation is however greatly limited 
because, in general, they do not sufficiently activate antigen presenting cells (APCs) and 
elicit an adaptive immune response. Therefore, to potentiate their immunogenicity, subunit 
vaccines are frequently formulated with an adjuvant. Cationic liposomes are interesting 
choices for the development of adjuvant delivery systems due to their ability to act as 
immunostimulators, inducing cell mediated immunity and humoral immune responses 
towards the associated antigens, and as nanocarriers for diverse drugs, DNA or different 
types of antigens.  
Formulating protein antigens into nanocarriers has emerged as one of the most 
promising strategies to trigger an immune response against the carried antigens. For the 
efficient design of nanoparticles composed of cationic liposomes, it is important to 
understand the delivery system-antigen interactions. The particulate adjuvant delivery system 
addressed in the present study is a cationic liposomal adjuvant, which is based on the cationic 
surfactant dioctadecyldimethylammonium bromide (DODAB) together with monoolein 
(MO), a naturally-occurring neutral surfactant and helper lipid. The χMO was critical for 
DODAB:MO liposomes and for BSA loaded DODAB:MO liposomal nanoparticle (BSA 
LNPs) colloidal stability, structural organization, and reduction of cytotoxicity and 
improvement of phagocytic cells ability to internalize antigens. At χMO (0.66), DODAB:MO 
not only functioned as a delivery vehicle that mediated initial contact with the cells but also 
facilitated subsequent activation of APCs.  
Currently, systemic infections caused by Candida species, mainly caused by  
Candida albicans, represent the fourth leading cause of nosocomial bloodstream infection in 
modern hospitals, despite the administration of antifungal agents that have potent activity in 
vitro and in vivo in preclinical studies. Clearly, prevention of this type of invasive fungal 
infections has become of paramount importance. The yeast cell wall is a unique microbial 
feature with an important role in antigen presentation and immunomodulation. Therefore, 
fungal cell wall protein antigens, exposed at the yeast surface, constitute excellent candidates 
for vaccine development. In fact, phagocytosis is mediated by receptors on the cell surface 
that recognize specific ligands on the pathogen surface. In this study, we developed a new 
method to assess yeast phagocytosis by flow cytometry. This method allowed a clear 
distinction between internalized and non-internalized yeast cells being of great usefulness 
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further in this thesis for comparison of phagocytosis rate between opsonized vs. non-
opsonized yeast cells.  
At the same χMO (0.66), DODAB:MO (1:2) liposomes were loaded with C. albicans 
cell wall surface proteins (CWSP). To understand the delivery system-antigen interactions 
different formulations were tested with distinct protein/lipid weight ratios. These 
formulations assembled as spherical liposomal nanoparticles and two were selected and 
further studied: ADS1 LNPs (protein/lipid weight ratio of 0.056) and ADS2 LNPs 
(protein/lipid ratio of 0.376). Both LNPs were stable with mean sizes around 200 nm, non-
cytotoxic and avidly taken up by macrophages. Moreover, the electrostatic interactions 
between the cationic liposomes and the anionic proteins were strong enough to retain the 
antigens at the LNPs surface for at least 3 days after preparation. 
The loading of the CWSP in DODAB:MO liposomes not only enhanced but also prolonged 
the activation of dendritic cells indicating that entrapped antigen is released in a slow and 
sustained manner when trapped in DODAB:MO liposomes. This behavior indicates that 
DODAB:MO liposomes adjuvant effect may be attributed to an increase in antigen uptake 
and to an enhancement of APC activation, two mechanisms already described for other types 
of delivery systems.  
In the mouse model, immunization with the ADSs induced strong antibody responses 
and cell-mediated immunity. Moreover, in contrast to immunization with CWSP alone, these 
systems induced higher levels of IL-17 and IFN-γ but lower levels of IL-10, indicating a 
polarization towards a Th1/Th17-type immune response and confirming their 
immunoadjuvant potential. Additionally, mice immunized with LNPs displayed strong 
humoral responses, producing antibodies (IgGs) against proteins different to those induced by 
CWSP alone, in particular the cell wall chitinase Cht3p. This protein is known to be unstable 
in vitro, indicating that these liposomes not only enhance the immune response against 
proteins from the pathogenic yeast C. albicans but also adsorb and efficiently deliver a 
protein that otherwise was not efficiently delivered due to its instability. 
Furthermore, in a mouse model of systemic candidiasis DODAB:MO ADS1 
liposomal nanoparticles, with a dose as low as 10 µg of antigenic proteins, elicited significant 
humoral and cellular immune responses in BALB/c mice, conferring protection against a 
lethal C. albicans systemic infection.   
Thus with this work we developed and characterized a novel delivery system, 
composed by DODAB:MO liposomes, that was able to enhance C. albicans antigens 
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immunogenicity and that adjuvant potential was crucial in protecting mice against systemic 
candidiasis (Figure 1).  
 
 
 
Figure 1: Schematic representation of the main conclusion of this work. 
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2. FUTURE PERSPECTIVES 
 
For the efficient design of liposomal-based adjuvant delivery systems, several 
parameters should be further considered, such as shelf-life of the delivery system, batch-to-
batch reproducibility and possibility of large-scale production of safe and efficient liposomal 
products. 
One of the main concerns regarding the previous study was the use of a bulk of  
C. albicans cell wall proteins (CWSP) as antigens, making the large-scale production and the 
batch-to-batch protein extractions laborious and difficult. In this study, immunoblotting 
assays showed that more than 90% of the CWSP-specific antibodies present in mice 
immunized with ADS1 were reactive to the Cht3p cell wall protein. These results led us to 
consider this protein as an antigen candidate to be loaded in DODAB:MO liposomes, 
replacing the CWSP.  
In order to fulfill these objectives, the following studies are being designed in our group: 
(1) Optimize and establish a protocol for the preparation of DODAB:MO liposomes with 
recombinant C. albicans chitinase rCht3p as antigen. 
(2)  Characterize and explore the assembled LNPs assessing their physicochemical 
properties. 
(3) Evaluate the humoral and cellular response of the LNPs towards the rCht3p antigen in 
order to assess their immunomodulatory effects;  
(4) Achieve an effective immune protection against systemic candidiasis and characterize 
the immunological mechanisms responsible for that protective effect;  
(5) Validate these LNPs as candidates for an experimental vaccine against systemic 
candidiasis.  
Recent perspectives forecast a new paradigm for future “third generation” vaccines 
based on similarities found in diverse pathogens or convergent immune defenses to such 
pathogens. These perspectives include what is known as convergent immunity, where 
antigens from non-target organisms that contain epitope homologs found in the target 
organism are applied in vaccines. Convergent immunity has a potential to promote protective 
efficacy not usually elicited by native antigens from a target pathogen. In fact, a C. albicans 
antigen was already described to confer convergent immunity in Staphylococcus aureus and 
C. albicans systemic infections. In this sense it would be interesting to explore CWSP/rCht3p 
loaded DODAB:MO liposomes efficiency in protecting mice infected with a non-target 
pathogen such as S. aureus.    
